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1
The prostate
The prostate is a small gland that is part of the male reproductive system. It is located 
beneath the urine bladder on top of the base of the penis and in front of the rectum 
(Fig. 1a). Together with the seminal vesicles, the prostate serves to produce and store 
the fluid portion of the semen. The gland is composed of different zones, with the 
main zones being the peripheral zone, transition zone and central zone (Fig. 1b). 
A band of anterofibromuscular stroma tissue extends downward from the bladder 
neck to the lowest part of the prostate, the apex.1,2 The upper part of the prostate is 
called the base. The urethra runs through the prostate and receives the ejaculatory 
ducts from the seminal vesicles and the ducts from the glandular part of the prostate.
In the younger male population, the prostate mainly comprises the central zone and 
peripheral zone. During aging, the transition zone starts to grow and tends to 
compress the central zone. This is a non-malignant process called benign prostatic 
hyperplasia and occurs in the transition zone only. The two predominant zones in the 
older male population therefore are the peripheral zone and transition zone. 
 In cancer, cells start to grow uncontrollably and do not only compress other 
structures, but also invade and destroy other nearby tissues or organs. Eventually, it 
can metastasize to lymph nodes or other distant regions in the body. 
Fig. 1   Side view of the prostate; a) location of the prostate in the body, b) prostate zones.
Source Fig. 1a: http://www.med.unc.edu/cares/urologic-surgery/prostate-cancer-treatment-1
Source Fig. 1b: http://www.cancer.ca/en/cancer-information/cancer-type/prostate/anatomy-and-physiology/ 
?region=on
a b
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Prostate cancer
Prostate cancer develops typically in middle aged or elderly men. The majority of 
prostate cancer arises in the peripheral zone (about 70%) and the remaining portion 
in the transition zone (25%) and central zone (5%).3,4 One out of seven men will be 
diagnosed with prostate cancer.5 However, not every prostate cancer is aggressive 
and the majority of these men will die with, rather than die from prostate cancer.6
 The suspicion of prostate cancer rises when there is an elevated prostate-specific 
antigen (PSA) level in the blood or an abnormal digital rectal examination. In current 
clinical practice, this is usually followed by an ultrasound examination to evaluate the 
prostate. During this examination, schematic transrectal ultrasound (TRUS) biopsies 
will be carried out to systematically sample the prostate (Fig. 2). Subsequently, the 
pathologist evaluates this biopsy tissue under the microscope. If the diagnosis 
Fig. 2  Systematic TRUS biopsy scheme as presented by Yacoub et al in RadioGraphics, 
2012.11 (a) Coronal (left) and axial (right) schematics show the positions of the needle 
and the locations that are sampled in the prostate with the standard sextant biopsy 
technique. (b) Coronal (left) and axial (right) schematics of the modified sextant 
biopsy technique show more lateral positions of the needle at the middle level (M) of 
the prostate with this technique, than with the standard technique. (c) Coronal 
schematics show the additional prostate locations (open circles) that may be sampled 
in an extended systematic biopsy, for a total of eight, 10, or 12 specimens. Filled 
circles indicate the six locations of sampling in a standard sextant biopsy.
AFS = anterior fibromuscular stroma, CZ = central zone, ED = ejaculatory ducts, NVB = neurovascular 
bundle, PUT = periurethral tissue, PZ = peripheral zone, TZ = transition zone.
a c
b
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cancer has been set by the pathologist, the Gleason grading system will be used to 
evaluate prostatic cancer tissue for its aggressiveness7: the higher the Gleason score, 
the more aggressive the cancer (Fig. 3). 
 Different treatment approaches exist, based on the aggressiveness and the 
extent of the tumor. Therefore, accurate staging is highly important. First, because 
aggressive prostate cancer needs radical treatment with curative intent, before the 
cancer gets the ability to metastasize to the lymph nodes or bones. Second, to prevent 
overtreatment of indolent types of prostate cancer, with associated complications 
such as impotence and urinary incontinence.
 The current clinical standard for the diagnosis and staging of prostate cancer 
lacks sensitivity and specificity. PSA has a high sensitivity, but a very low specificity8: 
an elevated PSA level in the blood only indicates that ‘something’ is wrong within the 
prostate, but this could be either inflammation, benign prostatic hyperplasia or 
cancer. Digital rectal examination has a very low sensitivity: any cancer that is not 
Fig. 3  Schematic diagram of the modified Gleason grading system as presented 
by Epstein JI, Am J Surg Pathol 2005.7
501341-L-bw-Vos
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located near the posterior part of the prostate cannot be felt by the clinician. Ultimately, 
TRUS biopsies are invasive and due to its systematic character they do not only have 
a low sensitivity but also tend to underestimate the Gleason score (Fig. 3 and 4).9-11 
Aim and outline of this thesis
Magnetic Resonance Imaging (MRI) plays an upcoming role in the management of 
prostate cancer, it serves as a non-invasive tool to acquire anatomic and functional 
information about the prostate. It has been shown that MRI can detect prostate 
cancer with a high sensitivity and specificity.12-14
In this thesis we try to take MRI a step further. The purpose of this thesis is twofold: 
the first part aims to evaluate functional MRI techniques for the assessment of 
prostate cancer aggressiveness; the second part aims to explore the possibilities of 
newly developed techniques for application in prostate cancer imaging. 
Chapter 2 begins with a brief introduction into the commonly used functional 
techniques of MRI. For prostate imaging, usually a combination of different techniques 
is used. The cornerstone of prostate imaging is T2-weighted imaging that provides 
anatomical information. With additional techniques such as dynamic contrast-en-
hanced (DCE) MRI, diffusion-weighted imaging (DWI) and magnetic resonance 
spectroscopic imaging (MRSI), more detailed functional information about the 
prostate can be acquired.
Fig. 4  TRUS biopsy, as presented by the clinical information brochure “One-stop 
diagnosis of prostate cancer” from the Prostate MR center of Excellence at the 
Radboud university medical center, Nijmegen, The Netherlands. The images above 
show a cross section of the prostate. Left image: needle penetrates next to the tumor 
or does not reach it. Middle image: wrong (non-aggressive) tumor is biopsied. Right 
image: wrong part of the tumor is biopsied.
501341-L-bw-Vos
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In Chapter 3, DWI has been evaluated for its application in the transition zone. 
Apparent diffusion coefficient (ADC) values acquired by DWI are related to 
histopathology outcomes using MR-guided biopsy specimens as the reference 
standard.  
DCE-MRI is evaluated for the assessment of prostate cancer aggressiveness in 
Chapter 4. Semi-quantitative parameters and pharmacokinetic parameters are 
correlated with the Gleason score from prostatectomy specimens as the reference 
standard. 
‘The proof is in the pudding.’ In Chapter 5, all techniques are brought together in a 
multiparametric MRI (mpMRI) examination for the assessment of prostate cancer 
aggressiveness. In this part the optimal combination of functional techniques is 
evaluated with the Gleason score from prostatectomy specimens as the reference 
standard. 
Next, in Chapter 6, a newly developed endorectal coil is investigated for possible 
future application in the field of prostate imaging. Quantitative and qualitative 
properties of the investigational coil are compared with the current clinically available 
endorectal coil. 
The feasibility of prostate imaging at a pre-clinical, ultra-high magnetic field strength 
is explored in Chapter 7. With the aid of both healthy volunteers and prostate cancer 
patients, an optimal T2-weighted imaging protocol has been developed at 7 Tesla.  
Chapter 8 investigates the image quality and cancer visibility of T2-weighted imaging 
of the prostate at 7 Tesla. In total, 17 prostate cancer patients are included in this 
study. In a substudy, a comparison with 3 Tesla was performed in the same set of 
subjects.
Finally, in Chapter 9 the main findings of this thesis are discussed. All the results are 
put in perspective and recommendations for future studies are provided. 
501341-L-bw-Vos
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Magnetic resonance imaging techniques 
in prostate cancer
Multiple magnetic resonance imaging (MRI) techniques exist. For prostate imaging, 
usually a combination of anatomical imaging and functional imaging is used. In this 
thesis, we describe the following techniques: T2-weighted imaging, diffusion-weighted 
imaging (DWI), dynamic contrast-enhanced (DCE) imaging, and magnetic resonance 
spectroscopic imaging (MSRI), often combined in what is called a multiparametric 
MRI (mpMRI) examination.
T2-weighted imaging
For mpMRI of the prostate, T2-weighted imaging is the most important basic 
technique. It provides anatomical information of the prostate (Fig. 1).1 In general, the 
peripheral zone, transition zone and seminal vesicles are easy to recognize. Benign 
prostate hyperplasia in the transition zone has a cauliflower-like appearance, with 
multiple well-demarcated round or oval structures, also known as ‘organized chaos’. 
Prostate cancer in the transition zone usually fades the organized structures, and 
appears as a homogeneous gray area with poorly delimited borders. Occasionally, 
the distinction between benign prostatic hyperplasia and prostate cancer is not 
obvious.
Fig. 1  Axial  T2-weighted MR images show normal zonal anatomy of the prostate. 
Benign prostate hyperplasia is present in the transition zone. 
NVB, neurovascular bundle; PZ, peripheral zone; TZ, transition zone.
501341-L-bw-Vos
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 In the peripheral zone, differentiation between prostate cancer and benign 
conditions such as inflammation can be much more difficult on T2-weighted imaging 
alone, since it all appears as a relatively dark area within the typical bright-appearing 
peripheral zone. The addition of functional techniques in an mpMRI exam can be 
helpful for a better detection of prostate cancer in both peripheral zone and transition 
zone.2-6 
 Recently, the PI-RADS classification has been introduced to serve as a guideline for 
image acquisition and as a standardization tool for image interpretation and reporting 
guidance for both anatomical as functional imaging.7,8 The first version PI-RADS v1 
has led to some confusion regarding its application and this resulted in variable 
approaches to image interpretation. Therefore, an improved second version (PI-RADS 
v2) was introduced in December 2014.9,10 A high quality T2-weighted image remains 
the basis for evaluating an mpMRI examination. However, additional techniques remain 
necessary for the overall risk assessment of patients with suspected prostate cancer. 
Diffusion-weighted imaging
An important functional technique for prostate imaging is DWI. Diffusion describes 
the movement of water molecules due to random (or Brownian) motion (Fig. 2).11,12 
Motion of the molecules can be restricted by boundaries, such as cell membranes or 
ligaments. This happens for example in fibrous tissue, but also in benign prostatic 
Fig. 2  Schematic illustration of water molecule movement, as presented by Qayyum 
in RadioGraphics, 2009.11 In (a), schematic water molecules (not to scale) in a container 
alone move randomly (Brownian motion). In (b), highly cellular tissue impedes the 
movement of water molecules. Their movement can be categorized as intravascular, 
intracellular, or extracellular. In (c), tissue of low cellularity or with defective cells permits 
greater water molecule movement.
a
c
Damaged cell
Cell
Water
b
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hyperplasia or prostate cancer where a lot of cells are closely packed together. It 
plays an upcoming role in the work-up of prostate cancer imaging.2,7,13
Water motion can be visualized with DWI by applying a pair of pulsed magnetic field 
gradients with specific amplitude, duration and spacing, expressed in the so-called 
b-value. Protons from stationary water molecules get dephased and exactly rephased 
by the gradient pulse pair. Protons moving in the gradient direction in the time 
between the pulsed gradients will not fully restore to their original signal with the 
rephasing gradient. Therefore molecules that are restricted in their motion will give a 
high signal in the DWI image, and signal loss occurs from the molecules that have 
moved in between the applied gradients. The most commonly used parameter of 
DWI is the apparent diffusion coefficient (ADC), which is the net displacement of 
molecules. It is calculated by plotting the logarithm of the signal intensity against the 
applied b-value and the ADC value corresponds to the slope of the plotted line. The 
more freely the water molecules can move, the higher the ADC value. The other way 
around, when there is restriction of motion, the ADC value is lower and this appears 
as relatively hypointens in the ADC map.11
Dynamic contrast-enhanced imaging
DCE-MRI provides additional information about the vascularization of the prostate 
and the permeability of blood vessels by intravenous administration of a contrast 
agent. In prostate cancer, angiogenesis results in the formation of more blood vessels 
with highly permeable endothelia compared to healthy tissue. Contrast agent will leak 
out of these vessels into the surrounding tissue where it temporarily changes the 
T1-relaxation time. This information can be used to distinguish prostate cancer from 
healthy tissue.14-17
 Different approaches exist for the interpretation of the parameters derived from 
DCE-MRI. The easiest way is to qualitatively judge the shape of the contrast-related 
T1-weighted signal intensity-time curve. Curve type 1 (continuous enhancement), 
curve type 2 (enhancement with subsequent plateau phase) and curve type 3 exist, 
the latter showing rapid wash-in and fast wash-out of contrast agent, which is 
indicative for prostate cancer (Fig. 3). 
 Next to qualitative interpretation, the T1-weighted signal intensity-time curves 
can also be fitted. The use of semi-quantitative parameters is relatively straightfor-
ward, fitting parameters that provide a description of the shape of the curve. 
Commonly used semi-quantitative parameters fitted to signal intensity-time curves 
are wash-in (upward slope of the first part of the curve), time-to-peak (time from the 
start of enhancement until the maximum enhancement), maximum signal-intensity, 
wash-out (slope of the second part of the curve after the first peak of enhancement) 
and area under the curve.17,18
501341-L-bw-Vos
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 The most challenging approach is to translate the signal intensity-time curves 
into a contrast agent concentration in the tissue, and to quantify the contrast leakage 
into the tissue by pharmacokinetic modeling. A frequently used model has been 
introduced about a decade ago by Tofts et al.19 The three main parameters described 
in this study are Ktrans (transfer constant), Kep (rate constant) and ve (extravascular 
extracellular space). For this, the prostate has been simplified as a two-compartment 
model, with the intravascular space as one compartment, the interstitial space as the 
second compartment and permeability as the limiting step for contrast exchange 
between different compartments within the prostate. Other models have been 
introduced in the literature20,21, but this is beyond the scope of this thesis. 
Magnetic Resonance Spectroscopic Imaging
MRSI gives insight in the presence of metabolite pools in prostatic tissue. The 
technique reflects the protons that resonate at a specific frequency, unique for a 
certain metabolite. The different metabolites are displayed in a spectrum with peaks 
present at their corresponding chemical shift values in parts per million (ppm) relative 
to a reference frequency.22,23
 Typically, metabolites that are of interest in prostate imaging are citrate (protons 
resonating at approximately 2.60 ppm), creatine (approximately 3.04 ppm) and 
choline (approximately 3.20 ppm).24,25 Also polyamine signals from spermine 
(approximately 3.15 ppm) can become visible in between the creatine peak and the 
choline peak, although these three peaks are usually difficult to distinguish because 
of quite substantial spectral overlap in this region. The healthy prostate contains a 
high amount of citrate that is found in glandular tissue of the peripheral zone and in 
lesser extent in the transition zone. In prostate cancer the citrate decreases and total 
choline levels increase, possibly because of increased cell density and extensive cell 
Fig. 3  Curve types representing enhancement patterns, as presented by Johnson in 
Nat Rev Clin Oncol, 2014.6
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proliferation. The changes in metabolites can be displayed by a ratio of the different 
fitted signal integrals (Fig. 4). Commonly used ratios are the choline + spermine + 
creatine over citrate (CSC/C) ratio and the choline over spermine + creatine (C/SC) 
ratio. Both ratios are increased in prostate cancer compared to healthy prostatic 
tissue.26,27 
Fig. 4  MRSI in prostate cancer as presented by Kobus in NMR in Biomed, 2014.22 
(a) T2-weighted image of the prostate, with prostate cancer in the left transition zone. 
(b) Spectrum of normal peripheral zone tissue [left sphere in (a)] containing choline 
(Cho), creatine (Cr), spermine (Spm) and citrate (Cit) resonances. (c) Spectrum of 
tumour tissue [right sphere in (a)] showing increased Cho and decreased Cit levels 
compared with (b). (d) Corresponding slice of the excised prostate indicating the 
tumour. Hematoxylin and eosin-stained normal tissue (e) and tumour tissue (e) of the 
patient.
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Abstract
Objectives
The objective of this study was to evaluate the apparent diffusion coefficient (ADC) of 
diffusion-weighted magnetic resonance (MR) imaging for the differentiation of transition 
zone cancer from non-cancerous transition zone with and without prostatitis and for 
the differentiation of transition zone cancer Gleason grade (GG) using MR-guided 
biopsy specimens as a reference standard.
Materials and methods
From consecutive MR-guided prostate biopsies (2008 – 2012) in our referral center, 
we retrospectively included patients from whom diffusion-weighted MR imaging ADC 
values were acquired during MR-guided biopsy and whose biopsy cores had a 
(cancer) core length 10 mm or greater and originated from the transition zone. Two 
radiologists, who were blinded to the ADC data, annotated regions of interest on 
biopsy sampling locations of MR-guided biopsy confirmation scans in consensus. 
Median ADC (mADC) of the regions of interest was related to histopathology outcome 
in MR-guided biopsy core specimens. Mixed model analysis was used to evaluate 
mADC differences between 7 histopathology categories predefined as MR-guided 
biopsy core specimens with primary and secondary GG 4-5 (I), primary GG 4-5 
secondary GG 2-3 (II), primary GG 2-3 secondary GG 4-5 (III) and primary and 
secondary GG 2-3 cancer (IV), and non-cancerous tissue without (V) or with degree 
1 (VI) or degree 2 prostatitis (VII). Diagnostic accuracy was evaluated using areas 
under the receiver operating characteristic (AUC) curve.
Results
Fifty-two patients with 87 cancer-containing biopsy cores and 53 patients with 101 
non-cancerous biopsy cores were included. Significant mean mADC differences 
were present between cancers (mADC, 0.77-0.86 x 10-3 mm2/s) and non-cancerous 
transition zone without (1.12 x 10-3 mm2/s) and with degree 1 to 2 prostatitis (1.05-1.12 
x 10-3 mm2/s; p < 0.0001-0.05). Exceptions were mixed primary and secondary GG 
cancers versus a degree 2 of prostatitis (p = 0.06-0.09). No significant differences were 
found between subcategories of primary and secondary GG cancers (p = 0.17-0.91) 
and between a degree 1 and 2 prostatitis and non-cancerous transition zone without 
prostatitis (p = 0.48-0.94).
 The mADC had an AUC of 0.84 to differentiate cancer versus non-cancerous 
transition zone. AUCs of 0.84 and 0.56 were found for mADC to differentiate prostatitis 
from cancer and from non-cancerous transition zone. The mADC had an AUC of 0.62 
to differentiate a primary GG 4 versus GG 3 cancer.
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Conclusions
The mADC values can differentiate transition zone cancer from non-cancerous 
transition zone and from a degree 1, and from most cases of a degree 2 prostatitis. 
However, because of substantial overlap, mADC has a moderate accuracy to 
differentiate between different primary and secondary GG subcategories and cannot 
be used to differentiate non-cancerous transition zone from degrees 1 to 2 prostatitis. 
Diffusion-weighted imaging ADC may therefore contribute in the detection of transition 
zone cancers; however, as a single functional MR imaging technique, diffusion- 
weighted imaging has a moderate diagnostic accuracy in separating higher from 
lower GG transition zone cancers and in differentiating prostatitis from non-cancerous 
transition zone.
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Introduction
Prostate cancer is the second most frequently diagnosed cancer in men worldwide.1 
Based on radical prostatectomy and saturation biopsy specimens, at least 30% to 
45% of diagnosed cancers are situated in the prostate transition zone.2,3 In patients 
with an elevated prostate-specific antigen (PSA) and cancer-negative transrectal 
ultra sound-guided biopsies, high proportions of transition zone cancer (57% – 63%) 
are detected upon magnetic resonance (MR)-guided biopsy.4,5
 The latter finding reflects that many transition zone cancers are missed by 
transrectal ultrasound-guided biopsy, probably because of undersampling of the 
ventral prostate transition zone. Performing MR imaging6 and MR-guided biopsy in 
patients with an elevated PSA and negative transrectal ultrasound-guided biopsies 
may therefore improve detection of transition zone prostate cancer. However, upon 
MR imaging of the prostate transition zone, differentiation of prostate cancer from 
healthy tissue is difficult because of the overlap of signal intensities and quantitative 
parameters between prostate cancer and stromal benign prostatic hyperplasia.7,8
 Prostate cancer should also be differentiated from prostatitis, which is often 
present also in the transition zone.9 In prostatitis, inflammatory infiltrates may increase 
cellular density and may therefore decrease T2-weighted MR imaging signal intensity 
and diffusion-weighted MR imaging apparent diffusion coefficient (ADC) values. For 
the peripheral zone, prostatitis can be differentiated from healthy tissue and from 
low-Gleason grade (GG) cancer; however, for the transition zone, differentiation of 
prostatitis from a high-GG cancer and from healthy tissue has not been described 
earlier.10
 Once a transition zone cancer is detected on MR imaging, accurate determination 
of its Gleason score is important because transition zone cancers are known to have 
lower Gleason scores and lower biochemical recurrence rates.11 Lower diffusion- 
weighted imaging ADC values have been related to higher prostate cancer Gleason 
scores, predominantly for peripheral zone cancers.12,13 Most of these studies have 
been performed using radical prostatectomy specimens as a reference standard. 
However, exact alignment of MR imaging slices with prostatectomy specimen 
sections remains difficult because of differences in angulations of imaging slicing 
and specimen sectioning and because of prostate shrinkage during histopathology 
processing. Furthermore, observer bias is almost unavoidable in attributing a certain 
region of interest (ROI) on MR imaging to a tumor, which is identified in a prostatectomy 
specimen section.14 Recently, size and positioning of an ROI were shown to influence 
tumor ADC measurements and interobserver variability in rectal cancer.15
 Magnetic resonance-guided biopsy specimens may be a reference-standard 
alternative for radical prostatectomy specimens because the highest GG of an 
MR-guided biopsy specimen has a high concordance (88%) with the highest GG of 
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the radical prostatectomy specimen.16 This high concordance rate is caused by the 
ability of multiparametric MR imaging and especially of diffusion-weighted MR 
imaging to predict and localize the cancer areas with the highest GG.17 When using 
MR-guided biopsy as a reference standard, T2*-weighted gradient echo images, 
which confirm needle positioning, are available.5 Locations where prostate cancer 
biopsy specimens were sampled can be determined from signal voids of the biopsy 
needle on these MR-guided biopsy confirmation scans. Because annotation of 
biopsy sampling areas on confirmation scans is unrelated to the ADC map, it may 
reduce observer bias in relating ADC values to MR-guided biopsy histopathology.
 Therefore, our purpose was to evaluate the ADC of diffusion-weighted MR 
imaging for the differentiation of transition zone with and without prostatitis and for the 
differentiation of transition zone cancer GGs using MR-guided biopsy specimens as 
a reference standard. 
Materials and methods
Patients
The need for informed consent for this retrospective study was waived by the 
institutional review board. From all consecutively performed MR-guided biopsies 
between March 2008 and February 2012 in our referral center, we included patients 
using the following inclusion criteria:
- Performed diffusion-weighted imaging and ADC maps as part of the MR-guided 
biopsy procedure.
- Magnetic resonance-guided biopsy cores with prostate cancer in a cancer core 
length of 10 mm or greater and a transition zone location on MR-guided biopsy 
confirmation scans. A cancer core length of 10 mm or greater is 60% of a 
standard needle notch length of 17 mm and was chosen to limit variation because 
of mADC measurements in non-cancerous tissue. By choosing this limit, at least 
60% of the annotated ROI was related to prostate cancer. 
- Magnetic resonance-guided biopsy cores without prostate cancer with a core 
length of 10 mm or greater and a transition zone location of the needle sample 
on MR-guided biopsy confirmation scans. 
The exclusion criteria were an existing diagnosis of prostate cancer before the 
MR-guided biopsy (n = 50) or unavailable biopsy histopathology specimens from 
external hospitals (n = 5). Also, needle positions for which MR-guided biopsy core 
identification was impossible were excluded. The latter was caused by simultaneous 
unspecified sampling of more cores referred for histopathology analysis as 1 sample 
unit (n = 22) or caused by a lack of MR-guided biopsy confirmation scans with 
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needle artifacts (n = 1) or caused by impossible accurate registration of the ADC 
map to the confirmation scans (n = 1). Patient selection is depicted in a flow diagram 
in Figure 1. 
Magnetic Resonance Imaging and MR-Guided Biopsy Acquisition
Two 3-T whole-body systems (MAGNETOM Trio and MAGNETOM Skyra; Siemens 
Medical Solutions, Erlangen, Germany) were used to perform MR imaging and 
MR-guided biopsy. An MR-compatible manual biopsy device, an endorectal needle 
guider, and an 18-gauge biopsy gun (all from Invivo, Gainesville, FL) were used to 
perform the MR-guided biopsy. To detect prostate cancer, MR-guided biopsies were 
performed on the basis of the results of a previously performed multiparametric MR 
imaging examination, consisting of T2-weighted, diffusion-weighted and dynamic 
contrast-enhanced MR imaging.5 The multiparametric MR imaging and MR-guided 
biopsy sequence parameters are depicted in Table 1. Two radiologists with 10 and 19 
years of experience in prostate MR imaging (J.J.F. and J.O.B.) evaluated the initial MR 
images on a clinical software workstation while having access to patient data.18 
Cancer suspicious regions were defined as described earlier.19
 The patients received antibiotic prophylaxis of 2 daily doses of 500 mg 
ciprofloxacin orally for 3 days and the biopsy was performed on the second day. 
Biopsies were performed by 1 radiologist with 3 years (C.M.A.H.), 1 radiologist with 2 
years (J.G.R.B.), and 1 radiologist (E.K.V.) with 1 year of experience in MR-guided 
biopsy.19 Initially, T2-weighted MR imaging and diffusion-weighted imaging were 
performed for the re-identification of previously defined cancer suspicious regions. 
Consequently, sagittal and axial balanced gradient echo sequences were acquired 
during the repositioning of an endorectally inserted needle guide towards a can-
cer-suspicious region. When the needle guide was accurately targeted at a can-
cer-suspicious region, biopsies were taken by insertion of the 18-gauge needle 
biopsy gun through the needle guide. Directly after the MR-guided biopsy with the 
needle situated in the prostate, gradient echo sequences were repeated to confirm 
the position of the (sampling part of the) needle in a cancer-suspicious region. 
Acquisition times for the axial and sagittal confirmation scans for MAGNETOM Trio 
and Skyra were 8.9 and 9.0 seconds for the axial scans and 7.5 and 7.6 seconds for 
the sagittal scans, respectively.
Histopathology
Biopsy core specimens were directly fixated in formalin. The cores were fixated and 
analyzed separately. All cores were histopathologically re-evaluated by 1 experienced 
urogenital pathologist with 20 years of experience (C.A.H.), who was blinded to the 
MR imaging results. Gleason grade was evaluated using the 2005 International 
Society of Urological Pathology-modified Gleason grading criteria.20 Prostatitis was 
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defined as the presence of inflammatory infiltrates in the prostate.21 A degree 1 (mild), 
2 (moderate) and 3 (severe) prostatitis were respectively defined as follows: an 
MR-guided prostate biopsy specimen core tissue area involvement of 1 lower than 
10% by inflammatory cell infiltrates consisting of individual cells, separated by distinct 
intervening spaces (< 100 cells/mm2), 2 10% to 50% consisting of confluent sheets of 
inflammatory cells with no tissue destruction of lymphoid nodule or follicle formation 
(100-500 cells/mm2), 3 greater than 50% consisting of confluent sheets of inflammatory 
Fig. 1  Study flow-diagram. 
ADC indicates apparent diffusion coefficient in diffusion weighted MR imaging; DWI, diffusion-weighted MR 
imaging; MRGB, MR guided prostate biopsy; n, number of patients; PSA, prostate specific antigen.
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cells with tissue destruction or nodule/follicle formation (> 500 cells/mm2).21 Differen-
tiation was made between chronic, chronic active, and granulomatous prostatitis.21
Annotation of MR-Guided Biopsy Confirmation Scans
Magnetic resonance-guided biopsy confirmation scans were analyzed with an 
in-house–developed software.18 Two radiologists (one with 3 years [C.M.A.H.] and 
one with 1 year [E.K.V.] of experience in prostate MR imaging) annotated ROIs in 
consensus while they were blinded for histopathology results. In case of prostate 
displacement during the MR-guided biopsy procedure, the ADC maps were manually 
registered with the post-biopsy confirmation scans to correct for this displacement. 
Slices that most optimally represented the middle of the needle artifact were identified 
on both the sagittal and the transversal post-biopsy T2-weighted balanced gradient 
echo images. Subsequently, the presumed in vivo needle track of 22 mm was 
measured from the visible needle tip inside the signal void, taking into account a 
signal void of the needle artifact (2-3 mm) in front of the needle trajectory. The last 17 
mm of this 22 mm represented the needle notch, where the tissue core was obtained. 
This last 17 mm area was annotated on the transverse T2-weighted balanced gradient 
echo image. The notch length of 17 mm was annotated with overlapping ROIs (4.0 x 
4.0 x 4.0 mm) matching the visible needle within the artifact signal void. An example 
of our annotation method is depicted in Figure 2. The radiologists annotated all cores 
over entire core length (17 mm) in all patients. In patients in whom the core sample 
involved extraprostatic tissue, only the core parts situated in the prostate were 
annotated. All ROIs of 1 notch length represented 1 core and were analyzed as a unit. 
For every annotated core, the mean, the SD and the median ADC (mADC) were 
calculated by the software using the ADC values from all annotated ROIs in the core. 
Statistics
The analyses were performed using Predictive Analytics SoftWare (PASW) Statistics 
version 18 (SPSS, Inc, Quarry Bay, Hong Kong). The threshold for significance was 
defined as P < 0.05. Differences in patient characteristics were evaluated using 
independent t tests for parametric continuous variables and the Mann-Whitney test 
for non-parametric continuous variables. 
 The ROI ADC was related to the histopathology outcome in MR-guided biopsy 
specimens, which served as a reference standard. Linear multilevel mixed model 
analysis was used to evaluate mADC differences for 7 histopathology categories, 
defined as MR-guided biopsy core specimens with a primary and secondary GG 4-5 
(I), primary GG 4-5 secondary GG 2-3 (II), a primary GG 2-3 secondary GG 4-5 (III) 
and primary and secondary GG 2-3 cancer (IV), and non-cancerous transition zone 
tissue without (V) of with degree 1 (VI) or degree 2 prostatitis (VII). To correct for 
possible correlations between different cores coming from 1 patient, patients were 
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Fig. 2  A to C, Illustration of the annotation of an MR-guided biopsy core on a 
T2-weighted balanced gradient echo confirmation scan. Note the appearance of the 
inserted needle with a signal void around it, exaggerating the true size of the needle 
(diameter, 1.27 mm). The needle is visible within this signal void. A, Measurement of 
the needle pathway of 22 mm in the needle artifact on a transversal T2-weighted 
balanced gradient echo confirmation scan (repetition time [TR], 4.48 milliseconds; 
echo time [TE], 2.24 milliseconds). B, Annotation of the core length (the last 17 mm of 
the 22 mm as depicted in A with ROIs on a transversal T2-weighted balanced gradient 
echo confirmation scan (TR, 4.48 milliseconds; TE, 2.24 milliseconds). This anatomical 
scan was used to reconfirm correct positioning of the whole needle sampling part 
within the prostate transition zone. C, Completed annotation of an MR-guided biopsy 
core. Regions of interest are appended in 1 unit for analysis. The location of the annotated 
core (IV) can be seen in the baseline diffusion-weighted image (TR, 3300 milliseconds; 
TE, 60 milliseconds) (I), baseline T2-weighted image (TR, 3620 milliseconds; TE, 103 
milliseconds) (II), and the corresponding sagittal T2-weighted balanced gradient 
echo confirmation scan (TR, 4.48 milliseconds; TE, 2.24 milliseconds) (III).
A
C
B
501341-L-bw-Vos
47
DWI IN THE TRANSITION ZONE
3
used as a random factor in this model. Because non-cancerous parts in cancer-con-
taining cores may have caused mADC variation, we compared mADC for cancer 
core lengths of respectively 10 to 12, 13 to 15, and greater than 15 mm.
 Receiver operating characteristic (ROC) analyses were performed to evaluate 
diagnostic accuracy for mADC to differentiate between predefined histopathological 
categories. 
Results
 
We included 87 MR-guided biopsy cores containing transition zone cancer in 52 
patients and 101 non-cancerous transition zone cores in another 53 patients. Patient 
characteristics are depicted in Table 2. For every patient, MR-guided biopsy cores 
were taken from 1 cancer-suspicious region. A patient example is depicted in Figure 3. 
 Of the 87 cancer-containing cores, 27 cores had a primary and secondary GG 
4-5, 12 cores had a primary GG 4-5 and a secondary 2-3, 24 cores had a primary GG 
2-3 and a secondary GG 4-5, and another 24 cores had both primary and secondary 
GG 2-3. Of the 101 non-cancerous transition zone cores, 46 cores existed out of 
healthy transition zone tissue without prostatitis, 50 cores contained a degree 1 
prostatitis (of which 88% [44/50] were of a chronic type and 12% [6/50] were of a 
chronic active type), and 5 cores involved prostatitis up to a degree of 2 (2 of the 
chronic and 3 of the chronic active type). Because the subtotals of cores with a 
chronic (active) type of prostatitis were very small, no further analyses were performed 
to differentiate between the chronic and chronic active types of prostatitis. 
 Upon linear mixed model analysis, significant mADC differences were present 
between transition zone cancers (mean mADC, 0.77-0.86 x 10-3 mm2/s) and 
non-cancerous transition zone without (1.12 x 10-3 mm2/s) and with degrees 1 to 2 
prostatitis (1.05-1.12 x 10-3 mm2/s); p < 0.0001-0.05). The exceptions were transition 
zone cancers with a primary GG 4-5 and a secondary GG 2-3 or a primary GG 2-3 
and a secondary GG 4-5 versus a degree 2 of prostatitis (p = 0.06-0.09). No 
significant differences were found between subcategories of transition zone cancer 
primary and secondary GG (p = 0.17-0.91) and between healthy transition zone 
without prostatitis versus both degree 1 and 2 prostatitis (p = 0.48-0.94). In Figure 4, 
boxplots of mADC values for MR guided biopsy specimen histopathological 
categories are presented. Comparing the cores with a Gleason score 3+3 (n = 14) 
versus a Gleason score 4+4 (n = 6) only, the mean ADC values were 0.85 x 10-3 
mm2/s (95% confidence interval [CI], 0.70-0.99 x 10-3 mm2/s) and 0.79 x 10-3 mm2/s 
(CI 0.57-1.01 x 10-3 mm2/s), respectively (p = 0.66). Because only 1 core had a single 
GG 5 pattern, this core was left out of the analysis. For cancer-containing cores, a 
scatterplot depicting mADC values for different Gleason scores is shown in Figure 5. 
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Fig. 3  Projection of annotated cores on the MR-guided biopsy ADC maps. A 63-year-old 
man with a PSA of 20 ng/mL and 1 previous negative transrectal ultrasound biopsy 
session. During the MR-guided biopsy, a GG 3+5 prostate cancer was detected in 
100 volume percent of the depicted core. A, The annotated MR-guided biopsy core 
on a transversal T2-weighted balanced gradient echo confirmation scan (TR, 4.48 
milliseconds; TE, 2.24 milliseconds). B, Gradient echo image (A) fused with the diffu-
sion-weighted imaging ADC map in color. The diffusion-weighted imaging ADC 
values within the annotated MR-guided biopsy core (black demarcations) are visible. 
In the middle of the core, the ADC was 0.4 x 103 mm2/s, whereas, at both core ends, 
the ADC was 0.7-0.9 x 10-3 mm2/s. The color scale of the ADC map on image B and 
C was as follows: red-pink, 0.135 x 10-3 mm2/s or less; dark blue, 0.852 x 10-3 mm2/s 
or less; light blue, 1.330 x 10-3 mm2/s or less; and green-yellow 1.750 x 10-3 mm2/s or 
less. C, The same annotated MR-guided biopsy core (black demarcations) over a 
sagittal projection of the diffusion-weighted imaging ADC map. D, Hematoxylin and 
eosin-stained tissue section of the prostate biopsy core with indications of GG at 
scanning magnification of x10. This core is corresponding to the core in A to C. I to III, 
Higher magnifications of the different areas indicated by the boxes (x20). The lower 
ADC value in the middle of the core agrees with a primary GG 5 situated in between 
lower GGs.
A
D
B C
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Taking into account the MR-guided biopsy cancer core length, no significant mADC 
differences were present for cancer core lengths of, respectively, 10 – ≤12, >12 – ≤15 
and greater than 15 mm for patients with primary GG 3 (p = 0.22-0.87), 4 (p = 0.05- 
0.85), and 5 cancers (p = 0.70-0.91). 
 Receiver operating characteristic analysis for mADC to differentiate transition 
zone cancer cores (n = 87) from non-cancerous transition zone cores (n = 46) 
resulted in an AUC of 0.84 (95% CI, 0.77-0.91). For the differentiation between the 
cancerous (n = 87) and non-cancerous cores with prostatitis (n = 55), the AUC also 
was 0.84 (0.77-0.90). The AUC for differentiating the non-cancerous cores with any 
degree of prostatitis (n = 55) versus the non-cancerous cores without (n = 46) 
prostatitis was 0.56 (0.44-0.67). The mADC had an AUC of 0.62 (0.49-0.74) for the 
differentiation of primary GG 4-5 (n = 39) from GG 2-3 (n = 48) cancers. 
Discussion
Our results show that mADC values can differentiate the transition zone cancer from 
the non-cancerous transition zone (AUC 0.84) and from any degree of prostatitis 
(AUC 0.84). However, because of substantial overlap, mADC has a poor accuracy to 
distinguish primary GG 4-5 from GG 2-3 transition zone cancers (AUC 0.62) and 
cannot be used to differentiate between non-cancerous transition zone with and 
without prostatitis (AUC 0.56). 
Fig. 5  Scatterplot of median ADC values in annotated ROIs on MRGB needle artifacts 
versus MRGB core specimen Gleason scores. ADC indicates apparent diffusion 
coefficient; MRGB, MR guided biopsy; ROI, region of interest.
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 Our significant mADC differences for transition zone cancer versus non-cancerous 
transition zone confirm findings in other studies.8,13,22,23 The ADC for transition zone 
cancer in these studies varied between 0.61-1.13 x 10-3 mm2/s versus the ADC values 
for non-cancerous transition zone of 1.08-1.73 x 10-3 mm2/s. In so far as the ADC 
values can be compared for diffusion-weighted MR imaging sequences with different 
b-values, our mean mADC values for both cancer (0.77-0.86 x 10-3 mm2/s) and for 
non-cancerous transition zone tissue (1.12 x 10-3 mm2/s) were in the lower range of 
these reported values. As we targeted cancer-suspicious regions using MR-guided 
biopsy specimens as a reference standard, our ADC values may have been in the 
lower ranges of the former radical prostatectomy-referenced studies. 
 To our knowledge, one other study also used MR-guided biopsy specimens as 
a reference standard for diffusion-weighted imaging ADC.10 Our significant mADC 
differences between degrees 1 and 2 of prostatitis and most transition zone cancers 
confirmed the results of the latter study, in which a significant ADC difference between 
prostatitis and low-GG transition zone cancer was found (p < 0.001).10
 Inflammatory infiltrates in prostatitis lead to an increased cellular density an may 
therefore decrease ADC.21 In a healthy transition zone, a large ADC variation may be 
present because of higher variability of the different tissue components with different 
cellular densities. Stromal benign prostatic hyperplasia has a more compact and 
more homogeneous cell density and is known to have lower ADC values (1.27 x 10-3 
mm2/s) compared with glandular benign prostatic hyperplasia (1.73 x 10-3 mm2/s).8 
Therefore, a relative local ADC decrease due to focal chronic prostatitis may not be 
discerned in the transition zone. The higher the degree of the prostatitis is, the lower 
the mADC is, as is depicted in Figure 4. Despite only including 5 cores with a degree 
2 of prostatitis, we showed that, because of a lower ADC in a higher degree of 
prostatitis, a significant mADC difference between the magnetic resonance-guided 
prostate biopsy (MRGB) specimen cores with degree 2 prostatitis (mADC, 1.12 x 10-3 
mm2/s) versus the primary GG 4-5 and secondary GG 2-3 transition zone cancers 
and vice versa (histopathological categories II and III) did not exist (p = 0.06-0.09). 
This significant mADC difference did exist for cores with a degree 1 prostatitis (mADC, 
1.05 x 10-3 mm2/s), which had a higher ADC compared with any transition zone cancer 
(p < 0.0001).
 Our mean mADCs for primary GG 2-3 and 4-5 cancer-containing cores (mean 
[SD], 0.84-0.85 x 10-3 mm2/s and 0.77-0.86 x 10-3 mm2/s, respectively) differ from the 
ADC values reported for primary GG 2-3 versus 4-5 cancers upon the radical 
prostatectomy by Kobus et al.13 (respectively, minimum 25th percentiles of 0.51-0.95 x 
10-3 mm2/s and 0.61 x 10-3 mm2/s) and by Kitajima et al.22 (respectively, mean ADC of 
1.12-1.21 x 10-3 mm2/s and 0.64-1.01 x 10-3 mm2/s). Kobus et al.13 reported minimum 
25th percentiles, which are lower compared with our mean 50th percentiles, whereas 
Kitajima et al.22 reported mean ADC values, which may be higher compared with our 
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median values. Next to differences in image to histopathology correlation between 
studies, these ADC differences may have been caused by the application of b-values 
of 50, 500, and 800 s/mm2 in our study.22
 Our ADC value of 0.84 for discriminating transition zone cancer from non- 
cancerous transition zone tissue agrees with the results reported by Kitajima et al.22 
(0.87-0.89) and by Oto et al.18 (0.78-0.99). To our knowledge, our study is the first to 
report AUC values for mADC differentiation of prostatitis from the transition zone 
cancer (0.84) and from the non-cancerous transition zone (0.56).
 Our moderate AUC value for differentiation of a primary GG 4-5 versus a GG 2-3 
in MR-guided biopsy cores acquired in the transition zone (0.62) is comparable with 
AUC values of 0.61 to 0.62 found by Verma et al.12 for differentiation of a radical 
prostatectomy specimen Gleason score higher than 6 versus 6 or lower in the 
transition zone using both mean ADC and tumor volume. Our moderate accuracy in 
differentiating primary GG 4 from GG 3 cancer cores was caused by mADC overlap 
between the GGs, which, itself, may have been the result of mADC variations. mADC 
variations may have been caused by the inclusion of a secondary GG core tissue and by 
inter-patient and intra-patient mADC variations.24 Variation of the amount of non- 
cancerous tissue in the cancer-containing cores did not cause significant mADC 
differences when we analyzed mADC for the primary GG 3 and 4 transition zone 
cancer cores with a cancer core length of 10 – ≤12, >12 – ≤15, and >15 mm (p = 0.22-0.87). 
 This study has limitations. First, our results are subject to selection bias. Because 
we used a cancer core length of 10 mm and greater, we excluded smaller cancers 
from our retrospective analysis. However, because MR-guided biopsy is performed 
in a larger patient group compared with patients undergoing surgery, still, less patient 
selection bias is present compared with radical prostatectomy specimens. Second, 
as mentioned, including secondary GG tissue that was different from the primary GG 
may have reduced accuracy of our differentiation of primary GG 4 from primary GG 
3 cancers. Although present in a smaller volume compared with the primary GG, the 
presence of a different secondary GG causes variation and overlap in ADCs for 
primary GG. As mentioned earlier, our results clearly showed a larger ADC difference 
and less overlap for a secondary GG, which was identical to the primary GG compared 
with a secondary GG, which was different from the primary GG. Furthermore, 
inaccuracies in our measurements may have been caused by possible needle, 
prostate, or patient movement in the short time gap between the actual biopsy and 
the acquisition of confirmation scans.25 Despite our manual registration of confirmation 
scans to the diffusion-weighted imaging ADC maps, some variation in measurements 
due to patient movement throughout the whole MR-guided biopsy procedure may 
still have occurred. Third, we took into account a larger apparent size of the needle tip 
artifact on the MR images compared with the actual needle size. However, we did not 
adjust this measure for the angle of needle insertion with the static field (B0) of the MR 
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scanner, which may influence the apparent needle size.26 Fourth, because our 
reference standard MR-guided biopsy was based on targeting MR imaging cancer- 
suspicious regions, selection bias may have occurred. Cancer-suspicious regions 
may have a relatively higher cell density, resulting in lower ADC values compared with 
the whole transition zone.
 To clinically apply our detected mADC differences for different histopathology 
entities in the transition zone, variation of ADC values should be reduced. In a recent 
study, correction for inter-patient variation of healthy peripheral zone ADC significantly 
improved (p = 0.04; AUC, 0.91-0.96) differentiation of GG 4 and/or 5 versus GG 2 
and/or 3 cancers.27 This principle may also be applied for cancers located in the 
transition zone. 
In conclusion, mADC values can differentiate the transition zone cancer from the 
non-cancerous transition zone and from degree 1 and, sometimes, from degree 2 
prostatitis. However, because of mADC overlap between the histopathology categories, 
mADC had a poor accuracy to distinguish between different subcategories of transition 
zone cancer primary and secondary GG and cannot be used for differentiation 
between non-cancerous transition zone with and without prostatitis. Diffusion-weighted 
MR imaging ADC may therefore contribute in the detection of transition zone cancers, 
but as a single functional MR imaging technique, diffusion-weighted MR imaging has 
a moderate diagnostic accuracy in separating higher versus lower GG components 
in transition zone cancers and in differentiating prostatitis from non-cancerous 
transition zone. 
501341-L-bw-Vos
55
DWI IN THE TRANSITION ZONE
3
Reference list
1.  Ferlay J. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127: 
2893-2917.
2.  McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation 
with histologic pattern and direction of spread. Am J Surg Pathol. 1988; 12: 897-906.
3.  Patel V, Merrick GS, Allen ZA, et al. The incidence of transition zone prostate cancer diagnosed by 
transperineal template-guided mapping biopsy: implications for treatment planning. Urology. 2011; 77: 
1148-1152.
4.  Hambrock T, Somford DM, Hoeks C, et al. Magnetic resonance imaging guided prostate biopsy in men 
with repeat negative biopsies and increased prostate specific antigen. J Urol. 2010; 183: 520-527.
5.  Hoeks CM, Schouten MG, Bomers JG, et al. Three-tesla magnetic resonance-guided prostate biopsy in 
men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal 
ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol. 2012; 62: 902-909.
6.  Scheenen TW, Fütterer J, Weiland E, et al. Discriminating cancer from noncancer tissue in the prostate 
by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter 
validation study. Invest Radiol. 2010; 45: 121-125.
7.  Akin O, Sala E, Moskowitz CS, et al. Transition zone prostate cancers: features, detection, localization, 
and staging at endorectal MR imaging. Radiology. 2006; 239: 784-792.
8.  Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign 
prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. 
Radiology. 2010; 257: 715-723.
9.  Delongchamps NB, de la Roza H, Chanan V, et al. Evaluation of prostatitis in autopsied prostates – is 
chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol. 2008; 179: 
1736-1740.
10.  Nagel K, Schouten MG, Hambrock T, et al. Differentiation of prostatitis and prostate cancer using 
diffusion weighted imaging and MR guided biopsy at 3T. Radiology. 2013; 267: 164-72.
11.  Augustin H, Erbersdobler A, Hammerer PG, et al. Prostate cancers in the transition zone: part 2; clinical 
aspects. BJU Int. 2004; 94: 1226-1229.
12.  Verma S, Rajesh A, Morales H, et al. Assessment of aggressiveness of prostate cancer: correlation of 
apparent diffusion coefficient with histologic grade after radical prostatectomy. AJR Am J Roentgenol. 
2011; 196: 374-381.
13.  Kobus T, Vos PC, Hambrock T, et al. Prostate cancer aggressiveness: in vivo assessment of MR 
spectroscopy and diffusion-weighted imaging at 3 T. Radiology. 2012; 265: 457-467.
14.  Selnaes KM, Heerschap A, Jensen LR, et al. Peripheral zone prostate cancer localization by multipara-
metric magnetic resonance at 3T: unbiased cancer identification by matching to histopathology. Invest 
Radiol. 2012; 47: 624-633.
15.  Lambregts DM, Beets GL, Maas M, et al. Tumour ADC measurements in rectal cancer: effect of ROI 
methods on ADC values and interobserver variability. Eur Radiol. 2011; 21: 2567-2574.
16.  Hambrock T, Hoeks C, Hulsbergen-van de Kaa CA, et al. Prospective assessment of prostate cancer 
aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a 
systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol. 2012; 61: 177-184.
17.  Somford DM, Hambrock T, Hulsbergen van de Kaa CA, et al. Initial experience with identifying high-grade 
prostate cancer using diffusion-weighted MR imaging (DWI) in patients with a Gleason score ≤3+3=6 
upon schematic TRUS-guided biopsy: a radical prostatectomy correlated series. Invest Radiol. 2012; 47: 
153-158.
18.  Vos PC, Hambrock T, Hulsbergen-van de Kaa CA, et al. Computerized analysis of prostate lesions in the 
peripheral zone using dynamic contrast enhanced MRI. Med Phys. 2008; 35: 888-899.
19.  Hambrock T, Fütterer JJ, Huisman HJ, et al. Thirty-two-channel coil 3T magnetic resonance-guided 
biopsies of prostate tumor suspicious regions identified on multimodality 3T magnetic resonance 
imaging: technique and feasibility. Invest Radiol. 2008; 43: 686-694.
501341-L-bw-Vos
56
CHAPTER 3
20.  Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology 
(ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29: 
1228-1242.
21.  Nickel JC, True LD, Krieger JN, et al. Consensus development of a histopathological classification 
system for chronic prostatic inflammation. BJU Int. 2001; 87: 797-805.
22.  Kitajima K, Takahashi S, Ueno Y, et al. Clinical utility of apparent diffusion coefficient values obtained 
using high b-value when diagnosing prostate cancer using 3 tesla MRI: comparison between ultra-high 
b-value (2000 s/mm2) and standard high b-value (1000 s/mm2). J Magn Reson Imaging. 2012; 36: 
198-205.
23.  Yoshizako T, Wada A, Hayashi T, et al. Usefulness of diffusion-weighted imaging and dynamic contrast- 
enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer. Acta Radiol. 
2008; 49: 1207-1213.
24.  Hosseinzadeh K, Schwarz SD. Endorectal diffusion-weighted imaging in prostate cancer to differentiate 
malignant and benign peripheral zone tissue. J Magn Reson Imaging. 2004; 20: 654-661.
25.  Pondman KM, Fütterer JJ, ten Haken B, et al. MR-guided biopsy of the prostate: an overview of 
techniques and a systematic review. Eur Urol. 2008; 54: 517-527.
26.  Schouten MG, Ansems J, Renema WK, et al. The accuracy and safety aspects of a novel robotic needle 
guide manipulator to perform transrectal prostate biopsies. Med Phys. 2010; 37: 4744-4750.
27.  Litjens G, Hambrock T, Hulsbergen-van de Kaa CA, et al. The effect of interpatient normal peripheral 
zone apparent diffusion coefficient variation on the prediction of prostate cancer aggressiveness. 
Radiology. 2012; 265: 260-266.
501341-L-bw-Vos
57
DWI IN THE TRANSITION ZONE
3
501341-L-bw-Vos
501341-L-bw-Vos
Assessment of prostate cancer 
aggressiveness using dynamic 
contrast-enhanced magnetic 
resonance imaging at 3 T
E.K. Vos
G.J. Litjens
T. Kobus
T. Hambrock
C.A. Hulsbergen-van de Kaa
J.O. Barentsz
H.J. Huisman
T.W.J. Scheenen
Published in European Urology
(Eur Urol 2013; 64: 448-455)
4
501341-L-bw-Vos
60
CHAPTER 4
Abstract
Background
A challenge in the diagnosis of prostate cancer (PCa) is the accurate assessment of 
aggressiveness.
Objective
To validate the performance of dynamic contrast-enhanced (DCE) magnetic resonance 
imaging (MRI) of the prostate at 3 tesla (T) for the assessment of PCa aggressiveness, 
with prostatectomy specimens as the reference standard.
Design, settings, and participants
A total of 45 patients with PCa scheduled for prostatectomy were included. This study 
was approved by the institutional review board; the need for informed consent was 
waived.
Outcome measurements and statistical analysis
Subjects underwent a clinical MRI protocol including DCE-MRI. Blinded to DCE-images, 
PCa was indicated on T2-weighted images based on histopathology results from 
prostatectomy specimens with the use of anatomical landmarks for the precise 
localization of the tumor. PCa was classified as low-, intermediate-, or high-grade, 
according to Gleason score. DCE-images were used as an overlay on T2-weighted 
images; mean and quartile values from semi-quantitative and pharmacokinetic 
model parameters were extracted per tumor region. Statistical analysis included 
Spearman’s ρ, the Kruskal-Wallis test, and a receiver operating
characteristics (ROC) analysis.
Results and limitations
Significant differences were seen for the mean and 75th percentile (p75) values of 
wash-in (p = 0.024 and p = 0.017, respectively), mean wash-out (p = 0.044), and 
p75 of transfer constant (Ktrans) (p = 0.035), all between low-grade and high-grade 
PCa in the peripheral zone. ROC analysis revealed the best discriminating 
performance between low-grade versus intermediate-grade plus high-grade PCa in 
the peripheral zone for p75 of wash-in, Ktrans, and rate constant (Kep) (area under the 
curve: 0.72). Due to a limited number of tumors in the transition zone, a definitive 
conclusion for this region of the prostate could not be drawn.
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Conclusions
Quantitative parameters (Ktrans and Kep) and semi-quantitative parameters (wash-in 
and wash-out) derived from DCE-MRI at 3 T have the potential to assess the 
aggressiveness of PCa in the peripheral zone. P75 of wash-in, Ktrans, and Kep offer the 
best possibility to discriminate low-grade from intermediate-grade plus high-grade 
PCa. 
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Introduction
Prostate cancer (PCa) is the most common malignancy in the Western male 
population and the third leading cause of cancer-related death in developed 
countries.1 Primary methods to diagnose PCa are prostate-specific antigen (PSA) 
and digital rectal examination (DRE), usually followed by transrectal ultrasound 
(TRUS) systematic biopsy. Histopathology of the biopsy ultimately confirms the 
presence and Gleason score (GS) of PCa. Characterization of PCa based on the 
combination of PSA level, DRE findings and GS from TRUS biopsy are used for the 
choice of treatment. However, both PSA and DRE have a low specificity and a low 
sensitivity.2 In addition, TRUS biopsies are invasive, have a relatively low sensitivity 
and tend to underestimate the GS and thus aggressiveness.3,4 Because not all PCas 
are life-threatening, accurate assessment of aggressiveness is essential to prevent 
overdiagnosis and thus overtreatment of indolent cancers.5
 Magnetic Resonance imaging (MRI) will play an important upcoming role in the 
diagnosis and management of PCa. In addition to T2-weighted (T2w) imaging for 
detailed anatomical information, functional MRI techniques for additional information 
such as diffusion-weighted imaging (DWI), MR spectroscopic imaging (MRSI) and 
dynamic contrast-enhanced (DCE) MRI have already proved their usefulness in the 
detection of PCa.6
 DCE-MRI is based on the permeability of blood vessels and extravasation of 
contrast agent into the surrounding tissue. In PCa, fast angiogenesis results in the 
formation of leaky endothelia with a higher permeability than normal vessels. When a 
contrast agent is administered into the vessels it will leak out of the capillaries into 
tissue, where it temporarily changes the T1-relaxation time. A straightforward way of 
representing contrast-related signal intensity changes is with semi-quantitative 
parameters. These parameters are derived from a signal intensity-time curve and are 
relatively easy to calculate, but may not accurately reflect contrast concentration in 
tissue. Quantification of contrast leakage by pharmacokinetic modeling represents 
direct vascular information by estimating the concentration of contrast leakage into 
tissue. This is challenging, though, because multiple approaches for calibration and 
modeling exist, and each model makes its own assumptions that may not be valid for 
every tissue or tumor type. 
 In a recent discussion about the value of MRI in PCa, authors proposed the need 
for implementing multiparametric MRI assessment with defined thresholds that 
should contribute to prevention of overdetection and overtreatment of indolent PCa.7 
A few studies have already shown that DWI and MRSI have the potential to assess 
aggressiveness of PCa.8-10 For DCE-MRI at 1.5 Tesla (T), results are inconsistent 
regarding correlations with aggressiveness and GS.11-15 Literature about the use of 
DCE-MRI for the assessment of PCa aggressiveness at 3 T is lacking. Before a full 
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multiparametric MRI protocol can be implemented for the characterization of PCa, 
each technique has to be evaluated for its value prior to combining all the techniques 
together.
 Our purpose was to validate retrospectively the performance of semi-quantitative 
parameters and pharmacokinetic model parameters derived from DCE-MRI of the 
prostate at 3 T for assessing PCa aggressiveness, with the GS of cancer foci from 
prostatectomy specimens as the reference standard. 
Materials and methods
Patient Characteristics
The institutional review board waived the need for informed consent. Between 2007 
and 2009, all patients with newly biopsy-proven, organ-confined PCa, who had 
undergone a 3 T MR exam with the use of an endorectal coil including DCE-MRI prior 
to radical prostatectomy (RP), without any previous therapy for PCa, were enrolled 
in the study. 
Data acquisition
All imaging was performed using a 3 T whole-body system (Magnetom Trio, Siemens, 
Erlangen, Germany). An endorectal coil (Medrad Inc, Pittsburgh, PA, USA) filled with 
approximately 40 ml of perfluorocarbon and a pelvic phased-array coil were used 
for signal reception. Peristalsis was suppressed with an intramuscular injection of 
1 mg glucagon (GlucaGen, Nordisk, Gentofte, Denmark) and 20 mg butylscopol-
amine bromide (Buscopan, Boehringer-Ingelheim, Ingelheim, Germany) prior to the 
examination.
 The in-house clinical protocol was performed including high-resolution T2w 
turbo spin-echo imaging in three orthogonal directions, in accordance with recently 
published guidelines.16 DCE-MRI was acquired by using turbo fast low-angle shot 
three-dimensional spoiled gradient-echo imaging with the following parameters: TR 
2.4–2.9 ms, TE 1.35–1.51 ms, flip angle 10°–14°, partition thickness 3.0–4.0 mm, 
in-plane resolution 1.8 x 1.8–1.5 x 1.5 mm and a temporal resolution of 3 s before, 
during and after 15 ml intravenous bolus injection of gadolinium chelate (Dotarem, 
Guerbet, France), which was administered with a power injector (Spectris Solaris, 
Medrad Inc, Indianola, USA) and followed by a 20 ml saline flush. Minor differences 
in parameters were due to a clinical protocol change during the study.
Histopathology analysis
All RP specimens were processed and completely embedded according to a 
standard protocol as previously described.9 PCa was categorized in three different 
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aggressiveness levels according to GS: low-grade with only Gleason grades (GGs) 
2 or 3 present, intermediate-grade with a secondary or tertiary GG of 4 but no 5 
component, and high-grade with a primary GG of 4 and/or any 5 component.
Magnetic resonance imaging analysis
PCa was indicated on T2w images by one radiologist based on the histopathology 
results and blinded to the DCE-MRI data. Because it remains a challenge to correctly 
register pathology findings with MR images, we tried to overcome this by slicing the 
resected prostate with similar angulation with respect to the rectal wall surface as 
the slices of MRI. Subsequently, a region of interest (ROI) of the histopathologic size 
of the cancer focus was drawn on the anatomical T2w images based on the 
histopathology results (Fig. 2a and 2b), taking into account the deformation of the 
prostate on MR images due to the use of an endorectal coil and shrinkage of the 
prostate after removal from the body. Anatomical landmarks such as benign prostatic 
hyperplasia nodules and urethra were also used for reference. A non-cancer part of 
the peripheral zone (PZ) was used for patient-specific calibration of pharmacokinetic 
modeling, which was done according to a permeability-limited two-compartment 
model17 and a reference tissue method to estimate a patient-dependent arterial input 
function (AIF).18-20 Our in-house developed software was used to calculate statistics 
of the ROIs from semi-quantitative parameters wash-in (slope of the wash-in phase 
of the curve), time to peak (time between start of enhancement and maximum 
enhancement), wash-out (slope of the late-wash phase of the curve), relative 
enhancement (signal intensity of peak enhancement divided by signal intensity at 
start of enhancement) and pharmacokinetic model parameters transfer constant 
(Ktrans), rate constant (Kep) and extravascular extracellular space (ve). 
Statistical analysis
PZ and transition zone (TZ) cancer were evaluated separately. For all parameters 
the mean values of each cancer ROI were determined. To incorporate possible 
heterogeneity within tumors, we additionally determined the 75th percentile (p75) for 
wash-in, relative enhancement, Ktrans, Kep and ve. For time to peak and wash-out, an 
inverse correlation with tumor aggressiveness was expected, so for these the 25th 
percentiles (p25) were calculated. 
 All parameters were tested for correlation with aggressiveness and lesion size 
using Spearman’s ρ. Only for parameters that correlated significantly with aggressiveness, 
the median values of all data in each aggressiveness level were compared with each 
other using the Kruskal-Wallis test with the Dunn multiple comparison posttest. 
Finally, the area under the curve (AUC) of receiver operating characteristics (ROC) 
analysis was determined to study the performance of discriminating low-grade from 
intermediate-grade plus high-grade PCa. 
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 Graphpad Prism v.5.0 (GraphPad Software, San Diego, CA, USA) and MATLAB 
R2012a (MathWorks, Natick, MA, USA) were used to perform statistical analyses. 
For all statistical tests, a p value < 0.05 was considered significant.
Results
 
A total of 15 patients were excluded from the analysis, because the entire PZ consisted 
of PCa and thus did not contain non-cancer PZ tissue as reference for calibration 
(n = 2); cancer covered both PZ and TZ, so a clear distinction between origin could 
not be made (n = 2); no reliable pathology results (n = 1); patients only had lesions 
of insignificant size (< 0.5 cm3; n = 9); or the endorectal coil was not filled with perfluoro-
carbon (n = 1).
 Overall, 57 clinically significant cancer foci > 0.5 cm3 according to histopathology 
were present in the remaining 45 patients (Table 1; Fig. 1). In a typical example, a large 
tumor enhanced clearly with contrast agent administration (Fig. 2).
 A significant correlation with aggressiveness in the PZ was found for wash-in 
(mean:  ρ = 0.43, p = 0.006; p75: ρ = 0.45, p = 0.004), Ktrans (mean: ρ = 0.38, p = 0.01; 
p75: ρ = 0.41, p = 0.008), Kep (mean: ρ = 0.43, p = 0.006; p75: ρ = 0.45, p = 0.004) 
and a significant negative correlation for wash-out (mean: ρ = –0.39, p = 0.01; p25: 
ρ = –0.33, p = 0.04). Only wash-in correlated significantly with lesion size (mean: 
ρ = 0.36, p = 0.02; p75: ρ = 0.37, p = 0.02). Wash-out and Ktrans only just approached 
significance with lesion size in the PZ.
 In the TZ, only the p75 of Ktrans correlated significantly with aggressiveness (ρ = 0.52, 
p = 0.04). All other parameters did not show any correlation with aggressiveness. 
For lesion size, p75 of Ktrans showed a significant correlation as well (ρ = 0.54, 
p = 0.03) while the mean only just approached significance (ρ = 0.48, p = 0.06).
 Comparison of the medians of the aggressiveness levels revealed a significant 
difference for the semi-quantitative parameters wash-in (mean: p = 0.024; p75: 
p = 0.017) and wash-out (mean: p = 0.044) for the PZ (Fig. 3, Table 2). For the 
quantitative parameters, only the p75 of Ktrans (p = 0.035) showed a significant 
difference for the PZ (Fig. 4, Table 2). All differences were found between the 
low-grade and high-grade level. 
 Although Ktrans did show a correlation with aggressiveness in the TZ, no statistically 
significant differences were found between the medians of the aggressiveness levels 
(Fig. 5). Table 2 lists the median values and interquartile range for the parameters per 
aggressiveness level for both zones.
 With the use of ROC analysis, the highest discriminating performance between 
low-grade versus intermediate-grade plus high-grade PCa was seen for the p75 of 
wash-in, Ktrans and Kep (all with AUC: 0.72) in the PZ and for the p75 of K
trans (AUC: 0.75) 
in the TZ. 
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Table 1  Characteristics of patients and tumors. 
No. of patients 45
PSA, median (range), mg/ml 6.90 (2.08 – 40.96)
Age, median (range), yr 64 (48 – 70)
Gleason score No. of tumors
Peripheral zone:
  2 + 3
  3 + 2 
  3 + 3
  3 + 3 + 4 
  3 + 4
  3 + 4 + 5 
  4 + 3
  4 + 3 + 5
  4 + 4
  4 + 5
  5 + 3
Transition zone:
  2 + 3
  3 + 2
  3 + 3
  3 + 2 + 4
  3 + 4
  2 + 4 + 5
  4 + 2
  4 + 3
  4 + 3 + 5
  4 + 5
Low*
Low
Low
Intermediate
Intermediate
High
High
High
High
High
High
Low
Low
Low
Intermediate
Intermediate
High
High
High
High
High
1
1
13
1
9
3
8
1
1
2
1
2
3
1
1
1
1
1
1
4
1
Low: 15
Intermediate: 10
High: 16
Total: 41
Low: 6
Intermediate: 2
High: 8
Total: 16
*  Cancers are classified in classes according to their aggressiveness, solely based on the localized 
Gleason score rather than the full D’Amico risk classification.
PSA  = prostate specific antigen
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Fig. 1  Flow diagram of inclusion and exclusion criteria and classification of patient 
subcohorts.
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Fig. 2  Dynamic contrast-enhanced magnetic resonance imaging of a 66-yr-old 
patient with Gleason 4 + 3 prostate cancer (PCa) in the left peripheral zone: (a) T2- 
weighted (T2w) image with a region of interest of PCa (left peripheral zone, red 
outline) and non-cancer tissue (right peripheral zone, green outline, used as reference 
tissue for calibration), based on (b) the histopathologic results of the prostatectomy 
specimen (cancer region in red outline, indicated by the pathologist on the photographed 
slice). An overlay of (c) the wash-out (late-wash phase) and (d) the transfer constant 
(Ktrans) on the T2w image shows wash-out and enhancement of the cancer region, 
respectively. Qualitative signal-intensity curves over time of (e) non-cancer and (f) 
high-grade cancer: The curve of non-cancer tissue shows slow wash-in and 
continuing wash-in during the late-wash phase (yellow dashed line), the curve of the 
high-grade cancer tissue shows rapid wash-in (steeper slope of the wash-in phase 
than for non-cancer tissue) and fast wash-out in the late-wash phase (red dashed 
line).
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Fig. 3  Semi-quantitative parameters for the peripheral zone. Box-and-whisker plot 
(range: 5–95th percentile) of (a) the mean and (b) the 75th percentile (p75) of wash-in 
values and (c) mean and (d) 25th percentile (p25) of wash-out values per cancer 
aggressiveness class. A significant difference between low-aggressive and high- 
aggressive prostate cancer was found for both the mean and the p75 values of 
wash-in ( p = 0.024 and p = 0.017, respectively) and for the mean values of wash-out 
( p = 0.044).
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Fig. 4  Quantitative parameters for the peripheral zone. Box-and-whisker plot (range: 
5–95th percentile) of (a) the mean and (b) the 75th percentile (p75) values of the 
transfer constant (Ktrans) and (c) the mean and (d) the p75 values of the rate constant 
(Kep) per cancer aggressiveness class for the peripheral zone. A significant difference 
was found for the p75 values ( p = 0.035) between low-grade and high-grade class, 
where the mean only just approached significance ( p = 0.050). For Kep, no significant 
differences were found.
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Fig. 5  Quantitative parameters for the peripheral zone. Box-and-whisker plot (range: 
5–95th percentile) of (a) the mean and (b) the 75th percentile (p75) values of the 
transfer constant (Ktrans) and (c) the mean and (d) the p75 values of the rate constant 
(Kep) per cancer aggressiveness class for the peripheral zone. A significant difference 
was found for the p75 values ( p = 0.035) between low-grade and high-grade class, 
where the mean only just approached significance (p = 0.050). For Kep, no significant 
differences were found.
Table 3  Areas under the receiver operating characteristic curves for studying  
the performance of discriminating low-grade from intermediate-grade plus 
high-grade prostate cancer. 
Peripheral zone AUC p
Wash-in mean
75p
0.71
0.72
0.03
0.02
Wash-out mean 
25p
0.65
0.70
0.03
0.11
Ktrans mean 
75p
0.68
0.72
0.06
0.02
Kep mean 
75p
0.70
0.72
0.03
0.02
Transition zone AUC p
Ktrans mean 
75p
0.72
0.75
0.18
0.12
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Discussion
This study showed that both quantitative (Ktrans and Kep) and semi-quantitative 
(wash-in and wash-out) parameters derived from DCE-MRI can be helpful tools to 
assess PCa aggressiveness in the PZ. For the parameters that either positively or 
negatively correlated with aggressiveness, differences in median ranks between 
low-grade and high-grade PCa were found, but not with intermediate-grade PCa. 
Although there is a significant difference between low-grade and high-grade PCa in 
the PZ, considerable overlap exists. According to the recent literature, it is of great 
importance to recognize indolent PCa to prevent overtreatment of these low-grade 
tumors.5,7 Therefore, not only a correlation with aggressiveness is interesting, but it is 
of clinical value to separate low-grade from all higher grade PCa. Our results revealed 
that discriminating low-grade from intermediate-grade plus high-grade PCa is 
possible with a fair performance with quartile values of the parameters wash-in (p75), 
washout (p25), Ktrans, and Kep (both p75) in the PZ, and p75 of K
trans in the TZ. Perhaps 
the more heterogeneous vascularization pattern of TZ tumors21 could explain the lack 
of more than one parameter correlating with aggressiveness, although our number of 
TZ tumors in this work could be too small to conclude this conclusively. The plausible 
hypothesis of a relation between DCE-MRI and microvascular density has been 
confirmed in PCa13,22, although conflicting results of a correlation between micro -
vascular density and GS have been found.23,24
 At 1.5 T, a significant correlation of wash-out and GS was previously found15, 
although other studies concluded that both semi-quantitative and pharmacokinetic 
parameters of DCE-MRI were only useful for detection of PCa.11-14 At 3 T, few studies 
exist, most with the main objective to detect PCa rather than to analyze for a correlation 
with GS.25-27 Turkbey et al.28 suggested that sensitivity for the detection of PCa 
increases with higher GS when using DCE-MRI next to T2-weighted imaging, but 
here Ktrans and Kep maps were evaluated visually instead of quantitatively. Moradi et 
al.29 did find a positive correlation between GS and DCE-MRI, although they did not 
quantify the pharmacokinetic parameters. Our use of a higher temporal resolution, 
probing the first phase of enhancement more accurately, and the use of a patient- 
specific AIF instead of a population-based AIF contribute to a better signal 
enhancement curve and improved pharmacokinetic modeling. Together with the use 
of whole-mount histopathology as reference standard this could explain our 
correlations of multiple DCE parameters with GS.
 We used a permeability-limited two-compartment model based on the Tofts 
model, with a per-patient calibrated AIF and non-cancer PZ as reference tissue. With 
this model the intravascular space is considered as one compartment and the 
interstitial space as the second compartment, so one assumes that exchange of 
contrast agent will take place between those two compartments with permeability as 
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the limiting step. Some authors argue that a blood flow-limited model is preferred in 
cancer tissue or that use of a three-compartment model, which comprises the 
vascular volume as one compartment with the addition of two sequential interstitial 
compartments with slow and fast exchange, better represents the distribution of 
contrast agents.30 We assumed that in PCa a permeability-limited model is a better 
way of representing the spread of contrast agent because the prostate is a highly 
vascularized organ and thus blood flow as the limiting step is less plausible. Moreover 
we decided to not further expand the number of pharmacokinetic parameters by 
keeping the number of modeled compartments at two.  
 This study had several limitations. First, this is a validation study with a limited 
number of patients; therefore confirmation of these findings and the performance in 
a prospective predictive setting is essential before it can be implemented in clinical 
practice. Because of the limited number of cancers in the TZ, we cannot draw a 
proper conclusion for this region. Second, because we used prostatectomy 
specimens as the gold standard, there might be some selection bias because 
patients with a very low or a very high GS and extracapsular extension usually do not 
undergo a prostatectomy. Third, our method for pharmacokinetic calibration is 
impossible in the cases of complete fill of the PZ area with tumor because there 
would be no non-cancer PZ tissue as reference available for our specific calibration 
method of the pharmacokinetic model parameters. Fourth, in this study design, only 
histopathologically proven cancer areas were assigned on anatomical MR images, 
and non-cancer areas were not assessed (only for patient-specific pharmacokinetic 
calibration). Therefore, negative predictive values of parameters derived from DCE-MRI 
cannot be calculated and should be determined in a prospective predictive study.
 Our results could be of important clinical relevance. DCE-MRI can be a valuable 
tool in the diagnostic process for differentiating low-aggressive from higher aggressive 
PCa within the PZ, so that overtreatment of indolent types of organ-confined PCa can 
be prevented by selecting suitable patients for active surveillance and for recognizing 
those that will need immediate treatment. However, too much overlap in both 
semi-quantitative and pharmacokinetic model parameters exists to use DCE-MRI as 
a sole technique. In studies of Hambrock et al.8 and Kobus et al.9, DWI and MRSI, 
respectively, were correlated with aggressiveness. Subsequently, Kobus et al. 
combined the two functional techniques to evaluate if both techniques have 
complementary value for the assessment of PCa localization and aggressiveness.31 
In a next step, the combination of all parameters from a full multiparametric MRI 
examination needs to be validated for its performance in PCa characterization, 
followed by a predictive study to confirm its true prognostic value. DCE-MRI can 
contribute best to this analysis with the use of quartile values of wash-in, wash-out, 
Ktrans, and Kep. Pharmacokinetic modeling can only be performed in specialized 
institutions with dedicated software programs, so for institutions that do not have this 
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expertise the use of semi-quantitative parameters wash-in and wash-out might be 
sufficient.
Conclusions
Quantitative parameters (Ktrans and Kep) and semi-quantitative parameters (wash-in 
and wash-out) derived from DCE-MRI have potential to assess PCa aggressiveness 
in the PZ at 3 T, despite overlap between aggressiveness classes. P75 of wash-in, 
Ktrans, and Kep offer the best possibility to discriminate low-grade from intermediate- 
grade plus high-grade PCa. These initial results are preliminary but promising for 
selecting those patients with organ-confined low-aggressive PCa suitable for active 
surveillance and thus preventing overtreatment.
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Abstract
Objective
The aim of this study was to determine and validate the optimal combination of 
parameters derived from 3-T diffusion-weighted imaging, dynamic contrast- enhanced 
imaging, and magnetic resonance (MR) spectroscopic imaging for discriminating 
low-grade from high-grade prostate cancer (PCa).
Materials and Methods
The study was approved by the institutional review board, and the need for informed 
consent was waived. Ninety-four patients with PCa who had undergone multipara-
metric MR imaging (MRI) before prostatectomy were included. Cancer was indicated 
on T2-weighted images, blinded to any functional data, with prostatectomy specimens 
as the reference standard.
 Tumors were classified as low-grade or high-grade based on Gleason score; 
peripheral zone (PZ) and transition zone (TZ) tumors were analyzed separately. In a 
development set (43 patients), the optimal combination of multiparametric MRI 
parameters was determined using logistic regression modeling. Subsequently, this 
combination was evaluated in a separate validation set (51 patients).
Results
In the PZ, the 25th percentile of apparent diffusion coefficient (ADC) derived from 
diffusion-weighted imaging and wash-out (WO25) derived from dynamic contrast- 
enhanced MRI offered the optimal combination of parameters. In the TZ, WO25 and 
the choline over spermine + creatine ratio (C/SC) derived from MR spectroscopic 
imaging showed the highest discriminating performance. Using the models built with 
the development set, 48 (74%) of 65 cancer lesions
were classified correctly in the validation set.
Conclusions
Multiparametric MRI is a useful tool for the discrimination between low-grade and 
high-grade PCa and performs better than any individual functional parameter in both 
the PZ and TZ. The 25th percentile of ADC + WO25 offered the optimal combination 
in the PZ, and the choline over spermine + creatine ratio + WO25 offered the optimal 
combination in the TZ. The ADC parameter has no additional value for the assessment 
of Pca aggressiveness in the TZ.
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Introduction
Magnetic Resonance Imaging (MRI) is an emerging technique for the diagnosis and 
management of prostate cancer (Pca). T2-weighted imaging (T2WI) enables good 
visualization of morphology and anatomical details, whereas other techniques can 
provide additional functional information; diffusion-weighted imaging (DWI) represents 
motion and restriction of water molecules, dynamic contrast-enhanced (DCE) MRI 
provides information about perfusion and vascular permeability of prostate tissue, 
and MR spectroscopic imaging (MRSI) gives insight in tissue metabolism. Combining 
these techniques is commonly referred to as multiparametric MRI (mpMRI), and it is 
increasingly used for detection and localization of suspicious lesions within the 
prostate.1-6
 After detection, an accurate assessment of aggressiveness is of crucial importance, 
as a substantial proportion of all PCa is considered indolent.7,8 Current clinical tools 
such as systematic transrectal ultrasound biopsies often fail to accurately characterize 
the disease and do not always include anterior sampling of the prostate.9,10 This 
increases the risk for underestimation of the disease. Current overtreatment of indolent 
prostate cancer is an unfortunate consequence of lack of trust in assessment of 
aggressiveness. Development of more accurate diagnostic and surveillance tools will 
improve the selection of treatment options, enabling the urologist to discriminate 
patients suitable for active surveillance from those who need immediate radical 
treatment.11 
 Currently, MRI is gaining interest for the assessment of aggressiveness of PCa. 
Several studies have shown that DWI12-15, DCE-MRI16, and MRSI17 have potential to 
achieve this. Despite promising results, substantial overlap existed between different 
aggressiveness levels, hampering the use of single functional parameters to separate 
between aggressiveness classes on an individual patient basis. Alternatively, few 
studies have explored the additional value of combining two techniques18,19, and did 
not describe the predictive performance. Moreover, an evaluation of all three functional 
techniques to determine the optimal combination to predict PCa aggressiveness has 
not been carried out thus far. 
 Therefore, the purpose of this study was twofold –– determining the optimal 
combination of functional parameters derived from DWI, DCE-MRI, and MRSI in an 
mpMRI setting to discriminate between low-grade and high-grade PCa, followed by 
a validation study to confirm its value.
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Materials and methods
Patient characteristics
The institutional review board waived the need for informed consent. Between 2007 
and 2013, all patients who had undergone a full mpMRI protocol (including all three 
techniques –– DWI, DCE-MRI, and MRSI) before radical prostatectomy were enrolled 
in the study. Exclusion criteria were examinations with a combination of only two of 
the functional imaging techniques, previous therapy for PCa (eg, radiotherapy, 
hormonal therapy), and the usual contraindications for MRI (eg, cardiac pacemaker). 
One hundred nine patients were included. Of these, the first 51 subjects scanned 
between 2007 and 2009 were assigned to the development set used to determine a 
model with a combination of parameters that best reflects PCa aggressiveness. The 
remaining 58 subjects scanned between 2010 and 2013 were enrolled in a separate 
validation set to test the model (Fig. 1).
Data acquisition
All imaging was performed on a 3-T whole-body system (Magnetom Trio; Siemens, 
Erlangen, Germany). Between 2007 and 2009, an endorectal coil (Medrad inc, 
Pittsburgh, PA, USA) filled with approximately 40 mL of perfluorocarbon and a pelvic 
phased-array coil were used for signal reception. Between 2010 and 2013, a pelvic 
phased-array coil, either alone or in combination with the endorectal coil, was used 
for signal reception. Peristalsis was suppressed with an intramuscular injection of 
1 mg glucagon (GlucaGen; Nordisk, Gentofte, Denmark) and 20 mg butylsco-
polamine bromide (Buscopan; Boehringer-Ingelheim, Ingelheim, Germany), plus an 
additional intravenous injection of 20 mg Buscopan. High-resolution T2W turbo 
spin-echo imaging was performed in three orthogonal directions. Subsequently, DWI, 
3-dimensional MRSI, and DCE-MRI were acquired (Table 1), altogether well within 
1 hour. 
Histopathologic analysis
Immediately after the surgery, the prostatectomy specimen was processed according 
to a clinical protocol. After inking of the surface and fixation with formalin, the prostate 
was sliced with similar angulation with respect to the rectal wall surface as the slices 
of the MRI (ie, perpendicular to the rectal wall surface). Subsequently, one expert 
pathologist with over 20 years of experience in urological pathology (C.A.H.V.D.K.) 
indicated all cancer lesions on photographed slices of the serially sectioned prostate, 
and a Gleason score was provided for each lesion.20 Prostate cancer was categorized 
into aggressiveness classes based on the Gleason growth pattern (GG): low-grade 
with only GG 3 or less and high-grade with any GG 4 or more. Lesions were classified 
as peripheral zone (PZ) or transition zone (TZ) cancer.
501341-L-bw-Vos
85
MPMRI FOR PROSTATE CANCER AGGRESSIVENESS
5
Fi
g.
 1
  F
lo
w
 d
ia
gr
am
 o
f i
nc
lu
si
on
 a
nd
 e
xc
lu
si
on
 c
rit
er
ia
 a
nd
 c
la
ss
ifi
ca
tio
n 
of
 p
at
ie
nt
 s
ub
co
ho
rt
s
501341-L-bw-Vos
86
CHAPTER 5
Ta
b
le
 1
  I
m
ag
in
g 
pa
ra
m
et
er
s.
 
S
eq
ue
nc
e
TR
 
(m
s)
TE (m
s)
In
-p
la
ne
 r
es
ol
ut
io
n 
(m
m
)
S
lic
e 
/ p
ar
tit
io
n 
th
ic
kn
es
s 
(m
m
)
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l +
 e
nd
or
ec
ta
l c
oi
l (
20
07
 –
 2
00
9)
  T
2w
 a
xi
al
30
30
 –
 5
46
0
84
 –
 1
16
0.
4 
x 
0.
4
3
  T
2w
 s
ag
itt
al
33
60
 –
 5
71
0
98
 –
 1
25
0.
5 
x 
0.
5
3
  T
2w
 c
or
on
al
24
00
 –
 4
29
0
98
 –
 1
27
0.
5 
x 
0.
5
3
  D
W
I
23
00
 –
 4
10
0
81
 –
 9
6
1.
5 
x 
1.
5
3
  3
D
 M
R
S
I
75
0
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 5
x5
x5
 o
r 6
x6
x6
 m
m
;
sp
he
ric
al
 v
ox
el
 s
iz
e:
 0
.3
7/
0.
64
 c
m
3
  3
D
 D
C
E-
M
R
I
2.
4 
– 
2.
9
1.
35
 –
 1
.5
1
1.
5 
x 
1.
5 
/ 1
.8
 x
 1
.8
3 
– 
4 
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l +
 e
nd
or
ec
ta
l c
oi
l (
20
10
 –
 2
01
3)
T2
w
 a
xi
al
40
60
 –
 5
86
0 
99
0.
4 
x 
0.
4
3
T2
w
 s
ag
itt
al
42
90
 –
 5
02
0 
98
0.
5 
x 
0.
5
3
T2
w
 c
or
on
al
35
90
 –
 3
91
0 
98
0.
5 
x 
0.
5
3
D
W
I
26
00
 –
 3
00
0 
70
 –
 9
0 
1.
5 
x 
1.
5 
/ 2
.0
 x
 2
.0
3
3D
 M
R
S
I
75
0
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 5
x5
x5
 o
r 6
x6
x6
 m
m
; 
sp
he
ric
al
 v
ox
el
 s
iz
e:
 0
.3
7/
0.
64
 c
m
3
3D
 D
C
E-
M
R
I
2.
1
1.
4
1.
5 
x 
1.
5
3 
– 
4 
S
eq
ue
nc
e
TR
 
(m
s)
TE (m
s)
In
-p
la
ne
 r
es
ol
ut
io
n 
(m
m
)
S
lic
e 
/ p
ar
tit
io
n 
th
ic
kn
es
s 
(m
m
)
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l o
nl
y 
(2
01
0 
– 
20
13
)
T2
w
 a
xi
al
40
00
10
1
0.
6 
x 
0.
6
3
T2
w
 s
ag
itt
al
40
00
10
1
0.
6 
x 
0.
6
3
T2
w
 c
or
on
al
40
00
10
1
0.
6 
x 
0.
6
3
D
W
I
31
00
59
2.
2 
x 
1.
6
3.
6
3D
 M
R
S
I
75
0 
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 7
x7
x7
 m
m
;
sp
he
ric
al
 v
ox
el
 s
iz
e:
 1
.0
 c
m
3
3D
 D
C
E-
M
R
I
3.
85
1.
42
1.
6 
x 
1.
6
3.
6
S
lig
ht
 d
iff
er
en
ce
s 
in
 p
ar
am
et
er
s 
w
er
e 
du
e 
to
 a
 c
lin
ic
al
 p
ro
to
co
l c
ha
ng
e 
du
rin
g 
th
e 
st
ud
y 
or
 w
he
th
er
 a
n 
en
do
re
ct
al
 c
oi
l w
as
 u
se
d 
or
 n
ot
. D
W
I w
as
 re
co
rd
ed
 w
ith
 b
-v
al
ue
s 
of
 5
0,
 5
00
 a
nd
 8
00
 o
r 1
00
, 4
00
 a
nd
 8
00
, d
ep
en
di
ng
 o
n 
th
e 
pr
ot
oc
ol
 u
se
d.
 A
n 
ap
pa
re
nt
 d
iff
us
io
n 
co
ef
fic
ie
nt
 (A
D
C
) m
ap
 w
as
 c
al
cu
la
te
d 
au
to
m
at
ic
al
ly
 b
y 
th
e 
sc
an
ne
r. 
D
C
E-
M
R
I w
as
 a
cq
ui
re
d 
be
fo
re
, d
ur
in
g 
an
d 
af
te
r a
 1
5 
m
L 
in
tra
ve
no
us
 b
ol
us
 in
je
ct
io
n 
of
 g
ad
ol
in
iu
m
 c
he
la
te
 (D
ot
ar
em
, G
ue
rb
et
, F
ra
nc
e)
, w
hi
ch
 w
as
 a
dm
in
is
te
re
d 
w
ith
 a
 
po
w
er
 in
je
ct
or
(S
pe
ct
ris
 S
ol
ar
is
, M
ed
ra
d 
In
c,
 In
di
an
ol
a,
 P
A
, U
S
A
) a
nd
 fo
llo
w
ed
 b
y 
a 
20
 m
L 
sa
lin
e 
flu
sh
. T
em
po
ra
l r
es
ol
ut
io
n 
of
 3
 s
ec
 (2
00
7 
– 
20
09
) a
nd
 4
.2
 s
ec
 (2
01
0-
20
13
) w
ith
 to
ta
l a
cq
ui
si
tio
n 
tim
e 
of
 5
 m
in
ut
es
. N
om
in
al
 a
nd
 s
ph
er
ic
al
 v
ox
el
 s
iz
e 
be
fo
re
 a
nd
 a
fte
r a
po
di
za
tio
n 
w
ith
 th
e 
H
an
ni
ng
 fu
nc
tio
n.
TR
, r
ep
et
iti
on
 ti
m
e;
 T
E
, e
ch
o 
tim
e;
 T
2w
, T
2-
w
ei
gh
te
d;
 D
W
I, 
di
ffu
si
on
-w
ei
gh
te
d 
im
ag
in
g;
 3
D
, 3
-d
im
en
si
on
al
; M
R
S
I, 
m
ag
ne
tic
 re
so
na
nc
e 
sp
ec
tro
sc
op
ic
 im
ag
in
g;
 D
C
E-
M
R
I, 
dy
na
m
ic
 c
on
tra
st
-e
nh
an
ce
d 
m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 A
D
C
, a
pp
ar
en
t d
iff
us
io
n 
co
ef
fic
ie
nt
.
501341-L-bw-Vos
87
MPMRI FOR PROSTATE CANCER AGGRESSIVENESS
5
Ta
b
le
 1
  I
m
ag
in
g 
pa
ra
m
et
er
s.
 
S
eq
ue
nc
e
TR
 
(m
s)
TE (m
s)
In
-p
la
ne
 r
es
ol
ut
io
n 
(m
m
)
S
lic
e 
/ p
ar
tit
io
n 
th
ic
kn
es
s 
(m
m
)
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l +
 e
nd
or
ec
ta
l c
oi
l (
20
07
 –
 2
00
9)
  T
2w
 a
xi
al
30
30
 –
 5
46
0
84
 –
 1
16
0.
4 
x 
0.
4
3
  T
2w
 s
ag
itt
al
33
60
 –
 5
71
0
98
 –
 1
25
0.
5 
x 
0.
5
3
  T
2w
 c
or
on
al
24
00
 –
 4
29
0
98
 –
 1
27
0.
5 
x 
0.
5
3
  D
W
I
23
00
 –
 4
10
0
81
 –
 9
6
1.
5 
x 
1.
5
3
  3
D
 M
R
S
I
75
0
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 5
x5
x5
 o
r 6
x6
x6
 m
m
;
sp
he
ric
al
 v
ox
el
 s
iz
e:
 0
.3
7/
0.
64
 c
m
3
  3
D
 D
C
E-
M
R
I
2.
4 
– 
2.
9
1.
35
 –
 1
.5
1
1.
5 
x 
1.
5 
/ 1
.8
 x
 1
.8
3 
– 
4 
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l +
 e
nd
or
ec
ta
l c
oi
l (
20
10
 –
 2
01
3)
T2
w
 a
xi
al
40
60
 –
 5
86
0 
99
0.
4 
x 
0.
4
3
T2
w
 s
ag
itt
al
42
90
 –
 5
02
0 
98
0.
5 
x 
0.
5
3
T2
w
 c
or
on
al
35
90
 –
 3
91
0 
98
0.
5 
x 
0.
5
3
D
W
I
26
00
 –
 3
00
0 
70
 –
 9
0 
1.
5 
x 
1.
5 
/ 2
.0
 x
 2
.0
3
3D
 M
R
S
I
75
0
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 5
x5
x5
 o
r 6
x6
x6
 m
m
; 
sp
he
ric
al
 v
ox
el
 s
iz
e:
 0
.3
7/
0.
64
 c
m
3
3D
 D
C
E-
M
R
I
2.
1
1.
4
1.
5 
x 
1.
5
3 
– 
4 
S
eq
ue
nc
e
TR
 
(m
s)
TE (m
s)
In
-p
la
ne
 r
es
ol
ut
io
n 
(m
m
)
S
lic
e 
/ p
ar
tit
io
n 
th
ic
kn
es
s 
(m
m
)
P
el
vi
c 
p
ha
se
d
-a
rr
ay
 c
oi
l o
nl
y 
(2
01
0 
– 
20
13
)
T2
w
 a
xi
al
40
00
10
1
0.
6 
x 
0.
6
3
T2
w
 s
ag
itt
al
40
00
10
1
0.
6 
x 
0.
6
3
T2
w
 c
or
on
al
40
00
10
1
0.
6 
x 
0.
6
3
D
W
I
31
00
59
2.
2 
x 
1.
6
3.
6
3D
 M
R
S
I
75
0 
14
5
no
m
in
al
 v
ox
el
 s
iz
e:
 7
x7
x7
 m
m
;
sp
he
ric
al
 v
ox
el
 s
iz
e:
 1
.0
 c
m
3
3D
 D
C
E-
M
R
I
3.
85
1.
42
1.
6 
x 
1.
6
3.
6
S
lig
ht
 d
iff
er
en
ce
s 
in
 p
ar
am
et
er
s 
w
er
e 
du
e 
to
 a
 c
lin
ic
al
 p
ro
to
co
l c
ha
ng
e 
du
rin
g 
th
e 
st
ud
y 
or
 w
he
th
er
 a
n 
en
do
re
ct
al
 c
oi
l w
as
 u
se
d 
or
 n
ot
. D
W
I w
as
 re
co
rd
ed
 w
ith
 b
-v
al
ue
s 
of
 5
0,
 5
00
 a
nd
 8
00
 o
r 1
00
, 4
00
 a
nd
 8
00
, d
ep
en
di
ng
 o
n 
th
e 
pr
ot
oc
ol
 u
se
d.
 A
n 
ap
pa
re
nt
 d
iff
us
io
n 
co
ef
fic
ie
nt
 (A
D
C
) m
ap
 w
as
 c
al
cu
la
te
d 
au
to
m
at
ic
al
ly
 b
y 
th
e 
sc
an
ne
r. 
D
C
E-
M
R
I w
as
 a
cq
ui
re
d 
be
fo
re
, d
ur
in
g 
an
d 
af
te
r a
 1
5 
m
L 
in
tra
ve
no
us
 b
ol
us
 in
je
ct
io
n 
of
 g
ad
ol
in
iu
m
 c
he
la
te
 (D
ot
ar
em
, G
ue
rb
et
, F
ra
nc
e)
, w
hi
ch
 w
as
 a
dm
in
is
te
re
d 
w
ith
 a
 
po
w
er
 in
je
ct
or
(S
pe
ct
ris
 S
ol
ar
is
, M
ed
ra
d 
In
c,
 In
di
an
ol
a,
 P
A
, U
S
A
) a
nd
 fo
llo
w
ed
 b
y 
a 
20
 m
L 
sa
lin
e 
flu
sh
. T
em
po
ra
l r
es
ol
ut
io
n 
of
 3
 s
ec
 (2
00
7 
– 
20
09
) a
nd
 4
.2
 s
ec
 (2
01
0-
20
13
) w
ith
 to
ta
l a
cq
ui
si
tio
n 
tim
e 
of
 5
 m
in
ut
es
. N
om
in
al
 a
nd
 s
ph
er
ic
al
 v
ox
el
 s
iz
e 
be
fo
re
 a
nd
 a
fte
r a
po
di
za
tio
n 
w
ith
 th
e 
H
an
ni
ng
 fu
nc
tio
n.
TR
, r
ep
et
iti
on
 ti
m
e;
 T
E
, e
ch
o 
tim
e;
 T
2w
, T
2-
w
ei
gh
te
d;
 D
W
I, 
di
ffu
si
on
-w
ei
gh
te
d 
im
ag
in
g;
 3
D
, 3
-d
im
en
si
on
al
; M
R
S
I, 
m
ag
ne
tic
 re
so
na
nc
e 
sp
ec
tro
sc
op
ic
 im
ag
in
g;
 D
C
E-
M
R
I, 
dy
na
m
ic
 c
on
tra
st
-e
nh
an
ce
d 
m
ag
ne
tic
 re
so
na
nc
e 
im
ag
in
g;
 A
D
C
, a
pp
ar
en
t d
iff
us
io
n 
co
ef
fic
ie
nt
.
501341-L-bw-Vos
88
CHAPTER 5
Magnetic Resonance Imaging analysis
Parameter maps of the functional techniques were calculated in each patient. In case 
of misalignment to T2WI, manual registration of the functional techniques onto T2WI 
was performed by using an in-house developed software tool. For MRSI, parameters 
of interest were the maximum choline + spermine + creatine over citrate ratio 
(CSC/C) and the maximum choline over spermine + creatine ratio (C/SC).21 From 
DWI, the apparent diffusion coefficient (ADC) map was calculated and used as 
parameter. For DCE-MRI, descriptive parameters wash-in (slope of the wash-in phase) 
and wash-out (slope of the late-wash phase) of the dynamic contrast-enhancement 
curve were used based on a simplified model as described previously.22
 
Development set: determining the optimal combination of parameters
For the development set, cancer lesions were indicated by a radiologist (T.H.) on 
T2WI based on the prostatectomy specimens and blinded to any functional imaging 
parameter. Anatomical landmarks were used as reference when registering pathology 
slices to the MRI. The size and grid position of individual spectroscopy voxels was 
used as a region of interest (ROI) because MRSI was the technique with the lowest 
spatial resolution. Multiple ROIs were drawn to cover each entire tumor lesion (Fig. 2, 
A–C). Only lesions with a size of 0.5 cm3 or larger were taken into account. 
 Subsequently, the ROIs that were drawn on the T2WI were transferred onto the 
DWI and DCE-MRI parameter images. Because these images had a higher spatial 
resolution than MRSI, ROIs comprised many voxels in these images, allowing an 
automated calculation of percentile values for these parameters per ROI. Percentile 
values of the parameters of functional imaging data were extracted for each ROI per 
cancer lesion. To account for possible heterogeneity of PCa, for each parameter, the 
most deviating ROI in each lesion was chosen as representative for that lesion: the 
maximum CSC/C and C/SC were used from MRSI, the value of the ROI with the 
lowest 25th percentile of the ADC (ADC25) map was used from DWI, and for DCE-MRI, 
the values of the ROI with the highest 75th percentile of the wash-in gradient (WI75) 
and of the ROI with the lowest 25th percentile of the wash-out gradient (WO25) were 
used. The choice for these parameters was based on previous studies illustrating 
their potential to correlate with PCa aggressiveness.16,18 
Logistic regression modeling (LRM) was used to find the optimal combination of 
parameters for discriminating low-grade from high-grade PCa. This was done using 
the stepwise backward elimination approach, by eliminating the parameter with the 
lowest contributing value (ie, lowest Wald statistic) to the model. Logistic regression 
modeling models were evaluated using receiver operating characteristic (ROC) curve 
analysis, using the area under the ROC curve (AUC) as a figure of merit. Peripheral 
zone and TZ were analyzed separately. 
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Fig. 2  Example of a 59-year-old patient with a high-grade PCa lesion (GG ≥4) in the 
transition zone. A, Annotation of the cancer lesion on axial T2-weighted imaging, with 
multiple regions of interest (ROIs) covering the entire cancer area. B, One ROI with 
the size of a spectroscopy voxel, per cancer lesion, the 1 most aberrant value of each 
parameter of all ROIs is selected for analysis. C, Corresponding prostatectomy slice 
with the cancer area (blue outline, indicated by the pathologist). D, the washout 
overlay shows clear washout in a part of the cancer area. E, Spectrum of the selected 
ROI from Figure 1B; a high choline peak is visible (yellow line), resulting in a high C/
SC ratio.
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Validation set: model evaluation
The performance of the LRM models was evaluated in the validation set. First, PCa 
was indicated by a radiologist (E.K.V.) on T2WI in the same way as for the development 
set, based on the prostatectomy specimens and blinded to any functional imaging 
parameter and Gleason score. Second, after the indication of the tumor lesions on 
T2WI, the ROIs were transferred onto the functional imaging data. Subsequently, 
functional imaging parameters were extracted from each ROI per cancer lesion. 
Again, for each lesion, the ROIs with the most aberrant value per parameter (ie, per 
lesion, the maximum CSC/C and C/SC, the lowest ADC25 and WO25, and the highest 
WI75) were used for analysis.
 With the use of the models built in the development set, each lesion was given a 
probability (P) between 0 and 1 of being a high-grade cancer based on their parameter 
values. To test this model, a cutoff point near 0.50 with a relatively high sensitivity 
(88%) on the ROC curve was chosen to separate high-grade from low-grade cancer, 
and the corresponding probability value P was determined. Cancer lesions in the 
validation set with an outcome P of the LRM below the selected cutoff value were 
considered low-grade and above this cutoff value as high-grade. One ROC curve 
was made, regardless of the zonal origin, to evaluate the discriminating performance 
in the validation setting.
  Statistical analyses were performed using GraphPad Prism v.5.0. (GraphPad 
Software, San Diego, CA, USA) and IBM SPSS statistics for Windows, version 20 
(IBM Corp, Armonk, NY, USA).
Results
Eight patients were excluded from the development set because of failed DCE-MRI 
(n = 1) or because the subjects only had lesions of insignificant size (< 0.5 cm3 
according to histopathology; n = 7). Overall, 54 cancer lesions were present in the 
remaining 43 patients (Fig. 1; Table 2). 
 In the validation set, 7 patients were excluded because no reliable pathology 
results were available (n = 2) or subjects only had cancer lesions smaller than 0.5 
cm3 (n = 5). In total, 68 cancer lesions were present in the remaining 51 patients. 
Three cancer lesions (all within the TZ) were excluded from analysis because of an 
insufficient signal-to-noise ratio of the MRSI spectra. Finally, 65 cancer lesions were 
included in the validation set (Fig. 1; Table 2).
 In the development set, the best discriminating performance in the PZ was 
achieved using an LRM model containing ADC25 and WO25, giving an AUC of 0.85. 
Separately, these parameters showed AUCs of 0.82 and 0.81, respectively (Table 3). 
Adding any other parameters to the model did not contribute to the discriminating 
performance. 
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Table 2  Characteristics of patients and tumors. 
DEVELOPMENT SET VALIDATION SET
No. of patients 43 52
PSA, median (range), mg/ml 7.5 (2.1 – 41.0) 7.0 (2.5 – 44.9)
Age, median (range), yr 64 (42 – 70) 62 (48 – 70)
Gleason score No. lesions Gleason score No. lesions
Peripheral 
zone:
  3 + 2
  3 + 3 
  3 + 3 + 4
  3 + 4 
  3 + 4 + 5 
  4 + 3
  4 + 3 + 5
  4 + 4
  4 + 4 + 5
  4 + 5
  5 + 3
Transition 
zone:
  2 + 3
  3 + 2
  3 + 3
  3 + 4
  4 + 2
  4 + 3 + 5
  4 + 5
Low*
Low
High
High
High
High
High
High
High
High
High
Low
Low
Low
High
High
High
High
2
11
1
9
2
9
1
1
1
2
1
Total: 40
Low: 13
High: 27
2
3
2
1
1
4
1
Total: 14
Low: 7
High: 7
Peripheral 
zone:
3 + 2
3 + 3
3 + 4
3 + 4 + 5
3 + 5
4 + 3 
4 + 3 + 5
4 + 4 
4 + 5
Transition 
zone:
1 + 2
2 + 3
3 + 2
3 + 3
2 + 3 + 4
3 + 2 + 4
4 + 3
4 + 3 + 5
Low
Low
High
High
High
High
High
High
High
Low
Low
Low
Low
High
High
High
High
1
14
16
3
3
4
4
1
2
Total: 48
Low: 15
High: 33
1
1
3
5
1
3
1
2
Total: 17
Low: 10
High: 7
*  Cancers are classified in classes according to their aggressiveness, solely based on the Gleason 
score. Any Gleason grade 4 or higher was considered as high-grade.
PSA, prostate-specific antigen
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 The optimal combination of parameters in the TZ proved to be C/SC and WO25, 
with an AUC of 0.92. Individually, these parameters separately showed AUCs of 0.83 
and 0.80, respectively (Table 3). In contrast to the PZ, ADC25 does not perform well 
in the TZ with only an AUC of 0.65. No additional value was found when any other 
parameters were included to the model. An example of the optimal parameter 
combination in a high-grade PCa in the TZ is shown in Figure 2.
 The validation set showed an AUC of 0.75 for the discrimination between low- 
grade and high-grade PCa, with the different combination of parameters for each 
zone as described previously. A selected cutoff value on the ROC curve with a sensitivity 
Table 3  AUC for discriminating between low-grade and high-grade prostate 
cancer lesions in the development set.
Peripheral zone Transition zone
Individual parameters
   ADC25 0.82 * 0.65
   WO25 0.81 0.80
   WI75 0.77 0.63
   CSC/C 0.74 0.71
   C/SC 0.69 0.83 †
Combination peripheral zone
   ADC25 + WO25 + WI75 + C/SC + CSC/C 0.85 ---
   ADC25 + WO25 + WI75 + C/SC 0.85 ---
   ADC25 + WO25 + WI75 0.85 ---
   ADC25 + WO25 0.85 * ---
Combination transition zone
   WO25 + C/SC + WI75 + ADC25 + CSC/C --- 0.92
   WO25 + C/SC + WI75 + ADC25 --- 0.92
   WO25 + C/SC + WI75 --- 0.92
   WO25 + C/SC --- 0.92 †
For the combination, parameters were excluded by using the backward elimination approach of the logistic 
regression model; in each step, the parameter with the least contributing value to the model was excluded. 
*† Difference between AUC of the ROC curves not statistically significant (p > 0.05).
ADC25, lowest 25th percentile of the apparent diffusion coefficient; WO25, lowest 25th percentile of the wash- out 
gradient; WI75, highest 75th percentile of the wash-in gradient; CSC/C, choline + spermine + creatine over 
citrate ratio; C/SC, choline over spermine + creatine ratio; ROC, receiver operating characteristic; AUC, 
area under the receiver operating characteristic curve.
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of 88% and corresponding specificity of 52% (P > 0.435) resulted in 18 cancers 
being classified as low-grade and 47 as high-grade. With this selected cutoff value, 
48 (74%) of 65 cancer lesions were classified correctly, 5 (7%) of 65 were classified as 
low-grade while being high-grade (although all with a primary Gleason 3 component; 
Table 4) according to histopathology (ie, false negative), and 12 (18%) of 65 were 
classified as high-grade while being low-grade (ie, false positive, Table 4). 
Table 4  Classification of aggressiveness in low-grade and high-grade  
prostate cancer lesions for the validation set, based on the models built using 
the development set.
mpMRI Histopathology results
Aggressiveness Aggressiveness GG Vol. (cm3)
Correct classification
   Peripheral zone (n = 36) Low ( n = 7) Low GG ≤3
High (n = 29) High GG ≥4
   Transition zone (n = 12) Low (n = 6) Low GG ≤3
High (n = 6) High GG ≥4
Incorrect classification
   Peripheral zone (n = 12) Low (n = 4) High 3 + 4 0.6
3 + 4 1.3
3 + 4 2.6
3 + 5 1.1
High (n = 8) Low 3 + 3 11.7
3 + 3 0.5
3 + 3 2.1
3 + 3 5.3
3 + 3 0.6
3 + 3 3.4
3 + 3 1.0
3 + 3 1.0
   Transition zone (n = 5) Low (n = 1) High 3 + 2 (+4) 10.0
High (n = 4) Low 3 + 3 2.5
3 + 3 0.7
3 + 2 1.0
3 + 2 1.3
mpMRI, multiparametric magnetic resonance imaging; GG, Gleason grade; Vol, volume.
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Discussion
The 25th percentile of the ADC + WO25 is the optimal combination for the PZ, and C/
SC + WO25 is the optimal combination for the TZ to discriminate between low-grade 
and high-grade PCa. These combinations showed a higher AUC compared to the 
use of any single parameter, illustrating the added value for the use of multiple 
techniques for the assessment of prostate cancer aggressiveness, although the 
differences between the best performing single parameter and the optimal 
combination of two parameters were not statistically significant. Therefore, larger 
validation studies are needed to confirm these findings. Adding more techniques to 
ADC25 + WO25 in the PZ and C/SC + WO25 in the TZ did not increase the 
discriminating performance at all. 
 In the validation setting, only few cancer lesions were underestimated (5/65) for 
their aggressiveness by MRI, and all of these had a primary GG 3 component: 3 + 4 
(n = 3) and 3 + 5 (n = 1) originating from the PZ and one lesion 3 + 2 with a tertiary 
4 component (n = 1, TZ). Although some authors argue that a Gleason score of 3 + 
4 could be considered as low-risk disease in specific cases23, we decided to consider 
any secondary or tertiary 4 or 5 component as high-grade because of our 
methodology (ie, using the ROI with the most aberrant value for analysis and with 
that, accounting for heterogeneity of PCa or a possible hot spot in the tumor lesion). 
Perhaps a percentage or volume of GG 4 component within the tumor, to be indicated 
by the pathologist, could help in this decision. Future work is warranted to correlate 
mpMRI with an even more meticulous analysis of the exact amount of Gleason 4 
component in a cancer lesion. A higher number of cancer lesions (12/65) were 
predicted more aggressive than the actual Gleason score. In the peripheral zone 
(n = 8), 7 of these cancers had a Gleason score of 3 + 3, and 1 lesion had a Gleason 
score of 3 + 2. In the TZ (n = 4), two of these cancers had a Gleason score of 3 + 3 
and two were 3 + 2. Most of these cancers are not aggressive according to Gleason 
score but may be significant in terms of size.24,25 However, size was not included in 
the model as a predictive factor because we only aimed to focus on assessment of 
aggressiveness according to Gleason score. In clinical practice, volume should be 
incorporated in the decision-making process for any treatment. In addition, the 
number of TZ lesions is relatively low. Although the outcome is very promising for the 
TZ, these results should be interpreted with caution. Future studies with a larger 
number of subjects are needed to confirm these preliminary results. 
 In our study setting, it was a deliberate decision to analyze only histologically 
proven cancer lesions because we aimed to focus on validation of mpMRI for 
aggressiveness solely, and thus no detection performance or reader study was 
carried out. To discriminate between low-grade and high-grade PCa in the validation 
setting, we selected a cutoff value with a relatively high sensitivity, to ensure that 
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fewer subjects would be classified false negative. Any cutoff point on the ROC curve 
could have been chosen; however, the rationale for selecting this point is that one 
needs to reduce the probability of underestimation of aggressiveness while at the 
same time definite highly aggressive PCa needs to be recognized reliably. As a next 
step, both the detection and characterization of PCa could be evaluated by 
incorporating our findings in this complete evaluation package, followed by a reader 
study to confirm its true prognostic value. 
 Over the last years, active surveillance has gained more interest for patients with 
low-risk PCa26,27, but concerns remain that the patient’s tumor is actually more 
aggressive than estimated on the basis of current diagnostic tools such as pros-
tate-specific antigen or systematic transrectal ultrasound biopsies.28 A recent study 
by Turkbey et al.29 showed that mpMRI provides useful additional information to 
existing clinical scoring systems, and it improves the assignment to either active 
treatment or active surveillance; however, the patient cohort and methods in that 
study are very different from ours (eg, in that study, only patients who met the criteria 
for active surveillance based on clinical scoring systems were included; MR 
parameters were evaluated on a suspicion-level basis; and no correlations of the 
individual parameters to Gleason scores were reported). Many other studies have 
been performed regarding mpMRI for prostate cancer. Most of these studies focused 
on the detection of prostate cancer rather than the assessment of aggressiveness 
and used transrectal ultrasound biopsies as a reference standard or did not evaluate 
the full combination of functional MRI techniques.1,2,6,30-33 To the best of our knowledge, 
this is the first study that evaluated all three functional techniques together, with a 
solid reference standard to find the optimal combination of parameters for the 
assessment of PCa aggressiveness, for the PZ and TZ separately.
 The reason for incorporating spermine into the metabolite ratios is that this peak 
can overlap with the creatine peak in the spectra. Neglecting this peak can lead to 
overestimation of the choline or creatine peak, and thus lead to an incorrect metabolite 
ratio. The rationale for using only semi-quantitative DCE-MRI parameters is that they 
are relatively easy to calculate in contrast to pharmacokinetic parameters. Moreover, 
pharmacokinetic parameters are not suitable for widespread application in different 
institutes with different acquisition protocols because of the fact that numerous 
approaches for modeling exist and calibration by using an arterial input function can 
be done in multiple ways. Implementation and interpretation of both MRSI and 
DCE-MRI require experience. Incorporation in clinical practice may thus be reserved 
for specialized institutions or require robust standardized automation for widespread 
clinical use. Our results indicate that both techniques show potential in the assessment 
of PCa aggressiveness, and it therefore may be worthwhile to indeed invest in stan-
dardization and automation of both MRSI and DCE-MRI for an mpMRI approach to 
characterize PCa. 
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 Our results could be of important clinical value. We found that different combinations 
of techniques should be used for the assessment of PCa aggressiveness in the PZ 
and TZ. Although ADC usually performs well for the detection of prostate cancer 
regardless of the location within the prostate, we have shown that ADC is not of any 
value for predicting the aggressiveness of cancer lesions in the TZ, and these results 
are in line with previous reports.34,35 In contrast, DCE-MRI regularly shows false 
positives in a detection setting, whereas our results show that WO25 is useful for the 
assessment of aggressiveness of an already detected and localized cancer lesion, 
when combined with ADC in the PZ and C/SC in the TZ. In the future, this can be 
relevant for follow-up of histopathologically proven PCa. The combination of techniques 
in mpMRI offers a noninvasive imaging tool as a method for the assessment of PCa 
aggressiveness and may provide useful information to incorporate in nomograms or 
in the decision-making process for selecting patients suitable to stay on active 
surveillance and thus preventing overtreatment of PCa.
In conclusion, mpMRI is a useful tool for the discrimination between low-grade and 
high-grade PCa and performs better than any single individual functional parameter 
in both PZ and TZ. For the PZ, the proposed optimal combination of parameters is the 
25th percentile of ADC derived from DWI and the 25th percentile of wash-out derived 
from DCE-MRI. For the TZ, wash-out may be combined with the C/SC acquired by 
MRSI, and ADC is not of any value. Adding any other technique does not increase the 
discriminating performance at all. 
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Abstract
Objectives
The objectives of this study were to test the feasibility of an investigational dual-channel 
next-generation endorectal coil (NG-ERC) in vivo, to quantitatively assess signal- 
to-noise ratio (SNR), and to get an impression of image quality compared with the 
current clinically available single-loop endorectal coil (ERC) for prostate magnetic 
resonance imaging at both 1.5 and 3 Tesla (T).
Materials and Methods
The study was approved by the institutional review board, and written informed 
consent was obtained from all patients. In total, 8 consecutive patients with prostate 
cancer underwent a local staging magnetic resonance examination with the successive 
use of both coils in 1 session (4 patients at 1.5 T and 4 other patients at 3 T). 
Quantitative comparison of both coils was performed for the apex, mid-gland and 
base levels at both field strengths by calculating SNR profiles in the axial plane on 
an imaginary line in the anteroposterior direction perpendicular to the coil surface. 
Two radiologists independently assessed the image quality of the T2-weighted and 
apparent diffusion coefficient maps calculated from diffusion-weighted imaging 
using a 5-point scale. Improvement of geometric distortion on diffusion-weighted 
imaging with the use of parallel imaging was explored. Statistical analysis included a 
paired Wilcoxon signed rank test for SNR and image quality evaluation as well as κ 
statistics for interobserver agreement.
Results
No adverse events were reported. The SNR was higher for the NG-ERC compared 
with the ERC up to a distance of approximately 40 mm from the surface of the coil 
at 1.5 T (p < 0.0001 for the apex, the mid-gland, and the base) and approximately 
17 mm (p = 0.015 at the apex level) and 30 mm at 3 T (p < 0.0001 for the mid-gland 
and base). Beyond this distance, the SNR profiles of both coils were comparable. 
Overall, T2-weighted image quality was considered better for NG-ERC at both field 
strengths. Quality of apparent diffusion coefficient maps with the use of parallel 
imaging was rated superior with the NG-ERC at 3 T.
Conclusions
The investigational NG-ERC for prostate imaging outperforms the current clinically 
available ERC in terms of SNR and is feasible for continued development for future 
use as the next generation endorectal coil for prostate imaging in clinical practice.
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Introduction
Magnetic resonance (MR) imaging is becoming the imaging modality of choice in the 
workup of prostate cancer1-5, therefore a high quality diagnostic MR examination is 
essential. For this purpose, a pelvic phased-array receive coil is commonly used. To 
enhance the signal-to-noise ratio (SNR), an endorectal coil (ERC) is introduced 
intrarectally so that it can be placed against the prostate.6 The use of such a surface 
coil leads to an increased SNR that can be utilized for a higher spatial resolution, 
which, in turn, leads to an improved staging performance with recognition of 
extracapsular extension and seminal vesicle invasion.7-10 Despite these advantages, 
controversy remains about the use of an ERC. Endorectal coil use is expensive, the 
insertion is time-consuming and needs expertise, deformation of the prostate is 
basically unavoidable, and a coil causes discomfort to the patient.11-13 A wide range of 
staging accuracies (53–98%) with ERC MR imaging has been reported, resulting in 
different recommendations regarding the use of an ERC.7,9,14-18 Improved coil 
properties may overcome some of these controversies and disadvantages.
 Recently, a dual-channel next generation ERC (NG-ERC; Medrad inc., Pittsburgh, 
United States) has been developed. The dual-channel configuration should demonstrate 
a gain in SNR compared with the single-loop ERC (Medrad inc., Pittsburgh, United 
States) and could create the possibility of parallel imaging (PI), enabling shorter 
acquisition times.19 One study demonstrated the feasibility of a double loop phased 
array ERC previously20; however, this was tested on a phantom and in one patient 
only at 3 T and without quantitative comparison with a single-loop ERC.
 Therefore, the purpose of this study was to test the clinical feasibility of the 
 investigational NG-ERC in vivo, to quantitatively assess SNR, and to get a qualitative 
impression of image quality compared with the currently available ERC for imaging 
prostate cancer at both 1.5 and 3 T. 
Materials and methods
Patient characteristics 
The study was approved by the institutional review board, and written informed 
consent was obtained from all patients. In August 2011, a total of eight consecutive 
patients with a median age of 64 (range, 56 – 72) years and newly diagnosed 
biopsy-proven prostate cancer with a median Gleason score of 6 (range, 6 – 9) who 
were scheduled for a staging MR examination were included. The MR imaging was 
performed at least four weeks after systematic transrectal ultrasound biopsy. 
Exclusion criteria were previous treatment, contraindications to MR imaging (eg, 
cardiac pacemakers, intracranial clips), contraindications to ERC insertion (eg, 
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anorectal surgery, inflammatory bowel disease), and metallic hip implants or any 
other metallic implant that distorts local magnetic field and compromises the quality 
of MR imaging. 
Coil design
The complete coil system consists of an interface device with system cable and coil 
plug as well as a reusable intermediate cable to connect to the disposable NG-ERC 
(Fig. 1).
 Different from the currently available ERC, which has only one channel for signal 
reception, the NG-ERC is a two-element receive-only surface coil with the elements 
arranged in a transverse configuration allowing PI capabilities. It contains active and 
passive decoupling circuits to minimize coupling to the externally-applied transmit 
field, which also serves to minimize local specific absorption rate (SAR) levels. The 
NG-ERC conductor is attached to an inflatable balloon and is covered by an outer 
balloon, all of which are affixed to a flexible shaft with a handle. The balloon of the 
NG-ERC (approximately 4.2 x 2 x 1.3 in) is slightly larger than the balloon for the 
traditional ERC (approximately 4.2 x 1.4 x 1.0 in), but is made of softer latex and a 
thinner coil wiring, which should make it easier to insert. After the NG-ERC has been 
inserted, the balloon can be expanded within the patient’s rectal cavity by inflating the 
balloon with liquid or air (liquid is preferred because it is known that the use of air can 
cause susceptibility artifacts) to ensure a correct and fixed position against the 
prostate.
 The NG-ERC conductors and resonating capacitors are realized by a multi-layer 
printed circuit board that also serves to mount the PIN diodes and inductors used for 
active decoupling. Coaxial cables are attached to the printed circuit board to route 
the individually received radiofrequency (RF) signals via an intermediate cable and 
interface to the MR system. The NG-ERC connector shell contains components that 
passively decouple the NG-ERC from the RF transmit field in the event where an 
operator inadvertently performs a scan with only the NG-ERC in place, without the 
interface device and intermediate cable connected. The intermediate cable has two 
cable traps along its length; these, along with a dual balun, serve to block transmit 
field-induced shield currents. This enhances safety by reducing local heating effects 
and serves to minimize local SAR around the cable. The intermediate cable is 
approximately 20 in (51 cm), which allows the interface device to be located some 
distance from the patient and closer to the MR scanner’s system connector. For the 
currently available ERC, a decoupling circuitry was incorporated in an external 
interface at approximately 10 in (25 cm) from the ERC.
 The interface device prototype is a unit that contains additional active decoupling 
control, RF amplification, RF signal routing and conditioning circuitry. The unit houses 
a cable trap and the circuitry required to identify the NG-ERC system to the scanner 
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hardware, thus allowing the proper coil configuration file to be selected. The 
identification code for the NG-ERC is supplied to the scanner only when the NG-ERC 
is electrically connected to the interface device through the intermediate cable, thus 
preventing scanning unless the proper connections are made. The interface device 
has a permanently connected system cable with a cable trap and system connector 
compatible with the scanner’s multichannel receive-only surface coil connector.
Acquisition protocol 
Magnetic resonance imaging was performed in four patients at 1.5 T (Avanto; 
Siemens Medical Systems, Erlangen, Germany) and in four other patients at 3 T 
(MAGNETOM Trio, Siemens Medical Systems, Erlangen, Germany) in the supine 
position. Peristalsis was suppressed through an intramuscular injection of 1 mg 
glucagon (GlucaGen Hypokit, Novo Nordisk, Bagswærd, Denmark) and 20 mg bu-
tylscopolamine bromide (Buscopan; Boehringer-Ingelheim, Ingelheim, Germany), 
plus an additional intravenous injection of 20 mg Buscopan.
 First, the NG-ERC was inserted and filled with approximately 60 mL of an inert 
perfluoropolyether liquid (Fomblin; Solvay Solexis, Bollate, Italy). This is a liquid 
invisible on MRI and minimizing artifacts from susceptibility differences between 
prostate and rectal cavity. The position of the coil was checked with a coil-localizer 
sequence, and the coil was adjusted into the correct position if necessary. The coil 
was considered as positioned correctly when it covers the entire prostate from apex 
level up to the seminal vesicles, with the active coil elements facing straight toward 
the prostate for optimal signal reception. After that, the standard in-house staging 
protocol (Table 1) was performed including the following: axial T2-weighted (T2w) 
images and diffusion-weighted imaging (DWI), both with and without PI. The two-fold 
acceleration factor in PI reduced the number of necessary excitations in the multi-shot 
multiple spin echo sequence (T2w) and enabled shortening of the single-shot 
echo-planar imaging echo train and, with that, the effective echo time in DWI. 
Because of fewer echoes per slice and equal amount of slices, the repetition time 
(TR) could also be reduced in DWI. Apparent diffusion coefficient (ADC) maps were 
calculated automatically by the scanner. Immediately after a precontrast proton 
density (PD) image set with a low flip angle and a long TR, a second identical image 
set with an excitation pulse of 0 V (PD0) was acquired to obtain a corresponding 
image set with only noise. Then, the NG-ERC was deflated as well as removed and 
the ERC was introduced in the same patient. After a careful coil repositioning, 
checked by the localizer sequence, the identical protocol, obviously apart from PI, 
was performed with the ERC filled with approximately 45 mL of the inert perfluoro-
polyether liquid (15 mL less than the NG-ERC due to differences in size of the inner 
balloon). 
501341-L-bw-Vos
109
COMPARISON BETWEEN ENDORECTAL COILS
6
Ta
b
le
 1
  S
ca
nn
in
g 
pa
ra
m
et
er
s.
 
S
eq
ue
nc
e
TR
/T
E
 
(m
s)
α (°
)
Vo
xe
l s
iz
e 
(m
m
3 )
E
TL
A
ve
.
A
cc
. f
ac
to
r
R
ef
. l
in
es
TA
 (
m
in
)
1.
5
T2
w
 a
xi
al
50
40
/1
20
15
0
0.
6 
x 
0.
6 
x 
3.
0
23
 *
2
N
on
e
3:
58
T2
w
 a
xi
al
, P
I
50
40
/1
20
15
0
0.
6 
x 
0.
6 
x 
3.
0
23
 *
3
2
32
3:
08
D
W
I
31
00
/9
9
1.
8 
x 
1.
7 
x 
3.
0 
80
8
N
on
e
4:
13
D
W
I, 
P
I
24
00
/8
6
1.
8 
x 
1.
7 
x 
3.
0
58
8
2
18
3:
21
P
D
  8
00
/1
.5
9
8
2.
7 
x 
1.
1 
x 
4.
0
1
N
on
e
1:
03
P
D
0 
(o
nl
y 
no
is
e)
  8
00
/1
.5
9
8
2.
7 
x 
1.
1 
x 
4.
0
1
N
on
e
1:
03
3 
T
T2
w
 a
xi
al
42
80
/9
9
12
0
0.
4 
x 
0.
4 
x 
3.
0
15
 †
1
N
on
e
4:
21
T2
w
 a
xi
al
, P
I
42
80
/9
9
12
0
0.
4 
x 
0.
4 
x 
3.
0
15
 †
2
2
32
3:
21
D
W
I
31
00
/7
6
2.
0 
x 
2.
0 
x 
3.
0
88
 
10
N
on
e
4:
42
D
W
I, 
P
I
23
00
/6
2
2.
0 
x 
2.
0 
x 
3.
0
62
10
2
18
3:
34
P
D
  3
00
/1
.5
1
10
1.
5 
x 
1.
5 
x 
3.
0
1
N
on
e
1:
26
P
D
0 
(o
nl
y 
no
is
e)
  3
00
/1
.5
1
10
1.
5 
x 
1.
5 
x 
3.
0
1
N
on
e
1:
26
Fo
r b
ot
h 
th
e 
ne
xt
-g
en
er
at
io
n 
en
do
re
ct
al
 c
oi
l a
nd
 th
e 
cu
rr
en
tly
 a
va
ila
bl
e 
en
do
re
ct
al
 c
oi
l, 
id
en
tic
al
 p
ro
to
co
ls
 w
er
e 
us
ed
 p
er
 fi
el
d 
st
re
ng
th
.
A
t 1
.5
 T
, b
 v
al
ue
s 
0,
 5
0,
 5
00
 a
nd
 8
00
 s
/m
m
2  w
er
e 
us
ed
. A
t 3
 T
, b
 v
al
ue
s 
50
, 5
00
 a
nd
 8
00
 s
/m
m
2  w
er
e 
us
ed
. 
A
pp
ar
en
t d
iff
us
io
n 
co
ef
fic
ie
nt
 m
ap
s 
w
er
e 
ca
lc
ul
at
ed
 a
ut
om
at
ic
al
ly
 b
y 
th
e 
sc
an
ne
r.
* 
 N
um
be
r o
f s
ho
ts
 in
 m
ul
tis
ho
t m
ul
ti-
ec
ho
 im
ag
in
g 
se
qu
en
ce
 c
ou
ld
 b
e 
re
du
ce
d 
by
 P
I f
ro
m
 2
3 
w
ith
ou
t P
I (
fo
r s
am
pl
in
g 
of
 2
56
 x
 2
56
 im
ag
in
g 
m
at
rix
) t
o 
12
 s
ho
ts
 w
ith
 P
I 
(fo
r 2
56
 x
 2
56
 m
at
rix
, b
ut
 w
ith
 3
 a
ve
ra
ge
s)
.
† 
 N
um
be
r o
f s
ho
ts
 in
 m
ul
tis
ho
t m
ul
ti-
ec
ho
 im
ag
in
g 
se
qu
en
ce
 c
ou
ld
 b
e 
re
du
ce
d 
by
 P
I f
ro
m
 6
0 
w
ith
ou
t P
I (
in
cl
ud
in
g 
10
0%
 o
ve
rs
am
pl
in
g 
of
 4
48
 x
 4
48
 im
ag
in
g 
m
at
rix
) t
o 
23
 s
ho
ts
 w
ith
 P
I (
in
cl
ud
in
g 
50
%
 o
ve
rs
am
pl
in
g 
of
 4
48
 x
 4
48
 m
at
rix
, b
ut
 w
ith
 2
 a
ve
ra
ge
s)
. 
α,
 fl
ip
 a
ng
le
; A
cc
, A
cc
el
er
at
io
n;
 A
ve
, a
ve
ra
ge
s;
 D
W
I, 
di
ffu
si
on
-w
ei
gh
te
d 
im
ag
in
g;
 E
TL
, e
ch
o 
tra
in
 le
ng
th
; P
D
, p
ro
to
n 
de
ns
ity
; P
D
0,
 p
ro
to
n 
de
ns
ity
 w
ith
 a
 ra
di
of
re
qu
en
cy
 
pu
ls
e 
of
 0
 V
ol
t; 
P
I, 
pa
ra
lle
l i
m
ag
in
g;
 R
ef
, r
ef
er
en
ce
; T
2w
, T
2-
w
ei
gh
te
d;
 T
A
, a
cq
ui
si
tio
n 
tim
e;
 T
E
, e
ch
o 
tim
e;
 T
R
, r
ep
et
iti
on
 ti
m
e.
501341-L-bw-Vos
110
CHAPTER 6
 The NG-ERC had to be inserted first in all examinations, because administration 
of contrast agent within the framework of dynamic contrast-enhanced MR imaging 
was incorporated in the clinical protocol and contrast agent can only be given once. 
 In all examinations, both the ERC and the NG-ERC were used as receive-only 
surface coils, with the body coil for signal transmission. Although receive-only coils 
with sufficient decoupling would not cause an increase in SAR, maximum SAR limits 
were lowered with a factor of 2 to ensure patient’s safety.
Quantitative image evaluation
A quantitative comparison between the ERC and the NG-ERC was performed by 
calculating SNR profiles in the prostate with the PD data set because of the negligible 
T1- and T2-weighting, and the PD0 dataset with only noise. On these images at the 
base, the mid-gland, and the apex level, the SNR profiles for each patient and the 
same anatomical location were calculated for both coils and field strengths with the 
use of IDL (Exelis Visual Information Solutions, Boulder, CO, USA). The MR signal 
intensity of the axial PD image along an imaginary line in the anterior-posterior 
direction in the axial plane perpendicular to the surface of the coil (Fig. 2) was 
normalized to the standard deviation of the noise of the corresponding PD0 image, 
providing the SNR profile. Values and location of the maximum SNR across the 
profiles were compared between coils, and if differences in SNR existed, the distance 
across the profile where SNR differed was recorded. The individual SNR profiles of 
the four patients at each field strength and location could be averaged into the final 
SNR profile for different coils and field strengths.
 For DWI, the shorter echo train from the use of PI could result in lower geometric 
distortion. This was evaluated by measuring the size of the prostate in the phase- 
encoding (ie, left-right) direction on axial DWI with and without PI and comparing this 
to the size of the prostate on axial T2-weighted images on both field strengths.
Qualitative image evaluation
Two radiologists (C.H. and D.Y.), both with three years of experience and more than 
400 examinations in prostate MR imaging, evaluated the datasets of T2w images and 
ADC maps for both coils in all patients independently. They were aware of the 
magnetic field strength of the image at hand and of the fact that patients had 
biopsy-proven prostate cancer. They were unaware of other clinical findings, coil 
type, and whether PI was used or not. The data sets were presented to the radiologists 
in random order at a digital workstation (Syngo MultiModality Workplace VE25A; 
Siemens AG, München, Germany) on separate days. The T2w images, the ADC 
maps with the use of PI, and the ADC-maps without the use of PI were evaluated 
separately. Care was taken not to present the radiologists with two image sets of the 
same patient on the same day to avoid recognition of the prostate by the radiologists.
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 An overall image quality estimate was given on a 5-point scale (1, poor; 2, 
moderate; 3, satisfactory; 4, good; 5, excellent) to each data set. For the T2w images, 
quality was based on the conspicuity of anatomical details (peripheral zone, transition 
zone, both neurovascular bundles and prostate capsule), coverage (did the coil 
reception profile cover the entire prostate from apex up to base? ie, correct positioning 
of the coil), and penetration depth (signal reception from further distance of coil 
surface due to potential inhomogeneous signal reception covering the prostate 
caused by the use of a surface coil). For the ADC maps, only coverage and penetration 
depth of the coil contributed to the overall image quality because DWI is not a typical 
image setting for evaluation of anatomical details (as opposed to anatomical T2w 
images). 
Statistical analysis
A paired Wilcoxon signed rank test was used to compare mean SNR values and to 
compare the mean qualitative scores per image characteristic for both coils per field 
Fig. 2  Example of an axial PD image (A) and a corresponding PD0 image (B) with 
only noise as used for the calculation of the SNR profiles. The yellow circle represents 
the prostate; the green circle, the ERC. The signal intensity of the red line through the 
rectum and the prostate in the anteroposterior direction was normalized to the 
standard deviation of the noise in the PD0 image to calculate the SNR profile. The 
black horizontal lines perpendicular to the red line represent the distance from the 
center of the coil (with the center between the coil conductors equal to 0 mm).
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strength. It is expected that the SNR would be higher for the NG-ERC compared with 
the ERC up to a certain distance; therefore, the cutoff point for analysis was chosen 
at that particular point where the SNR profile for the NG-ERC crosses the SNR profile 
of the ERC so that we could test whether the expected higher SNR of the NG-ERC 
differed significantly from the SNR of the ERC. P < 0.05 was considered statistically 
significant. Image quality analysis also included к statistics for interobserver 
agreement. The following qualitative terms were used to describe the strength of the 
agreement: 0.0 to 0.20, slight agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60, 
moderate agreement; 0.61 to 0.80, substantial agreement; and 0.81 to 1.0, almost 
perfect agreement. GraphPad Prism 5.0 for Windows (GraphPad Software, San 
Diego, CA, USA) and Statistical Package for the Social Sciences software 18.0.2 
(IBM Corp, Somers, NY, USA) were used for the statistical analysis.
Results
All patients completed the entire protocol with both coils. One example at both field 
strengths of anatomical T2w imaging and DWI is shown in Figure 3. During and after 
the protocol, no adverse events occurred. 
Quantitative image  evaluation
The NG-ERC showed an increase in SNR compared with the use of the ERC at both 
field strengths. The maximum SNR of all coils was found in the tissue closest to the 
coil surface and decays with increasing distance from the coil surface (Table 2). 
Maximum SNR was higher for the NG-ERC, compared with the ERC for the whole 
gland in all patients, except for two patients at 1.5 T for the base level (Table 2). 
Overall, the NG-ERC demonstrated an improvement of SNR up to a distance of 
approximately 40 mm (p < 0.0001) from the coil surface at 1.5 T (Fig. 4A). At 3 T, 
the NG-ERC showed improvement of SNR up to a distance of approximately 17 mm 
at apex level (p = 0.015) and 30 mm at the mid-gland and base levels (p < 0.0001; 
Fig. 4B). Beyond these distances, SNR profiles of both coils were comparable. 
 At 1.5 T, no differences were measured in geometric distortion on DWI with and 
without PI. At 3 T, in two patients, no geometric distortion was seen on DWI with PI; 
and the DWI without PI deviated 1.9% and 2.7% compared with the T2w images in 
these patients. In the other two patients, the geometric distortion on DWI without PI 
deviated 6.0% and 6.8% of the original size of the prostate that was measured on T2w 
images. The distortion in these patients was only 2.0% and 2.3%, respectively, with 
the use of PI. 
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Fig. 4  Mean SNR profiles of 4 patients at 1.5 T for the apex (upper part), mid-prostate 
level (middle part), and base (bottom part) (A) and 4 patients at 3 T for the apex 
(upper part), mid-prostate level (middle part), and base (bottom part) (B). The blue 
line represents the NG-ERC, and the red line represents the ERC. Error bars show the 
standard deviation. See also Figure 2 for a description of the x axis and the profile 
location.
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Qualitative image evaluation
Overall T2w image quality was rated higher with the NG-ERC compared with the ERC 
at both field strengths (Table 3). Imaging with PI was rated inferior than without PI 
when using the NG-ERC, however both were considered better than images obtained 
with the ERC. 
 For ADC maps at 1.5 T, imaging with the ERC scored higher for overall image 
quality compared with that with the NG-ERC. At 3 T, overall image quality of the ADC 
maps obtained with the ERC was better than with the NG-ERC; however, both were 
outperformed by results from NG-ERC with PI (Table 3). 
 None of the differences in qualitative image assessment were statistically 
significant. Interobserver agreement for the assessment of overall T2w image quality 
was fair at 1.5 T (к = 0.31) and substantial at 3 T (к = 0.63), and fair for ADC maps (к 
= 0.36 and 0.38 for 1.5 T and 3 T, respectively). 
Discussion
This study showed that the NG-ERC for prostate imaging outperforms the current 
clinical standard in terms of SNR and that it is feasible to pursue the development for 
future use as the next generation endorectal coil for prostate imaging in clinical 
practice. By significantly increasing the SNR up to a distance of 17 to 30 mm at 3 T 
and 40 mm at 1.5 T (and comparable SNR with the current ERC beyond these 
distances), the NG-ERC has the potential to create improved images. Prostates of 
elder men with large benign prostate hyperplasia nodules easily extend beyond 20 
mm from the coil surface12; thus, for full prostate coverage the significant increase in 
SNR up to these distances is desirable. The increase in SNR can be used to increase 
the spatial resolution, which may result in improved local staging performances in the 
future especially for the posterior region of the prostate where recognition of 
extracapsular extension and seminal vesicle invasion are highly relevant. Another 
way to benefit from the NG-ERC is in terms of time, by using PI. Even with a reduction 
of approximately 25% in scanning time for the T2w images and DWI, no significant 
differences in the image quality were observed compared with images acquired with 
the ERC. This proves that the production of high-quality images is still feasible while 
speeding up the examination. The dual-channel configuration of the NG-ERC thus 
provides an interesting tool that can be exploited in clinical practice. 
 The increase in SNR for the NG-ERC is less for the base level at 1.5 T, compared 
to the other prostate levels. This is most likely caused by differences in insertion 
depth of the NG-ERC in two patients, which was too shallow for the coil to optimally 
perform at the base. This was retrospectively confirmed with the sagittal images for 
checking of the coil position. These differences in insertion depth have led to the 
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larger standard deviation of the SNR profile for the base level at 1.5 T. Also, the large 
standard deviation in SNR for the apex level at 3 T was probably caused by a too-deep 
coil insertion in two patients. This illustrates the importance of checking the coil 
insertion depth relative to the prostate location in a sagittal view. 
 The maximum SNR levels of the coils between the different field strengths cannot 
readily be compared because the voxel size, the flip angle, and the repetition time of 
the PD data sets at both field strengths were different. Trying to correct for these for 
an absolute SNR comparison between 1.5 and 3 T introduces uncertainties and is 
beyond the scope of this work, in which the evaluation of a new ERC concept against 
existing coils was the main aim, rather than the comparison of magnetic field 
strengths. The large range in signal intensities of the NG-ERC coils will require a 
robust receive profile normalization filter or coil reception profile correction for image 
presentation with relatively homogeneous signal intensity. A fast low-resolution PD 
prescan could allow for this in clinical practice.
 Our results imply that imaging with the NG-ERC in combination with PI could be 
able to produce qualitatively better T2w images than the ERC at both field strengths. 
The differences in image quality, however, were not statistically significant. 
Interobserver variability existed, probably because of the use of a multiple-point 
scale and lack of clinical standard for scoring of these components. The lower scores 
for anatomical details on the images obtained with the ERC at 3 T were most likely 
caused by one dataset with severe motion artifacts (Fig. 3D) because, usually, 
anatomical details are well visible at T2w images. For quality of the ADC maps, only 
at 3 T PI seems to give an advantage over the ERC. It can be explained by the fact 
that, at 3 T, images may suffer more from susceptibility artifacts compared with 1.5 T. 
The susceptibility artifacts can be counteracted with the shorter echo train by using 
PI in DWI, resulting in lower geometric distortion at 3 T that also has been implied by 
our study. The fewer geometric distortion may yield a better image quality.
 Despite the promising results for improved image quality with the NG-ERC, 
limitations have to be considered. First, the total number of patients was adequate to 
assess the technical performance and SNR of the investigational coil, but too low for 
a full clinical evaluation with regard to staging performance. Therefore, we could only 
provide a first impression of image quality obtained by the investigational coil. In a 
next step, a prospective study with more patients need to be done to confirm its true 
value for staging performance compared with the current clinical standard. Second, 
both coils were tested in one session to ensure that both datasets were comparable 
regarding anatomy. As a result, patients had to stay in the scanner for a relatively long 
time and antiperistaltic agents might have partially worn off during the second part of 
the examination with the ERC. This could have led to motion artifacts that negatively 
influenced the qualitative analysis of the conventional ERC. 
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 Generally, the use of an ERC at 3 T may be questioned because of multiple 
reasons. Some are inherent to the use of an ERC, such as prostate deformation and 
the inhomogeneous receive profile. The latter can be dealt with by adequate image 
filters, relieving B1 inhomogeneity; the former can also be explained as fixation of the 
prostate to reduce motion artifacts. However, the purpose of this study was not to 
overcome or test these issues but rather to test the feasibility of an investigational 
dual-channel coil in patients, to compare SNR to the current coil, and to get a first 
impression of image quality. 
 Not only inflatable ERCs exist, but also rigid ERC concepts are available for 
prostate imaging.21,22 Each design has its own advantages, and the choice for a 
specific coil (and scanning protocol) should mainly be determined by the clinical 
question posed.23,24 The use of an ERC has advantages over the use of a pelvic 
phased-array coil only in certain patient cohorts. We showed that the NG-ERC is 
feasible to use in patients and that the increase in SNR with a dual-channel coil could 
improve imaging performances in the future, which makes this the next generation 
endorectal coil for prostate MR imaging.
In summary, on the basis of these preliminary results, we can conclude that the inves-
tigational NG-ERC for prostate imaging outperforms the current clinically available 
ERC for SNR and is thus feasible for continued development for future use as the next 
generation endorectal coil for prostate imaging in clinical practice. 
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Abstract
Purpose
To demonstrate that high quality T2-weighted turbo spin-echo (TSE) imaging of the 
complete prostate can be achieved routinely and within safety limits at 7 Tesla (T), 
using an external transceiver body array coil only. 
Methods
Nine healthy volunteers and 12 prostate cancer patients were scanned on a 7 T 
whole-body system. Preparation consisted of B0 and radiofrequency shimming and 
localized flip angle calibration. T1 and T2 relaxation times were measured and used 
to define the T2w-TSE protocol. T2w imaging was performed using a TSE sequence 
(pulse repetition time/echo time 3000-3640/71 ms) with prolonged excitation and 
refocusing pulses to reduce specific absorption rate.
Results
High quality T2w TSE imaging was performed in less than two minutes in all subjects. 
Tumors of patients with gold-standard tumor localization (MR-guided biopsy or 
prostatectomy) were well visualized on 7 T imaging (n = 3). The number of consecutive 
slices achievable within a 10-g averaged specific absorption rate limit of 10 W/kg was 
≥28 in all subjects, sufficient for full prostate coverage with 3 mm slices in at least one 
direction.
Conclusion
High quality T2w TSE prostate imaging can be performed routinely and within specific 
absorption rate limits at 7 T with an external transceiver body array. 
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Introduction
Multiparametric MR, including high-resolution anatomical imaging as well as 
functional techniques such as diffusion-weighted imaging, dynamic contrast-en-
hanced MRI, and proton MR spectroscopic imaging, plays an increasingly important 
role in the clinical management of prostate cancer.1-3 Increasing the static magnetic 
field strength B0 leads to an improved intrinsic signal-to-noise ratio (SNR) and spectral 
resolution. In prostate MR, increasing B0 from 1.5 Tesla (T) to 3 T has led to improved 
sensitivity and specificity in the detection, localization, and local staging of prostate 
cancer.4-7 Increasing B0 further, e.g., to 7 T, may lead to further improvements in image 
and spectral quality, and creates new opportunities for developing imaging 
biomarkers of prostate cancer aggressiveness, for instance using 31P-MRSI.8
 The advantage of an inherently higher SNR at ultra-high field strengths (≥ 7 T) 
compared with 3 T is counteracted by several effects. First, the wavelength in tissue 
of radiofrequency (RF) pulses at the 1H Larmor frequency at such high fields is 
smaller than the typical dimensions of the human body, leading to strongly 
inhomogeneous and patient-dependent transmit RF fields. Several methods aimed 
at either controlling the transmit RF distribution (e.g., transmit SENSE, RF shimming9-11) 
or exploiting it (e.g., time-interleaved acquisition of modes12) have been proposed of 
address this issue. In many cases, localized calibration of flip angles (FAs) becomes 
a requirement. Second, the absorption of RF power in human tissue increases with 
increasing frequency in the range of interest.13,14 This implies that with increasing field 
strength (i) a given amplitude of the transmit RF magnetic field B1
+ requires increased 
transmitted power; (ii) the received RF magnetic field B1
- is increasingly attenuated, 
reducing the achievable SNR; (iii) the specific absorption rate (SAR) of the RF electric 
field component increases, leading to increased tissue heating. These factors limit 
the SNR achievable within safety limits, especially for deeper lying organs such as 
the prostate. Dedicated, setup-specific simulations of RF-induced tissue heating are, 
therefore, needed to ensure patient safety at higher field strengths.8,11,15-17
 Clinical anatomical imaging of the human prostate predominantly relies on T2 
contrast, as proton density and T1 contrasts between the prostate peripheral zone 
(PZ), transition zone (TZ), and tumor tissue are negligible. Prostate anatomical 
images are, therefore, most commonly acquired using a T2-weighted (T2w) turbo 
spin echo (TSE) sequence. However, due to the high RF power deposition induced 
by the large number of refocusing pulses used by the TSE sequence, this sequence 
is not readily applicable at 7 T. TSE imaging at this field strength has been successfully 
performed in brain, the head and neck area, trabecular bone, and the knee.18-24 SAR 
was an important limiting factor in all of these studies and was dealt with by prolonging 
pulse repetition times (TRs), reducing the number of slices acquired, or reducing 
pulse amplitudes by reducing FAs and/or using modulated gradient waveforms.25 
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The feasibility of T2w TSE imaging at 7 T has been demonstrated in the prostate as 
well, but only using a limited number of slices due to SAR restrictions.15,26
 The aim of this work is to demonstrate that full prostate coverage with 3 mm 
slices can be achieved routinely and safely with high image quality in prostate cancer 
patients, using an external transceive (TxRx) body array coil only. We present the 
preparation and calibration steps used, as well as measurements of the T1 and T2 
relaxation times of the prostate and surrounding tissues in a group of healthy 
volunteers and prostate cancer patients. The results of these measurements are 
used to define the parameters of a T2w TSE imaging protocol. The image quality 
achieved with this protocol is consistently high, while allowing full coverage of the 
prostate gland within RF safety limits. 
Methods
Subjects
Nine healthy male volunteers with a median age of 29 (range 20 – 38) years and 
weight 75 (60 - 100) kg, as well as 12 prostate cancer patients with a median of age 
66 (range 57 – 72) years, weight 85 (70 – 100) kg, prostate specific antigen level 6.5 
(5.3 – 33.8) ng/mL, and biopsy Gleason score 6 (6 – 9) were included in this study. 
None of the subjects had a history of therapy for prostatic disease. Bowel motion 
was suppressed in patients by intramuscular injection of butylscopolamine bromide 
(Buscopan, Boehringer-Ingelheim, Ingelheim, Germany) and glucagon (Glucagen, 
Novo Nordisk, Copenhagen, Denmark), unless contraindications existed. The study 
was approved by the local institutional review board and all subjects gave written 
informed consent prior to the MR exam.
MR measurements
Scanner Setup
All experiments were performed on a 7 T whole-body MR system (Magnetom 7 T, 
Siemens Healthcare, Erlangen, Germany), using an 8-channel TxRx body array coil 
with meander elements16 driven by eight 1 kW amplifiers. The RF power deposited by 
each individual channel was monitored using in-house developed software written in 
LabView (National Instruments Austin, TX).8,17
Shimming and Calibration
Localizer images were obtained with the relative transmit phases of the individual RF 
coil elements set to circularly polarized mode (i.e., 45° relative phase difference 
between neighboring coil elements). Phase map based B0 shimming was performed 
on a shim volume placed closely around the prostate. First-order shim currents were 
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adjusted manually if necessary. B1 shimming was then performed using a series of 
low FA turboFLASH images of a single slice through the prostate midgland (TR = 
1000 ms, echo time (TE) = 5 ms, 1-2 averages, field of view 300 x 300 mm, acquisition 
matrix = 64 x 64, slice thickness 8 mm). Each of these images was acquired by 
transmitting with a single channel and receiving with all channels. This was repeated 
for all eight transmit channels, and the corresponding phase images were 
reconstructed. The relative phases between the individual coil elements were then 
adjusted to maximize phase coherence within a circular region of interest (ROI) drawn 
around the prostate11 using software written in Matlab (The Mathworks, Natick, MA). 
B0 shimming was repeated if necessary. 
 FA calibration was performed with a single-voxel spectroscopy sequence with a 
25 x 25 x 25 mm voxel placed at the center of the prostate. Adiabatic refocusing 
pulses were used to minimize sensitivity to B1
+ inhomogeneity (semi-localized by 
adiabatic selective refocusing (semi-LASER), duration of each refocusing pulse 20 
ms, TE 96 ms27). The RF amplitude of the excitation pulse was varied until a maximum 
magnitude of the water peak was reached. This was assumed to correspond to 90° 
excitation, and all RF amplitudes in subsequent sequences were scaled relative to 
this value. 
Relaxation Time Measurements
T1 relaxation times were measured in three healthy volunteers and three prostate 
cancer patients (minimum time after biopsy: seven weeks). This was done using a 
progressive saturation experiment with fixed TR and varying FA, using a spoiled 
gradient echo sequence with nominal FAs of 10°, 20°, 30°, and 40° (TR = 173 ms, TE 
= 4.6 ms, field of view 360 x 280 mm, acquisition matrix 256 x 200, slice thickness 3.5 
mm, scan time per FA 35 s). Magnitude signals produced by this sequence were 
modeled with the equation: 
1
1 1 icos∝E
iS = 0 sin i∝M
1E
[1]
Where is the equilibrium magnetization, is the ith FA, is the signal magnitude observed 
at FA  and E ∝ exp (–TR/T1). The signal curves were linearized, and quantitative T1 
maps were created by linear least-squares fits to the transformed data.28 ROIs were 
drawn on the prostate and adjacent smooth muscle, and mean T1 relaxation times 
were calculated. FA differences between prostate and muscle were assessed using 
B1
+ maps created using a single slice pre-saturated turbo-FLASH sequence (TR/TE: 
5000/5 ms, field of view 300 x 300 mm, acquisition matrix = 64 x 64, slice thickness 
8 mm, pre-saturation/excitation FA within the prostate ~60°/10°, 2 averages, scan 
time 20 s).29 The ratio of the mean B1 intensities in both ROIs was determined to 
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estimate the true FAs in muscle. Muscle-corrected T1 maps were calculated by 
inserting this corrected set of FAs into Eq. [1], and the corrected maps were used to 
calculate the mean T1 in muscle. 
 T2 relaxation times were measured in nine healthy volunteers and six prostate 
cancer patients, using a vendor-provided single-slice Carr-Purcell-Meiboom-Gill 
(CPMG) sequence with an echo spacing of 15 ms, a total number of 8 echoes, and a 
TR of 2.5 s (resolution 0.73 x 0.87 x 3.0 mm3, scan time 7 min). The durations of the 
excitation and refocusing pulses were set to 5.12 ms and 7.68 ms, respectively, and a 
ratio between the thicknesses of the refocusing and excitation slices of 150% was 
used to reduce bias due to stimulated echo contributions at the slice edge.30 Mono-
exponential decay curves were fitted to the MR signal magnitude as a function of TE 
in each voxel, according to 
iiS = 0M exp ( TE T/ 2) [2]
Signals from the first echo were disregarded to reduce possible bias due to incomplete 
refocusing. This resulted in quantitative T2 maps of the prostate and surrounding 
tissues. ROIs were drawn around the PZ, the TZ, and in the smooth muscle adjacent 
to the prostate. The mean and standard deviation of the T2 relaxation times within 
these ROIs were calculated. 
T2-Weighted Imaging
A T2w TSE imaging protocol was defined using an adapted vendor-provided pulse 
sequence. In order to reduce peak RF amplitude, and hence SAR, the durations of 
the excitation and refocusing pulses were prolonged to 5.12 ms and 7.68 ms, 
respectively, compared with the 3.58 and 5.12 ms used in the standard “Low SAR” 
setting of the sequence. In addition the FA of all but the first refocusing pulses was 
reduced to 150°, and the FA of the first refocusing pulse was set to 165° to facilitate a 
smooth transition to the pseudosteady state.31 Finally, a variable rate selective 
excitation (VERSE) method was used to further reduce RF power deposition.25 The 
resulting RF and gradient pulse shapes and their slice profiles are shown in Figure 1. 
 The median T2 relaxation times of PZ and TZ in the healthy volunteers were used 
to obtain the TE that would maximize the contrast between these tissues. This 
resulted in a protocol with TR/TE 3000-3640/71 ms, field of view 240 x 180 mm, matrix 
320 x 240, resolution 0.75 x 0.75 mm, phase encoding direction anterior-posterior, 
slice thickness 3 mm, slice gap 0.6 mm, interleaved slice acquisition, 9 echoes, echo 
spacing 17.8 ms, readout bandwidth 116 Hz/pixel, and 1 average. The total acquisition 
time varied between 1:30 and 1:53 min for TRs of 3000 and 3640 ms, respectively. 
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Results
The median (range) preparation times for RF shimming and FA calibration were 5 
(3 – 10) min and 6 (3 – 15) min, respectively. The mean and SD of the phase differences 
between transmitting coil elements resulting from RF shimming in the 12 patients are 
shown in Figure 2. The mean ± SD maximum achievable B1
+ magnitude resulting 
from these shims, as determined from FA calibration measurements, was 10.6 ± 1.3 
(range 7.7 – 12.2) µT. 
Fig. 1  Bloch simulations of the RF pulse envelopes used in the TSE imaging sequence 
used in this work. The left panel depicts the original RF and gradient pulse shapes 
(gray) and their corresponding VERSE modulated counterparts (black) normalized to 
the amplitude of the original pulse shapes, for both excitation (top) and refocusing 
pulses (bottom). The right panel shows slice profiles of 90° excitation pulses (top) and 
180° refocusing pulses (bottom) for a nominal slice thickness of 3 mm. Excitation 
pulses were applied along the +x axis assuming a starting magnetization parallel 
to the +z axis, for the original pulse shapes (left) and their VERSE counterparts 
(right), both for on-resonance magnetization representing water (black curves), and 
magnetization with a frequency offset of 1000 Hz, representing fat (gray curves). 
These profiles include the effect of a slice refocusing gradient lobe (not shown). 
Refocusing pulses were also applied along the +x axis, assuming a starting 
magnetization parallel to the -y axis, for the original pulse shapes (left) and with 
VERSE (right), both for water (black curves), and fat (gray curves). Relaxation effects 
were neglected in these simulations.
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Quantitative T1 maps and corresponding B1
+ maps were acquired in three healthy 
volunteers and three prostate cancer patients (Fig. 3). No contrast between the 
different prostatic zones was observed in the T1 maps. The mean ± SD T1 relaxation 
times in prostate and muscle were 1.8 ± 0.2 s and 1.6 ± 0.3 s in healthy volunteers 
and 1.1 ± 0.1 s and 0.9 ± 0.3 s in patients (Fig. 3c), where muscle T1 values were 
corrected for B1
+ magnitude differences as described above. 
 Quantitative T2 measurements are illustrated in Figure 4, with multiple spin-echo 
images of a healthy volunteer with TEs increasing from 15 ms to 120 ms in steps of 15 
ms (a–h), as well as the corresponding quantitative T2 (i) and proton density maps (j). 
The ROIs used for PZ, TZ and muscle are indicated on the T2 map. A plot of the mean 
Fig. 2  Schematic representation in transverse view of the geometric orientation of the 
eight transmitting coil elements with respect to the patient. The prostate is indicated 
in green. The mean ± SD transmit phase differences with respect to coil element 1 
obtained from RF shimming in 12 patients are indicated in the circle diagrams by the 
solid and dashed lines, respectively. The corresponding numbers are indicated with 
each diagram.
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signal magnitude observed within these ROIs at each TE (k) in the PZ (squares), TZ 
(circles), and muscle (triangles) shows that a monoexponential decay is well 
approximated if signals from the first echo are disregarded from the least-squares fits 
(dashed lines). These measurements were performed in nine healthy volunteers and 
six prostate cancer patients. The mean ± SD T2 relaxation times in PZ, TZ, and muscle 
in healthy volunteers were 73.1 ± 16.6, 55.6 ± 6.9, and 31.1 ± 2.3 ms, respectively 
(Fig. 5). Group means were statistically significantly different (repeated measures 
ANOVA p < 0.0001, post hoc paired t-tests with Bonferroni correction, p < 0.01 in all 
comparisons).  T2 was longest in the PZ and shortest in muscle in all healthy volunteers. 
The mean ± SD T2 relaxation times in normal-appearing PZ and muscle in prostate 
cancer patients were 120.4 ± 42.8 and 46.2 ± 11.0 ms, respectively. T2 relaxation 
times were not measured in the TZ of patients because of the strong heterogeneity 
observed in this tissue in these subjects (see Figs. 6 and 7). T2 relaxation times were 
significantly longer in patients than in healthy volunteers both in normal appearing PZ 
tissue and in muscle (unpaired t-test, p 0 <0.01 in both cases).
T2w TSE imaging was performed in all 21 subjects. Excellent anatomical detail within 
the prostate gland and surrounding tissues was obtained, as illustrated by the 
transverse, sagittal, and coronal images of a 70-year-old prostate cancer patient in 
Figure 6. The endorectal coil seen in the transverse and sagittal images was not used 
for signal reception: it was used for 31P spectroscopic imaging experiments performed 
Fig. 3  T1 relaxation time measurements: (a) quantitative T1 map and (b) corresponding 
B1
+ map of the prostate of a young healthy volunteer with ROIs in prostate (P) and 
smooth muscle (M). Mean T1 relaxation times for prostate and muscle ROIs are 
shown in (c) for three healthy volunteers (triangles) and three prostate cancer patients 
(squares). The T1 values in muscle are corrected for the reduced B1
+ magnitude in 
muscle compared with the prostate. Horizontal lines indicate group means.
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in conjunction with the experiments presented here (data not shown). A high image 
quality was obtained consistently in all subjects, as is illustrated in Figure 7, which 
depicts T2w TSE images of the first 6 prostate cancer patients included in this study. 
Gold-standard tumor localization was available in three patients, in the form of 
histopathology after radical prostatectomy of MR-guided biopsy. The tumors found 
on histopathology, which had Gleason scores of 3+4, 3+3, and 4+4, respectively, 
were clearly visible on T2w imaging (Fig. 7d–f).
Fig. 4  a–h: Multicontrast spin-echo images of the prostate of a 27-year-old healthy 
volunteer at 7 T, with echo times between 15 ms (a) and 120 ms (h) in increments 
of 15 ms, (i): quantitative T2 map with PZ, TZ, and smooth muscle (M) ROIs, (j): 
corresponding M0 map, (k): mean signal magnitude observed in the ROIs at each 
time point. The dashed lines indicate the average of per-voxel nonlinear least squares 
fits to the measured data; open symbols indicate that these data were excluded from 
the fitting procedure.
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Fig. 5  In vivo T2 relaxation times in PZ, TZ, and smooth muscle in nine healthy 
volunteers (triangles) and normal appearing PZ and muscle in six prostate cancer 
patients (squares). Horizontal lines indicate mean values. Differences between 
volunteers and patients as well as between tissue types were statistically significant 
(p ≤ 0.01 in all cases).
Fig. 6  Transverse (a), sagittal (b), and coronal (c) T2-weighted TSE images of a 
prostate cancer patient (age 70 years, weight 84 kg). The endorectal coil [asterisks in 
(a) and (b)] was tuned to 31P and was, therefore, not used for signal reception during 
the acquisition of these images.
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Discussion
Earlier work had demonstrated that subject-specific RF shimming can result in good 
quality prostate imaging in healthy volunteers at 7 T using external body transceiver 
arrays only.11 This result is reproduced in this work. However, the relatively low SDs in 
the RF shims (Fig. 2) suggest that an appropriately chosen default RF shim setting 
may also produce adequate results. Preliminary experiments in which a universal RF 
shim was derived from numerical simulations indeed showed promising results.32 
Similarly, the maximum achievable B1
+ magnitude was fairly constant across patients 
(SD/mean = 12%), suggesting that a default FA calibration setting may also be 
sufficient for achieving good image quality. Using such default settings could reduce 
calibration times, but could also increase SAR. On the other hand, although the 
median total time needed for RF shimming and FA calibration was ~11 min in our 
experiments, the total acquisition time for these procedures was only ~1.5 min. 
Fig. 7  Transverse T2-weighted TSE images of the prostate midgland (a–d) and apex 
(e, f) of the first six prostate cancer patients included in this study. Good quality was 
observed in all images, and no signal voids due to B1
+ inhomogeneity were observed 
within the prostate. Note the complete absence of signal from periprostatic lipids in 
all images. Accurate confirmation of the tumor location was available in the three 
patients displayed in the bottom row by histopathology after radical prostatectomy (d, 
e) and MR guided biopsy (f). Prostate cancers with Gleason Scores of 3+4 (d), 3+3 
(e), and 4+4 (f) are indicated by the arrows. Exact localization information of confirmed 
cancer was not available for the patients shown in (a–c).
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Therefore, automating the processing of these data would also accelerate the 
calibration procedure, without compromising SAR or image quality. 
 T1 and T2 relaxation times were in the same range as literature values reported for 
lower fields strengths.33-41 An increase of T1 and a decrease of T2 values, which may 
be expected when moving to higher fields, cannot be observed due to the large 
variability in the available literature values (T1 values range from 962 ms to 1570 ms at 
1.5 T39,42, and from 1520 to 1660 ms at 3 T33,34; T2 values range from 88 to 193 ms in 
the PZ at 1.5 T33,40, and from 74 to 142 ms at 3 T33,43). These differences are ascribed 
to differences in the methodologies used. In particular, monoexponential fitting of 
multispin-echo data may lead to overestimation of T2 values due to contributions of 
stimulated echo components from the edges of the slice profiles.44 Several measures 
were taken in this work to minimize these biases. The vendor-provided sequence 
used pulses with an optimized slice profile to minimize the contribution of the slice 
edges, and used a ratio between the thicknesses of the refocusing and excitation 
slices of 150%, further reducing bias.30 In addition, the first echo was excluded from 
the fitting procedure. Although this may not have completely eliminated the biases 
compared with more sophisticated methods which explicitly take the effects of 
stimulated echo contributions into account44,45, these are likely to be minor. 
 T2 relaxation times were significantly longer in patients than in healthy volunteers. 
T1 relaxation times were also shorter in patients than in healthy volunteers, although 
our subject population was too small to draw any definitive conclusions. We speculate 
that they are age related, as the healthy volunteers were considerably younger than 
the patients (median ages 29 and 66 years, respectively). To our knowledge, these 
effects have not been reported before for prostate, although age-related T2-lengthening 
of skeletal muscle has been demonstrated.46 Both the shorter T1 and the longer T2 
relaxation times in patients as compared with young healthy volunteers are beneficial 
to the SNR of T2w TSE imaging of prostate cancer patients. 
 The low average achievable peak B1
+ magnitude of 10.3 µT in the prostate was a 
limiting factor mostly for the adiabatic pulses used in the semi-LASER FA calibration 
sequence.47 Setting their duration to 20 ms resulted in a B1
+ magnitude at which 
adiabaticity was assured of ~5.9 µT. This corresponded to 76% of the peak B1
+ 
magnitude achievable in the patient with the lowest transmit efficiency (7.7 µT). The 
7.68 ms refocusing pulses used in TSE imaging would have needed a peak B1
+ 
magnitude of only 3.5 µT to reach a FA of 180°, illustrating that TSE imaging was 
limited by SAR rather than available RF power. 
 The high SAR levels observed in T2w TSE imaging, the workhorse of clinical 
anatomical prostate imaging, are caused by the large number of refocusing pulses 
per unit time used in this method. At 7 T, this limits the number of slices that can be 
acquired safely in a multislice experiment. Three methods were used to reduce SAR 
in this work: prolonging pulse durations, lowering the refocusing FAs, and applying a 
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VERSE technique. Numerical integration of the square of the RF pulse envelopes 
indicated that the pulse prolongation resulted in a SAR reduction of 32% compared 
with the standard “Low SAR” setting of the sequence. Setting the refocusing FAs to 
165° for the first pulse and 150° for all other pulses resulted in a further reduction of 
27%, and applying the VERSE algorithm to these pulses yielded an additional 
reduction of 21%. Combining all of these measures led to an overall reduction of the 
energy deposition of 61%. Finite integration technique simulations detailed by Bitz et 
al.17 indicated that a 10-g average SAR limit of 10 W/kg would be reached with a total 
power deposition of 33 W averaged over 6 min in our experiments.8 The 6 min average 
RF power deposited per TSE slice was noted in six patients and amounted to 1.0 ± 
0.1 W, corresponding to a maximum achievable number of consecutive TSE slices 
with 0.6 mm slice gaps in all patients examined in this study. Full coverage in the 
other two orthogonal orientations was equally achievable; however, a waiting time 
between TSE acquisitions was necessary in some cases to allow sufficient dissipation 
of RF-induced heat. 
 Prolonging the durations of the excitation and refocusing pulses to 5.12 and 7.68 
ms resulted in bandwidths of ~380 Hz and 250 Hz for the non-VERSE modulated 
pulses, respectively. With the chemical shift between fat and water at 7 T being ~1000 
Hz, this choice of bandwidths led to chemical shift displacements in the slice direction 
of fat of ~8 and 12 mm, respectively. The addition of VERSE modulation to these 
pulses resulted in virtually identical profiles of the water slices, but degraded slice 
profiles and an even further increased chemical shift displacement for fat (Fig. 1). As 
a consequence, the slices of fat experiencing excitation and refocusing during the 
same pulse train were completely spatially separated, so that no fat signal remained 
in the final image.48 This is indeed observed in Figures 6 and 7, in which no signal 
from periprostatic fat is visible. On the one hand, this has the advantage that fat 
saturation pulses do not need to be applied, reducing SAR. Conversely, it could have 
negative consequences for the detection of extracapsular extension of prostate 
cancer, which may benefit from the bright background provided by periprostatic fat. 
 The long echo spacing of 17.8 ms may be expected to lead to T2-induced image 
blurring; however, this effect is not observed in the images presented (see Figs. 6 
and 7). This may be due to the short echo train length used (9 echoes), which ensures 
a fast traversal of k-space, in combination with the use of refocusing FAs <180°. 
The latter leads to the contribution of stimulated echoes to the measured signal, 
prolonging the apparent T2. 
 Several opportunities remain for further improvement of the image quality in TSE 
imaging. For example, the TE used in the present protocol was selected so as to 
provide maximum contrast between the PZ and TZ in healthy volunteers, but this may 
not be the optimum setting for tumor visualization. Furthermore, it has been shown 
by Metzger et al. that the use of an endorectal receive coil in addition to an external 
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body array can lead to substantial increases in the SNR, albeit at the expense of 
image homogeneity.15 In addition, further SAR reductions may be achievable. The 
VERSE scheme provided with the vendor-supplied sequence was applied relatively 
mildly, reducing SAR by only 21%. Higher reduction factors are achievable, but may 
come at the cost of deteriorated slice profiles. Furthermore, more advanced schemes 
to modulate the refocusing pulse amplitude during the pulse train could be explored.49 
Such methods are commonly used at 3 T and have also been successfully applied at 
higher fields.50,51 Because such methods become more efficient with longer echo 
trains, their application would require a more elaborate optimization of the tradeoffs 
between, e.g., pulse lengths, shapes and FAs, echo train lengths, readout bandwidth, 
SNR, and SAR.
 
This work demonstrates that high quality T2w TSE imaging of the prostate can be 
achieved consistently and safely in prostate cancer patients at a magnetic field 
strength of 7 T. This was achieved by maximizing the transmit efficiency into the 
prostate by RF shimming and by localized spectroscopic calibration of the FAs. T1 
and T2 relaxation times in the prostate were determined. Altogether, this paves the 
way for providing anatomical detail to new functional (spectroscopic) imaging 
methods achievable at 7 T. 
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Abstract
Objectives
To assess the image quality of T2-weighted (T2w) magnetic resonance imaging of 
the prostate and the visibility of prostate cancer at 7 Tesla (T).
Materials & methods
Seventeen prostate cancer patients underwent T2w imaging at 7 T with only an 
external transmit/receive array coil. Three radiologists independently scored images 
for image quality, visibility of anatomical structures, and presence of artefacts. 
Krippendorff’s alpha and weighted kappa statistics were used to assess interobserver 
agreement. Visibility of prostate cancer lesions was assessed by directly linking the 
T2w images to the confirmed location of prostate cancer on histopathology.
Results
T2w imaging at 7 T was achievable with ‘satisfactory’ (3/5) to ‘good’ (4/5) quality. 
Visibility of anatomical structures was predominantly scored as ‘satisfactory’ (3/5) and 
‘good’ (4/5). If artefacts were present, they were mostly motion artefacts and, to a 
lesser extent, aliasing artefacts and noise. Krippendorff’s analysis revealed an α = 0.44 
between three readers for the overall image quality scores. Clinically significant cancer 
lesions in both peripheral zone and transition zone were visible at 7 T.
Conclusion
T2w imaging with satisfactory to good quality can be routinely acquired, and cancer 
lesions were visible in patients with prostate cancer at 7 T using only an external 
transmit/receive body array coil.
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Introduction
Magnetic Resonance Imaging (MRI) of the prostate is increasingly used in clinical 
practice for the detection, localization, and characterization of prostate cancer1-3, and 
is currently performed at field strengths of 1.5 Tesla (T) and preferably 3 T.4 Prostate 
anatomy is visualized by T2-weighted (T2w) imaging, while diffusion-weighted imaging, 
dynamic contrast-enhanced imaging, and/or MR spectroscopic imaging provide 
additional functional information in a multiparametric MRI (mpMRI) examination.5-10
 Moving to an ultra-high magnetic field strength (7 T) may have clinical advantages 
because of an intrinsic increase of the signal-to-noise ratio (SNR), which in theory 
could be used to increase spatial resolution or to reduce imaging time. Moreover, 
imaging at 7 T opens up the search for new, previously unreachable biomarkers for 
prostate cancer management. For example, phosphorus (31P) spectroscopic imaging 
can be performed at clinically relevant spatial resolutions and imaging times.11 Most 
often, any such functional technique would preferably be combined with adequate 
anatomical reference imaging.  
 Imaging at an ultra-high magnetic field is challenging, as several issues that can 
result in poorer image quality and reduction of the expected gain in SNR must be 
overcome. The first such issue is inhomogeneity in the transmit radiofrequency (RF) 
field or B1
+. This can lead to a heterogeneous distribution of flip angles, which can 
cause signal voids throughout images. Second, a higher RF power is needed to 
achieve desired flip angles. Third, the concomitant increased energy deposition 
within the body is limited by the maximum specific absorption rates (SAR). A 
dedicated multi-transmit hardware setup with local B1
+-shimming and multichannel 
SAR-monitoring is necessary to overcome these challenges.12 Other potential 
drawbacks when moving to an ultra-high magnetic field strength are the shorter 
T2-relaxation times and increased sensitivity to susceptibility artifacts.
13 A previous 
study showed that T2w imaging of the prostate at 7 T is technically feasible after 
adaptation of refocusing pulse duration and echo times.14 However, an assessment 
of image quality from a clinical point of view has not been performed, and it remains 
unknown to what extent the potential benefits outweigh the potential limitations of 
prostate imaging at this magnetic field strength in practice.
 The purpose of this study was to evaluate the development of prostate MRI at 7 
T by providing a clinical assessment of image quality and visualization of prostate 
cancer lesions on T2w images at 7 T.
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Material and methods
Subjects
Seventeen patients with biopsy-proven prostate cancer were included in this study. 
The median age of patients was 66 years (range, 56 – 72). The median body mass 
index was 26.6 kg/m2 (range, 22.6 – 32.7), and median prostate-specific antigen 
(PSA) level was 6.8 µg/L (range, 4.4 – 33.8). Exclusion criteria were contraindications 
to MRI (eg, cardiac pacemaker, intracranial clips), metallic implants anywhere in the 
body, and claustrophobia. This study was approved by the institutional review board, 
and written informed consent was obtained from all patients.
MR measurements
Imaging was performed in supine position on a whole-body 7 T MR-system 
(Magnetom 7T; Siemens Healthcare, Erlangen, Germany), using an 8-channel 
transmit/receive (TxRx) body array coil.15 An endorectal coil was inserted, but this coil 
was not used for 1H signal reception. Instead, the endorectal coil was only tuned to 
the phosphorus frequency at 7 T for experiments that were performed in conjunction 
with our measurements.16 Peristalsis was suppressed by an intramuscular injection of 
1 mg glucagon (GlucaGen Hypokit; Novo Nordisk, Bagswærd, Denmark) and 20 mg 
butylscopolamine bromide (Buscopan; Boehringer, Ingelheim, Germany). SAR-
monitoring, B0 and B1
+-shimming and flip angle (FA) calibration was performed as 
described previously.14 T2w fast spin-echo images covering the entire prostate were 
acquired in axial (ie, perpendicular to the rectal wall surface) and sagittal directions, 
using a protocol described previously. In short, the parameters were: TR 3000–3640, 
TE 71 ms, 9 refocusing pulses with FAs of 165° (first refocusing pulse) and 150° (all 
other refocusing pulses), matrix 320 x 261, in-plane resolution 0.75 x 0.75 mm of up to 
20 slices with 3 mm thickness. The total acquisition time for each direction varied 
between 1:30 and 1:53 minutes for repetition times between 3000 and 3640 ms, 
respectively.14
Image quality assessment
Three radiologists (R1, R2, R3), with 8, 10 and 17 years of experience in prostate MRI, 
independently evaluated the image datasets of each patient. Each dataset consisted 
of an axial and a sagittal T2w image series of one patient. Images were presented to 
the radiologists on an in-house developed digital workstation. 
 A subjective impression of overall image quality and visibility of anatomical 
structures (distinction between peripheral and transition zone, seminal vesicles, 
benign prostatic hyperplasia (BPH) nodules and delineation of the prostate) was 
assigned on a five-point scale (1 = unacceptable, 2 = poor, 3 = satisfactory, 4 = 
good, 5 = excellent). Presence of artefacts (motion, aliasing, susceptibility, noise or 
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other) was assigned on a different five-point scale (1 = pronounced, 2 = considerable, 
3 = moderate, 4 = minimal, 5 = none). Motion artefacts were defined as image 
artefacts influencing the prostate due to patient or bowel motion, causing blurry 
images, with or without ghosting, in the phase-encoding direction. Aliasing 
encompassed wrap-around artefacts in the image. Susceptibility artefacts were 
defined as image distortion together with large signal voids caused by susceptibility 
differences between organs or tissues, resulting in dark areas anywhere in the 
prostate region because of signal loss. Noise was specified as a subjective impression 
of a low SNR. If ‘other’ artefacts were present, radiologists had to specify the type of 
artefact.
Visibility of prostate cancer
One radiologist, with two years of experience in prostate MRI, qualitatively evaluated 
the visibility and appearance of cancer lesions in a descriptive manner by linking the 
images directly to the histopathology results to confirm the exact location of the 
cancer. This was performed only in those patients who had undergone a prostatectomy 
with whole-mount section histopathology after the MR examination (n = 3) or a 
targeted in-bore MR-guided biopsy (n = 4). In case of prostatectomy, a cancer lesion 
was indicated by the pathologist on photographed slices of the whole-mount 
histopathology sections, and these photographs were used to identify the cancer 
lesion on the axial 7 T images. The cancer lesions confirmed by MR-guided biopsy 
were identified on the 7 T images by comparing the axial T2w images of the detection 
scan and biopsy scan at 3 T prior to the biopsy, to the axial T2w images at 7 T. These 
biopsies were performed in the routine clinical workflow by in-bore MR-guidance. 
A 3 T mpMRI detection scan was performed to identify a lesion. Subsequently, 
in another scan session (preferably within two weeks after the detection MRI) the 
suspicious lesion was re-identified on the images with similar acquisition technique, 
and an in-bore biopsy was performed, as described previously.17 A confirmation scan 
with the needle in situ was acquired to ensure the correct positioning of the biopsy 
needle.
 Because the remaining 10 patients were diagnosed with prostate cancer by 
systematic transrectal ultrasound biopsy, an exact localization of the cancer was 
absent in these patients, and therefore they were not used to evaluate the visibility of 
prostate cancer on MR images.
Statistical analysis
Median scores for image quality, visibility of anatomical structures, and presence of 
artefacts were calculated overall and for each of the three readers separately. 
Interobserver agreement was assessed for all three readers, combined, using 
Krippendorff’s alpha for multiple readers with ordinal data. For mutual comparison 
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between each combination of any two readers, a weighted kappa (κ) statistic was 
used, with the level of agreement indicated on the following scale: 0.0 – 0.20 = poor 
agreement, 0.21 – 0.40 = fair agreement, 0.41 – 0.60 = moderate agreement, 0.61 
– 0.80 = substantial agreement, and 0.81 – 1.00 = almost perfect agreement. 
 GraphPad Prism 5.0 for Windows (GraphPad Software; San Diego, CA, USA) 
and SPSS software v20.0 (IBM Corp, Somers, NY, USA) were used for analysis. 
Results
All 17 patients completed the entire protocol (sagittal T2w imaging was not yet 
incorporated in the protocol for the first three patients). No adverse events occurred. 
Image quality assessment
Overall image quality of axial images was scored as satisfactory by one reader (R1) 
and good by the other two readers (R2 and R3). Overall sagittal image quality also 
yielded a score of satisfactory to good (Table 1). Typical examples of good as well as 
poor image quality are presented in Figures 1 and 2, respectively. 
 The visibility of anatomical details on both the axial and sagittal images was 
scored satisfactory to good. R1 and R2 rated the axial and sagittal images equally, 
while R3 considered the visibility of anatomical details better on the axial images than 
on the sagittal images. No differences were seen in intra-reader scores between the 
various anatomical details (Table 1).
 According to all three readers, moderate to minimal motion was present in both 
axial and sagittal images. Both R2 and R3 perceived no other artifacts, in contrast to 
R1, who observed moderate noise and considerable aliasing artefacts, albeit with a 
notification that these aliasing artefacts did not interfere with the prostate region itself. 
Table 1 provides an overview of the ratings of the quality assessment.
 Krippendorff’s analysis revealed an α = 0.44 between the three readers for the 
overall scores. Weighted kappa statistics showed moderate agreement between R2 
and R3 (κ = 0.49) and R1 showed less agreement with both of the other two readers 
(Table 2). 
Visibility of prostate cancer 
Lesions were visible on T2w images at 7 T in all seven patients with prostate cancer 
confirmed by MR-guided biopsy (Fig. 3; Table 3) or prostatectomy (Fig. 4; Table 3). 
In two patients, this involved a single transition zone cancer focus, and in two patients, 
a single peripheral zone cancer focus. In the three patients that had undergone 
a prostatectomy, multifocal prostate cancer was observed on the prostatectomy 
specimens. In the first patient, two peripheral zone lesions with a Gleason score (GS) 
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Table 1  Image quality assigned on a five-point scale by three independent 
readers for T2-weighted images at 7 T. The median of all 17 subjects for each 
category per reader is presented here.
7 Tesla
R1 R2 R3
Axial imaging
Overall image quality 3 (0.70) [12/17] 4 (0.70) [17/17] 4 (0.70) [16/17]
Visibility of anatomical structures:
Distinction PZ / TZ 3 (0.86) [12/17] 4 (0.71) [17/17] 4 (0.78) [17/17]
Seminal vesicles 3 (1.53) [11/17] 4 (1.43) [14/17] 4 (1.01) [15/17]
BPH-nodules 3 (1.11) [9/17] 4 (0.88) [17/17] 4 (0.85) [17/17]
Prostate delineation 3 (0.70) [15/17] 4 (0.75) [17/17] 4 (0.83) [16/17]
Artefacts:
Motion 3 (0.90) [12/17] 4 (0.79) [16/17] 4 (1.07) [15/17]
Aliasing 2 (2.01) [9/17] * 5 (0.39) [17/17] 5 (0.24) [17/17]
Susceptibility 5 (0.00) [17/17] 5 (0.62) [17/17] 5 (0.33) [17/17]
Noise 3 (1.01) [12/17] 5 (0.71) [17/17] 5 (0.33) [17/17]
Other 5 (0.00) [17/17] 5 (0.00) [17/17] 5 (0.00) [17/17]
Sagittal imaging
Overall image quality 3 (0.76) [7/14] 4 (0.84) [13/14] 3 (1.08) [10/14]
Visibility of anatomical structures:
Distinction PZ/TZ 3 (0.85) [7/14] 4 (1.02) [13/14] 3 (1.08) [10/14]
Seminal vesicles 3 (0.76) [8/14] 4 (1.23) [12/14] 3 (1.10) [9/14]
BPH-nodules 3 (0.76) [5/14] 4 (1.01) [13/14] 3 (1.07) [10/14]
Prostate delineation 3 (0.68) [11/14] 4 (1.02) [13/14] 3 (1.03) [10/14]
Artefacts:
Motion 3 (0.61) [9/14] 3 (1.03) [11/14] 3 (1.14) [8/14]
Aliasing 2 (1.70) [6/14] * 5 (0.36) [14/14] 5 (0.27) [14/14]
Susceptibility 5 (0.00) [14/14] 5 (1.16) [13/14] 5 (0.00) [14/14]
Noise 3 (1.03) [10/14] 5 (0.76) [14/14] 4 (1.16) [11/14]
Other 5 (0.00) [14/14] 5 (0.00) [14/14] 5 (0.00) [14/14]
The standard deviation for the median is provided between the parentheses. 
The number of cases with a score of ≥ is provided between the square brackets. 
*  Notification given by Reader 1, along with the scores for aliasing artefacts: these aliasing artefacts 
were present at the edge of the images and did not interfere with the prostate region itself.
R, reader; PZ, peripheral zone; TZ, transition zone, BPH, benign prostatic hyperplasia.
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of 3 + 3 = 6 (volume 0.60 cc and 0.45 cc) and two transition zone lesions with a GS 
of 3 + 2 = 5 (volume 0.25 cc and 0.13 cc) – of which only the largest peripheral zone 
cancer lesion was visible on the MR images (Fig. 4a) – were seen by the pathologist. 
In the second patient, three peripheral zone lesions were present with a GS of 5 + 4 
= 9 (volume 1.88 cc), GS 3 + 4 = 7 (volume 0.47 cc) and GS 2 + 3 = 5 (volume 2.01 
cc), and one transition zone lesion was found with a GS of 3 + 3 = 6 (volume 0.25 
cc). Of these four lesions, only the transition zone cancer lesion could not be 
recognized at the MR images. The third patient had three peripheral zone lesions on 
the prostatectomy specimens with a GS of 3 + 3 = 6 (volume 3.35 cc and 0.10 cc) 
and 3 + 2 = 5 (volume 0.07 cc), and only the largest peripheral zone cancer lesion 
was visible on the MR images (Fig. 4c).
Fig. 1  Good image quality at 7 T: example. T2-weighted imaging of the prostate at 
7 T in axial (a, c) and sagittal (b, d) direction in two patients. Note the endorectal coil 
in place, which was tuned to phosphorus and only used for 31P spectroscopic imaging 
performed in conjunction with our study (data not shown here). Throughout the study, 
T2-weighted imaging has been acquired with the external transmit/receive body array 
coil only.
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Fig. 2  Poor image quality at 7 T: example. T2-weighted imaging of the prostate at 7 T 
in axial (a) and sagittal (b) direction in one patient. Note the endorectal coil in place, 
which was tuned to phosphorus and only used for 31P-spectroscopic imaging 
performed in conjunction with our study (data not shown here). Throughout the study, 
T2-weighted imaging has been acquired with the external transmit/receive body array 
coil only.
Table 2  Inter-observer agreement of image quality comparison for all images. 
Krippendorff’s alpha shows the overall reliability between the three readers. 
Weighted kappa shows the agreement between each combination of any two 
readers.
Combination of readers:
Krippendorff’s alpha
R1 + R2 + R3 0.44
Weighted kappa
R1 + R2 0.26
R1 + R3 0.36
R2 + R3 0.49
R, Reader.
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Fig. 3  Prostate cancer lesions on axial T2-weighted images at 7 T, confirmed by 
targeted Magnetic Resonance-guided biopsy. A) A hypointense region is visible in 
the apex ventrally (white arrow). Targeted MR-guided biopsy of the lesion at 3 T as 
part of the routine clinical workflow confirmed an adenocarcinoma of the prostate 
with a Gleason score of 4+4=8. B) A hypointense area is visible in the ventral 
transition zone (white arrow). Targeted MR-guided biopsy of the lesion at 3 T as part 
of the routine clinical workflow confirmed an adenocarcinoma of the prostate with a 
Gleason score of 3+4=7. C) A well-defined hypointense lesion is visible in the right 
peripheral zone (white arrow). Targeted MR-guided biopsy of the lesion at 3 T as part 
of the routine clinical workflow confirmed an adenocarcinoma of the prostate with a 
Gleason score of 3+2=5. D) A hypointense area can be seen in the right peripheral 
zone (white arrow). This lesion had a Gleason score of 3+4=7, confirmed by 
MR-guided biopsy.
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 In both the peripheral zone and transition zone, the cancer lesions that were 
visible at 7 T appeared as homogeneous hypointense lesions, similar to current 
clinical field strengths of 1.5 T and 3 T. 
 Note the hypointensity of periprostatic lipid tissue surrounding the prostate, 
which was observed in each case in this study. Although evaluation of this tissue was 
not incorporated in the methodology, and thus has not been scored by the radiologists, 
the difference in appearance of periprostatic fat in comparison to 1.5 or 3 T images 
of the prostate is obvious. Generally, at current clinical field strengths of 1.5 and 3 T, 
periprostatic fat appears isointense or even hyperintense when compared to the 
signal intensity of healthy peripheral zone tissue on T2w imaging. 
Table 3  Characteristics of prostate cancer obtained by MR-guided biopsy  
or prostatectomy. Gleason scores and cancer volumes for the seven patients 
with confirmed localization of prostate cancer, either by MR-guided biopsy  
or prostatectomy.
Patient Gleason score Volume Zone Diagnostic confirmation
a 4 + 4 = 8 * TZ MR-GB
b 3 + 4 = 7 * TZ MR-GB
c 3 + 2 = 5 * PZ MR-GB
d 3 + 4 = 7 * PZ MR-GB
e 3 + 3 = 6 0.60 PZ Prostatectomy
3 + 3 = 6 0.45 PZ
3 + 2 = 5 0.25 TZ
3 + 2 = 5 0.13 TZ
f 5 + 4 = 9 * 1.88 PZ Prostatectomy
3 + 4 = 7 * 0.47 PZ
2 + 3 = 5 * 2.01 PZ
3 + 3 = 6 0.25 TZ
g 3 + 3 = 6 * 3.35 PZ Prostatectomy
3 + 3 = 6 0.10 PZ
3 + 2 = 5 0.07 PZ
Volume of the tumor is provided in cm3, according to the histopathology report of whole-mount prostatectomy.
* Cancer lesion visible on T2-weighted imaging at 7 Tesla. 
Patients a, b, c and d correspond to Fig. 3a, b, c and d, respectively.
Patients e, f and g correspond to Fig. 4a, b and c, respectively.
TZ, transition zone; PZ, peripheral zone; MR-GB, magnetic resonance-guided biopsy.
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Fig. 4  Prostate cancer lesions on axial T2-weighted images at 7 T, confirmed by 
whole-mount prostatectomy. A) A small elongated lesion is visible in the peripheral 
zone (white arrow), in accordance with the localization on whole-mount prostatectomy. 
This lesion had a Gleason score of 3+3=6. B) A hypointense lesion is visible in 
the right peripheral zone (white arrow). Whole-mount prostatectomy confirmed an 
adenocarcinoma of the prostate with a Gleason score of 5+4=9. C) A large hypo - 
intense area can be seen in the peripheral zone, in accordance with the localization 
on whole-mount prostatectomy. This lesion had a Gleason score of 3+3=6.
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Discussion
This study showed that T2w imaging at 7 T was achievable with an overall image 
quality of satisfactory to good by using an external 8-channel TxRx body array coil 
with dedicated multi-transmit hardware, local B1
+-shimming, multichannel SAR-
monitoring, and scan parameters optimized for imaging at 7 T.
 The majority of the mean ratings was satisfactory to good, and the presence of 
artefacts was predominantly none or minimal. Moderate motion artefacts were 
observed, mostly in the sagittal images, and to a lesser extent in the axial images. 
This might be explained by the fact that sagittal images were obtained later in the 
scan protocol, and the effect of antiperistaltic agents may have partially worn off 
during the protocol. Slight differences existed among the readers. In general, one 
reader (R1) appeared to be slightly more stringent with his ratings compared to the 
other two. Approximately, one-third of all scores were rated below satisfactory (ie, 
3/5) on the five point scale by R1, in contrast to R2 and R3, who rated about 5% and 
12%, respectively, of the total scores below satisfactory level. It should be noted that 
R1 observed aliasing artefacts at the edge of some images and thus rated these 
images as having considerable artefacts, albeit with a notification that these artefacts 
did not interfere with the prostate region itself. In view of the latter, the other two 
readers considered these images as having no artefacts. 
 In all seven patients with exact confirmation of the location of prostate cancer, 
at least one lesion was visible on the T2w images. In three patients, multifocal prostate 
cancer was diagnosed on whole-mount prostatectomy specimens. In total, six 
lesions with a low GS (3 + 3 = 6 and 3 + 2 = 5) and/or a small volume (< 0.50 cc) 
were not recognized at the T2w images. It is known that lesions with a relatively low 
GS or a small volume can be missed on T2w images at the current clinical field 
strengths18,19, and this is likely the reason why these lesions were not recognized at 7 T.
 In a recent study of Maas et al.14, it was already observed that periprostatic lipids 
appeared hypointense in comparison to healthy peripheral zone of the prostate itself. 
At 1.5 and 3 T, lipid tissue around the prostate has an equal or even higher MR signal 
intensity than the healthy peripheral zone of the prostate. At 7 T, the lipid signal 
intensity around the prostate is low. This effect results from the use of prolonged (ie, 
narrow bandwidth) refocusing pulses in our protocol. The low and highly different 
bandwidths of the RF pulses used for excitation and refocusing resulted in complete 
spatial separation of lipid signal excitation and refocusing, leading to complete fat 
suppression. Although one might expect that this hypointense periprostatic appearance 
of fat would affect the visibility of the delineation of the prostate, the scores for 
delineation of the prostate at 7 T in this study were satisfactory to good. Whether 
the absence of lipid signal at 7 T affects the detection of extracapsular extension of 
prostate cancer into periprostatic tissue needs to be investigated in a future study.
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 In this study we used a protocol that was previously optimized for application at 
7 T. Because a state-of-the-art protocol for current clinical field strengths is not 
necessarily the most optimal setting for 7 T, adaptations of scan parameters are 
unavoidable. The intrinsic SNR gain of a higher magnetic field strength at 7 T was not 
yet able to be translated into a higher spatial resolution, especially as we did not use 
an endorectal coil for 1H-signal reception. Also, local SAR deposition limited the total 
number of refocusing pulses that could safely be used for each image. This limited 
the maximum image matrix achievable with the number of slices needed to cover the 
entire prostate (approximately 20). Reducing the field of view to increase spatial 
resolution in order to compensate for this would have caused unacceptable fold-over 
artefacts. In the future, this issue may be mitigated by using more advanced coil 
setups. For instance, increasing the number of transmit channels from 8 to 16 or 32 
will lead to more efficient B1
+ shimming, reducing local SAR hotspots, and allowing 
more slices or larger matrix sizes. In addition, using an endorectal coil for signal 
reception will allow further reduction of the field of view without fold-over artifacts, 
while simultaneously boosting SNR20, which in turn can be used for a higher spatial 
resolution. More advanced schemes of modulating the refocusing pulse amplitude 
during the pulse train may also be explored for SAR reduction.21 
 This study represents a first step towards an mpMRI protocol at 7 T. Although 3 T 
remains the gold standard in prostate imaging at this time, the added value of 7 T for 
clinical use must now be established in future studies. As outlined in the introduction, 
7 T may enable new complementary functional imaging techniques; for example, 
spectroscopic imaging of low-concentration metabolites. Such mpMRI protocols will 
preferably be combined with a high-quality anatomical reference image. In our study, 
even with the use of only an external body array coil, satisfactory to good image 
quality at 7 T was achieved within a short acquisition time (1.30 – 1.53 minutes). One has 
to keep in mind that hardware engineering at 7 T is under continuous development. If local 
power deposition is mitigated at 7 T, higher SNRs can indeed be achieved, which could 
be used for higher spatial resolution or even further reduction in imaging time. The latter 
could be especially interesting in clinical practice, and warrants further investigation. 
 This study had several limitations. First, the number of patients is relatively low, 
although this number should be adequate for feasibility purposes (evaluating the 
technical development of prostate MRI by providing an assessment of image quality 
and visualization of prostate cancer lesions). A prospective study with a larger group 
of patients having a proper histopathological reference standard is needed to draw 
solid conclusions with regard to prostate cancer detection performance at 7 T. 
Second, this study only qualitatively assessed T2w images at 7 T. In the future, when 
similar endorectal receive coils exist for 7 T, a more quantitative comparison between 
7 T and the current clinical field strengths is necessary to explore the differences and 
potential benefits of 7 T compared to 1.5 and 3 T. 
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In summary, T2w imaging with satisfactory up to good image quality can be routinely 
acquired, and cancer lesions were visible in patients with prostate cancer at 7 T using 
only an external transmit/receive body array coil. We conclude that adequate 
anatomical imaging can be achieved, and the first step towards an mpMRI protocol of 
the prostate at 7 T has been achieved.
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Appendix 1
A sub analysis was performed in the same patient population that has undergone 7 
T imaging, to compare image quality of both the 3 T images and 7 T images. 
Material and methods
MR measurements at 3 T
Imaging at 3 T was performed in supine position using a whole-body 3 T system 
(Magnetom Skyra, Siemens Healthcare, Erlangen, Germany) as part of the routine 
clinical workflow. A 32-channel phased-array body coil and an inflatable ERC (Medrad 
Inc; Pittsburgh, United States) filled with an inert perfluoropolyether liquid (Fomblin; 
Solvay Solexis, Bollate, Italy) were used for signal reception. Peristalsis was 
suppressed by an intramuscular injection of 1 mg Glucagon (GlucaGen Hypokit; 
Novo Nordisk, Bagswærd, Denmark) and 20 mg butylscopolamine bromide 
(Buscopan; Boehringer-Ingelheim, Ingelheim, Germany). The clinical mpMRI protocol 
included T2w imaging in axial and sagittal planes, in accordance with recently 
published guidelines (table A.1).
Image quality comparison
The same three radiologists (R1, R2, R3) evaluated datasets of all patients at 3 T in 
conjunction with the evaluation of the images at 7 T. Each dataset consisted of an 
axial and a corresponding sagittal T2w image at a single field strength, and was 
presented to the radiologists in random order on an in-house developed, digital 
workstation. 
 A subjective impression of overall image quality, visibility of anatomical structures 
(distinction between peripheral and transition zone, seminal vesicles, benign prostatic 
hyperplasia (BPH) nodules and delineation of the prostate) and presence of artefacts 
(motion, aliasing, susceptibility, noise, other) were scored on a five-point scale. 
Motion artefacts were defined as blurry images with or without ghosting in the 
phase-encoding direction due to patient or bowel motion. Aliasing encompassed 
wrap-around artefacts in the image. Susceptibility artefacts were defined as image 
distortion together with large signal voids caused by susceptibility differences 
between tissues, resulting in dark areas anywhere in the prostate region because of 
signal loss. Noise was specified as a subjective impression of low SNR. If ‘other’ 
artefacts were present, radiologists had to specify the type of artefact.
501341-L-bw-Vos
159
IMAGE QUALITY AND CANCER VISIBILITY OF THE PROSTATE AT 7 TESLA
8
Statistical analysis
Scores for overall image quality, visibility of anatomical structures and presence of 
artefacts were compared between 3 T and 7 T datasets for each reader separately, 
using Wilcoxon’s paired signed rank test. GraphPad Prism 5.0 for Windows (GraphPad 
Software, San Diego, CA, USA) and SPSS software v20.0 (IBM Corp, Somers, NY, 
USA) were used for statistical analysis. P < 0.05 was considered statistically significant. 
Results
Image quality comparison
Overall axial image quality of both field strengths was scored as ‘good’, only R1 gave 
a median score of ‘sufficient’ to the axial 7 T images (significantly different from 3 T 
images, p = 0.008, table A.2). Overall sagittal image quality at 7 T yielded a score of 
‘satisfactory’ up to ‘good’. 
 The visibility of anatomical details on axial 7 T images was scored significantly 
lower than axial 3 T images by R1 for zonal distinction (p = 0.010), seminal vesicles 
(p = 0.014) and BPH-nodules (p = 0.007) and by R3 for seminal vesicles (p = 0.044, 
table 2). Aliasing artefacts were present in 7 T images; however, these artefacts did 
not interfere with the prostate. Noise and motion artefacts were significantly worse at 
7 T than in 3 T images. The 7 T images were scored qualitatively better than 3 T 
images for the subgroup ‘other artefacts’, due to ERC artefacts at 3 T (figure A.1), 
which were not present at 7 T. 
Fig. A.1  Coil artefact at 3 T.
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Table A.1  Scan parameters.
3 Tesla *
TR (ms) 4930
TE (ms) 101
FA (°) 120
Matrix 448 x 444
Resolution (mm) 0.4 x 0.4
Slice thickness (mm) 3
No. of slices 21
TA (min:s) 4:21
* in-house clinical protocol
TR, repetition time; TE, echo time; FA, flip angle; TA, acquisition time.
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Table A.2  Image quality as assigned on a five-point scale by three independent 
readers for T2-weighted images at 3 T and 7 T. The median of all seventeen 
subjects for each category per reader is presented.
3 Tesla 7 Tesla
R1 R2 R3 R1 R2 R3
Axial imaging
Overall image quality 4 4 4 3* (0.001) 4 4
Visibility of anatomical structures:
Distinction PZ / TZ 4 4 4 3* (0.010) 4 4
Seminal vesicles 4 4 4 3* (0.014) 4 4
BPH-nodules 4 4 4 3* (0.007) 4 4
Prostate delineation 4 4 4 3 4 4
Artefacts:
Motion 4 5 5 3* (0.005) 4* (0.029) 4
Aliasing 5 5 5 2* (0.005) 5 5
Susceptibility 5 5 5 5 5 5
Noise 4 5 5 3* (0.022) 5 5
Other 5 5 4† (0.0003) 5 5 5
Sagittal imaging
Overall image quality 3 4 4 3 4 3
Visibility of anatomical structures:
Distinction PZ/TZ 3 4 4 3 4 3
Seminal vesicles 2 3 4 3 4 3* (0.044)
BPH-nodules 3 4 4 3 4 3
Prostate delineation 3 4 4 3 4 3
Artefacts:
Motion 3 5 5 3 3* (0.003) 3* (0.005)
Aliasing 5 5 5 2* (0.003) 5 5
Susceptibility 5 5 5 5 5 5
Noise 3 5 5 3 5 4* (0.023)
Other 2† (0.008) 5 4† (0.010) 5 5 5
Five-point scale as used for ‘overall image quality’ and ‘visibility of anatomical structures’: 1=unaccept-
able, 2=poor, 3=satisfactory, 4=good, 5=excellent. Five-point scale as used for ‘artefacts’: 1=pro-
nounced, 2=considerable, 3= moderate, 4=minimal, 5= none.
R, reader; PZ, peripheral zone; TZ, transition zone; BPH, benign prostatic hyperplasia.
* = score at 7 T significantly lower than at 3 T. 
† = score at 3 T significantly lower than at 7 T. The p-value is provided between brackets.
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The value of multiparametric magnetic resonance imaging  
for prostate cancer aggressiveness
Several publications originating from different research institutes worldwide already 
proved that multiparametric magnetic resonance imaging (mpMRI) is useful for the 
detection of prostate cancer.1-9 As mentioned before, not every prostate cancer is 
lethal and different levels of aggressiveness exist. Therefore, we wanted to explore 
the value of mpMRI for the assessment of prostate cancer aggressiveness, by 
validating functional MR techniques both separately and combined. Multiparametric 
MRI usually includes any combination of parameters derived from diffusion-weighted 
imaging (DWI), dynamic contrast-enhanced (DCE) MRI or magnetic resonance 
spectroscopic imaging (MRSI).10,11 But up to date we do not exactly know which 
parameters really contribute to the differentiation between highly aggressive prostate 
cancer or indolent prostate cancer. And do we really need the full combination of all 
parameters together for the assessment of prostate cancer aggressiveness?
 DWI is quite straightforward: it is easy to perform and no difficult post-processing 
is needed to acquire the ADC value, which is the most commonly used parameter 
derived from this technique. The ADC can be used to distinguish between cancer 
and non-cancer tissue and shows a relatively strong correlation with aggressiveness 
in the peripheral zone of the prostate.12,13 Therefore, it seems logical that the ADC 
should be a permanent value in the multiparametric combination. However, based on 
our research we can conclude that ADC has only moderate accuracy for the 
assessment of aggressiveness in the transition zone (Chapter 3). This indicates that 
different combinations of techniques should be used for different zonal origin of 
prostate cancer. 
 Multiple parameters can be derived from DCE-MRI. Both semi-quantitative 
(wash-in and wash-out) and pharmacokinetic (Ktrans and Kep) parameters correlate 
with prostate cancer aggressiveness (Chapter 4). Especially the pharmacokinetic 
parameters may vary between datasets or research institutes, depending on the 
input values of the pharmacokinetic model (eg, arterial input function, model type). 
There is a lack of consensus among centers regarding specific DCE-MRI acquisition 
parameters. Moreover, pharmacokinetic modeling is mostly performed in specialized 
institutes with dedicated software programs. Therefore, for general clinical use we 
recommend the semi-quantitative approach. Wash-in and wash-out would then be 
the optimal parameters for the assessment of aggressiveness. 
 Based on the results of chapter 5, we can conclude that a different combination 
of techniques should be used for the assessment of prostate cancer aggressiveness 
in the peripheral zone, compared with the transition zone. The optimal combination 
of parameters in the peripheral zone is wash-out plus ADC, as opposed to the optimal 
combination in the transition zone, which is wash-out plus the choline over spermine 
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+ creatine ratio (C/SC). Although the ADC value performs best in the peripheral zone, 
it does not contribute to the differentiation of low-grade from high-grade prostate 
cancer in the transition zone, which is in line with the results of chapter 3 and another 
recently performed study.14 Based on our findings, in both peripheral zone and 
transition zone, there is no additional value for the use of all three functional imaging 
parameters combined. 
How should we translate these preliminary findings into clinical practice? First, we 
need to know if the results from our validation study make a difference in the 
perception of the radiologist. Future reader studies with multiple radiologists are 
necessary to prove that these combinations of parameters indeed help the radiologist 
in their final judgment of the tumor lesion, and to prove that the diagnosis may be 
more accurate with our proposed combinations compared with other (unsubstantiat-
ed?) combinations of parameters as used in current clinical practice. 
 Recently, the PI-RADS v2 classification for the detection of clinically significant 
prostate cancer with the use of mpMRI has been introduced. In this second version 
of the classification, a different dominant sequence is recommended depending on 
the zonal anatomy: for the peripheral zone lesions DWI is the primary determining 
sequence, and for the transition zone lesions T2-weighted imaging has become the 
primary determining sequence.15 Also, the role of DCE-MRI has become more limited, 
serving only to differentiate in those cases that are doubtful on the basis of T2-weighted 
imaging and DWI. The PI-RADS v2 classification is intended for the diagnostic 
evaluation and risk assessment of patients with suspected prostate cancer. As stated 
in a recently published editorial, which can be seen as a synopsis of the PI-RADS v2, 
the classification is “intended to be a ‘living’ document that evolves as clinical 
experience and scientific validation data accrue”.16 Maybe in the future an extension 
of the PI-RADS classification might be desirable regarding the assessment of 
aggressiveness of either newly detected suspected lesions or already proven 
prostate cancer lesions. This thesis then already indicates the different optimal 
combination of techniques for both peripheral zone and transition zone. 
 A remark has to be made about MRSI. Although it has proven to be useful for the 
assessment of prostate cancer aggressiveness17,18, extensive time-consuming and 
non-automated post-processing is currently needed before the images can be easily 
read by a radiologist. As long as the post-processing of MRSI is not automated, the 
prediction is that it shall not be used in routine clinical practice and it will only be 
performed in specialized institutes.
Over the last years, active surveillance has gained more interest in patients with 
low-risk prostate cancer19,20, but concerns remain that the patient’s tumor is actually 
more aggressive than estimated on the basis of current diagnostic tools such as 
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prostate-specific antigen or systematic transrectal ultrasound biopsies.21 Especially 
in an active surveillance setting, we believe that our results can be of important 
clinical value in the future. Follow-up of a known prostate lesion can be performed 
with mpMRI. Based on the zonal origin of the tumor, our proposed optimal combination 
of parameters may help to characterize this tumor lesion: can it still be categorized as 
indolent or should it be upgraded to high-grade prostate cancer followed by 
appropriate treatment? In cases of doubt, mpMRI may help to point a MR-guided 
biopsy towards the most suspicious hotspot in the lesion. 
Therefore we suggest to investigate the value of incorporating mpMRI in nomograms 
or decision-making programs for this particular clinical question posed.
Clinical advantages of the investigational endorectal coil
Limited information is present about the value of a dual-channel endorectal coil for 
prostate imaging. To the best of our knowledge, only one other study has been 
performed with an endorectal coil similar to the investigational endorectal coil that we 
used in our study and this was a rigid coil concept that was only evaluated at 1.5 T.22
 We showed that the investigational dual-channel endorectal coil is able to give a 
higher signal-to-noise ratio (SNR) up to 40 mm away from the surface of the coil, a 
distance that is desirable in larger prostates. Especially in the older male population, 
prostate size increases due to benign prostatic hyperplasia. The higher SNR may 
improve image quality by increasing the spatial resolution, without losing signal even 
further away from the coil. The higher signal-to-noise ratio can also be used in a 
different way: depending on the clinical question posed, one can choose to increase 
the spatial resolution or to decrease scan time. 
 For staging purposes, it is very important to accurately determine extracapsular 
extension of prostate cancer. If a radical prostatectomy is mandated, the surgeon 
needs to know whether it is necessary to resect tissue including the neurovascular 
bundle in case of tumor invasion, or if it is possible to perform a nerve-sparing 
operation when the extracapsular growth does not extend near or into the 
neurovascular bundle. The latter is of essential importance for the patient, as 
nerve-sparing surgery can better preserve potency and continence.
 In a recently published meta-analysis the use of the currently available endorectal 
coil yielded no additional benefit for extracapsular extension.23 However, with the 
opportunity to use parallel imaging techniques with the dual-channel endorectal coil, 
less geometric distortion is seen, which results in a better image quality. Also, with a 
higher spatial resolution, more detailed information should become visible on the MR 
images and this higher spatial resolution thus may improve local staging 
performances. Therefore, future reader studies with the use of the investigational 
dual-channel endorectal coil in a prospective setting are necessary to confirm this 
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hypothesis and to explore the true clinical value of the investigational endorectal coil 
regarding local staging of prostate cancer.
For the detection of prostate cancer, or when imagining a future screening program 
scenario, time is a very important clinical factor. In theory, for this purpose the higher 
signal-to-noise ratio can be used to decrease scan time, without losing image quality 
compared to the current clinically available endorectal coil. In practice, probably, for 
screening purposes the endorectal coil will not be used, as insertion and evaluation 
of coil position takes additional time, negating the possible scan time reduction by 
the increased SNR. Using an endorectal coil will also place an additional threshold in 
public willingness to participate in a screening program.
The 7 Tesla machine: nice or necessary?
Prostate MR imaging is put into a new perspective with our research at the 7 Tesla (T) 
MR scanner. However, imaging at 7 T is not straightforward. 
 First, only two 7 Tesla machines were present in The Netherlands (UMC Utrecht; 
Leiden UMC) at the time of our research program. A third 7 Tesla scanner is located 
in Germany (Erwin L. Hahn institute, Essen), at a driving distance of about 120 km. 
This institute is a shared initiative between the Radboud University and the University 
of Duisburg-Essen, and it is available for use for our team from Radiology for imaging 
of the prostate at 7 T. By the time of publication of this thesis, few more ultra-high 
magnetic field scanners have been taken into use in The Netherlands (Maastricht; 
Amsterdam). This information demonstrates that these machines are not widely 
available and that patients need to travel a significant distance before an examination 
at 7 T can be performed.
 Second, the required hardware for imaging at 7 T is not (yet) commercially 
available. Therefore, the endorectal receive coil and the external phased-array coil 
were designed and built by dedicated researchers and technicians in collaboration 
with our research team.24,25 
 Third, before an image at this ultra-high field strength can be acquired, system 
calibrations need to be performed manually for each individual patient. RF-shimming 
is performed to create a homogeneous RF-field, which is necessary for the prevention 
of drop-outs in the final image. This has been described previously in detail by 
Metzger et al.26 and has been explored and applied in chapter 7. A recent study by 
Rozenkrantz et al., showed other preparations for T2-weighted imaging at 7 T, 
although this was only performed in two patients.27
As concluded in Chapter 7 and 8, T2-weighted imaging at 7 T can be performed 
routinely and safely in prostate cancer patients, with an image quality of satisfactory 
up to good with the use of only an external phased-array coil. A sub study performed 
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in conjunction with these experiments (Chapter 8, appendix 1) showed that image 
quality of T2-weighted imaging at 3 T in our department was rated slightly better than 
at 7 T. Currently, imaging at 3 T therefore remains preferred over imaging at 7 T for 
clinical purposes. In this study, imaging at 3 T was performed with the use of both the 
external phased-array coil and endorectal coil, while the images in our study at 7 T 
were acquired with the external phased-array coil only. Recent developments in coil 
engineering at 7 T resulted in the possibility of imaging with the endorectal coil instead 
of the external phased-array coil only.28 With this, an even higher spatial resolution 
can be acquired because of the gain in SNR. As discussed earlier, a higher resolution 
results in more detailed images. The question remains whether a higher spatial 
resolution indeed can lead to more accurate diagnoses and with that, a more tailored 
treatment for the individual patient. Previous studies at 7 T in other body parts, such as the 
inner ear or the brain, suggest that there are benefits for imaging at 7 T over 3 T.29-33
 Future studies should compare image quality of T2-weighted prostate images at 
3 T and 7 T under fair circumstances with comparable hardware conditions, to 
investigate the true clinical value of T2-weighted imaging at 7 T. 
Imaging at an ultra-high magnetic field strength opens up the search for new 
biomarkers that are unreachable at lower fields strengths. For example, phosphorus 
(31P) spectroscopic imaging can be performed at 7 T.25,34,35 In the ‘standard’ proton 
(1H) spectroscopic imaging at 1.5 T and 3 T, the spectral peak of citrate directly 
represents the citrate intermediate in the Krebs cycle. However, the choline peak 
represents different choline-containing metabolites, which cannot be distinguished 
with 1H-MRSI at current clinical field strengths. At 7 T, these individual compounds 
within the choline peak can be distinguished with a reasonable spatial resolution with 
31P-spectroscopic imaging, because of the increase in 31P signal at 7T. This 
opportunity at ultra-high magnetic field strengths may lead to new information 
regarding prostate cancer aggressiveness. 
 A recent study by Lagemaat et al., performed in conjunction with our T2-weighted 
imaging studies at 7 T, preliminary results illustrated that the individual choline 
compounds phosphocholine and glycerophosphocholine may be related to prostate 
cancer aggressiveness.36 This was only seen in two patients with large, highly 
aggressive prostate cancer lesions, and the relatively large voxel size probably 
introduced partial volume effects in the remaining patients with smaller cancer 
lesions. This was the first study worldwide for spatially resolved in vivo measurements 
of 31P in patients with prostate cancer. Future studies are desirable to expand these 
initial measurements, both from a technical point of view (e.g. can we decrease voxel 
size to minimize partial volume effects?) and from a clinical point of view (are we able 
to introduce a new biomarker for prostate cancer aggressiveness, which is not visible 
at current clinical field strengths?). 
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 At present, imaging at 3 T remains the gold standard in clinical practice for 
prostate cancer management. But cancer research at 7 T is under continuous 
development and these preliminary results in our studies show that new opportunities 
in prostate cancer MR imaging research exist, which might lead to a more accurate 
prostate cancer diagnosis in the future.
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Multiparametric MR imaging and prostate cancer aggressiveness 
With the use of T2-weighted (T2w) imaging, information about the anatomy of the 
prostate can be acquired with a high spatial resolution and good tissue contrast. In a 
multiparametric setting, T2w imaging is usually combined with functional techniques 
such as diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) 
imaging and magnetic resonance spectroscopic imaging (MRSI) to provide additional 
information. Nowadays, multiparametric MRI (mpMRI) plays an important role in the 
detection of prostate cancer. 
 Since not every prostate cancer is lethal, different treatment approaches exist 
for different expressions of the disease. Therefore, it is important to accurately assess 
the aggressiveness of prostate cancer. The first aim of this thesis was to evaluate 
functional MRI techniques at 3 Tesla (T) for the assessment of prostate cancer 
aggressiveness.
In the first study, we evaluated DWI to detect and characterize cancer in the transition 
zone of the prostate. The apparent diffusion coefficient (ADC) value was used to 
differentiate between prostatitis and prostate cancer. Subsequently, ADC was 
evaluated for the differentiation between different Gleason grades. MR-guided biopsy 
specimens were used as the reference standard. We found that ADC values can 
differentiate between cancer and non-cancer tissue in the transition zone. However, 
due to substantial overlap, ADC has only a moderate accuracy (AUC 0.62) to 
distinguish between primary and secondary Gleason grade subcategories (Chapter 3).
 In another study, we evaluated DCE-MRI for the assessment of cancer 
aggressiveness in both the peripheral and transition zone of the prostate. Semi- 
quantitative parameters (wash-in, wash-out, time to peak and relative enhancement) 
and pharmacokinetic parameters (Ktrans, Kep en ve) were the parameters of interest. 
Prostatectomy specimens were used as the reference standard in this study. We 
found that wash-in, wash-out, Ktrans and Kep have potential for the assessment of 
aggressiveness in the peripheral zone, despite overlap between aggressiveness 
levels. The 75th percentile values of wash-in, Ktrans and Kep showed the best 
discriminating performance to separate low-grade from higher-grade peripheral 
zone prostate cancer (AUC 0.75). Due to a limited number of transition zone cancer 
lesions in this study population, we could not draw a solid conclusion about the 
performance of DCE-MRI in this zone (Chapter 4).
 Finally, in this study the ultimate combination of DWI, DCE-MRI and MRSI for the 
discrimination between low-grade and high-grade prostate cancer was explored in a 
subset of the study population. Subsequently, its prognostic value was evaluated in a 
validation setting in the remaining subjects. It was demonstrated that mpMRI is a 
useful tool to discriminate low-grade from high-grade cancer, and that it performs 
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better than any individual functional parameter. In the peripheral zone, the ADC value 
(derived from DWI) and wash-out (derived from DCE-MRI) offered the optimal 
combination of parameters (AUC 0.85). Addition of any other functional technique did 
not increase the discriminating performance, neither did the full combination of all 
techniques together. However, in the transition zone a different optimal combination 
of parameters was found: wash-out plus the choline over spermine + creatine ratio 
(C/SC, derived from MRSI) should be used to discriminate low-grade from high-grade 
prostate cancer (AUC 0.92). We could conclude that ADC is not of any value for the 
assessment of prostate cancer aggressiveness in the transition zone (Chapter 5).
(Pre-)clinical developments at different magnetic field strengths
Magnetic resonance imaging of the prostate is under continuous development. It is 
important to evaluate new ideas and newly developed imaging tools to find out 
whether it is worthwhile to proceed with these developments. The aim of the second 
part of this thesis is to evaluate new imaging tools and techniques for the application 
in prostate cancer imaging. 
In a prospective setting at 1.5 T and 3 T, we tested the feasibility of an investigational 
dual-channel endorectal receive coil for prostate MR imaging and compared the 
results with a clinically available single-channel endorectal coil (ERC). In eight 
patients, a quantitative analysis was performed to assess the signal-to-noise ratio 
followed by a reader study to get an impression of image quality. We showed that the 
investigational dual-channel ERC outperformed the single-channel ERC in terms of 
signal-to-noise ratio. Also, less geometric distortion was seen when parallel imaging 
was used to acquire T2w images and DWI with the dual-channel ERC. In general, 
image quality was considered better for the investigational dual-channel ERC 
compared to the clinically available single-channel ERC. Based on the results of this 
study, we concluded that it is feasible to pursue the development for future use as the 
next generation ERC for prostate imaging in clinical practice (Chapter 6).
 In our first study at 7 T, we demonstrated that T2w turbo spin-echo imaging can 
be achieved consistently and safely in healthy volunteers and prostate cancer 
patients at this ultra-high magnetic field strength. Radiofrequency (RF) shimming 
was performed, and both T1 and T2 relaxation times in the prostate were determined 
for each patient. With the use of these results, we proposed a standardized protocol 
for T2w imaging of the prostate at 7 T (Chapter 7). 
 Subsequently, this protocol was applied to 17 men that had been diagnosed with 
prostate cancer; herewith they became one of the few prostate cancer patients 
worldwide that were examined at a magnetic field strength of 7 T. Image quality and 
visibility of cancer lesions were assessed in all 17 patients. At 7 T, the lipid tissue 
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signal intensity around the prostate appeared hypointense, which is different from the 
hyperintense appearance of periprostatic lipid tissue at 1.5 or 3 T. Cancer lesions 
were visible in these patients, similar to the appearance at the usual clinical magnetic 
field strengths. Three experienced radiologists rated the overall T2w image quality at 
7 T as satisfactory to good (Chapter 8). 
Prostate cancer research at both 3 T and 7 T is under continuous development. The 
results and future perspectives of this thesis show improvements in the field, leave 
some scientific questions unanswered, and raise new questions. With that, it is clear 
that the era of prostate MR imaging research is far from closed.
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Multiparametrische MRI en agressiviteit van prostaatkanker 
Door middel van een T2-gewogen MRI sequentie kan de anatomie van de prostaat 
het beste weergegeven worden, met een hoge spatiële resolutie en met voldoende 
contrast. In een multiparametrische setting wordt T2-gewogen MRI meestal 
gecombineerd met aanvullende functionele technieken, zoals diffusie-gewogen MRI 
(diffusion-weighted imaging, DWI), dynamische contrastversterkte MRI (dynamic 
contrast-enhanced MRI, DCE-MRI) en MR spectroscopie (MR spectroscopic 
imaging, MRSI). Momenteel speelt multiparametrische MRI (mpMRI) een belangrijke 
rol in het opsporen van prostaatkanker. 
 Niet iedere prostaatkanker is dodelijk. Elke vorm van prostaatkanker wordt 
anders behandeld, afhankelijk van de agressiviteit van de kanker. Daarom is het van 
groot belang om prostaatkanker niet alleen te kunnen detecteren, maar ook om de 
agressiviteit goed te kunnen inschatten. Het eerste doel van dit proefschrift is het 
evalueren van de bestaande functionele MRI technieken (DWI, DCE-MRI en MRSI) 
voor het beoordelen van de agressiviteit van prostaatkanker. 
In het eerste artikel hebben we onderzocht of DWI prostaatkanker in de transitiezone 
kan opsporen en karakteriseren. Er werd getest of de ADC-waarde (apparent 
diffusion coefficient) een onderscheid kon maken tussen een ontsteking van de 
prostaat (prostatitis) en prostaatkanker. Vervolgens werd onderzocht of de 
ADC-waarde kon differentiëren tussen verschillende Gleason scores, oftewel 
prostaatkanker met verschillende agressiviteit. MRI-geleide biopten van de prostaat 
werden hierbij gebruikt als referentie standaard. Uit dit onderzoek bleek dat de 
ADC-waarde gebruikt kon worden om kanker te kunnen onderscheiden van 
niet-kanker weefsel in de transitiezone van de prostaat. Echter, vanwege grote overlap 
had de ADC-waarde slechts een matige accuratesse (AUC 0,62) om te differentiëren 
tussen verschillende pathologische gradaties voor agressiviteit (Hoofdstuk 3).
 In een andere studie hebben we de waarde van DCE-MRI bestudeerd voor het 
bepalen van de agressiviteit van prostaatkanker in zowel de perifere zone als de 
transitiezone. Semi-kwantitatieve parameters (wash-in, wash-out, time to peak en 
relative enhancement) en farmacokinetische parameters (Ktrans, Kep, ve) werden 
onderzocht. Histopathologie van prostatectomie preparaten werd gebruikt als de 
referentie standaard. De parameters wash-in, wash-out, Ktrans en Kep boden de 
mogelijkheid om de agressiviteit van prostaatkanker in de perifere zone te kunnen 
inschatten, ondanks enige overlap. Het 75e percentiel van wash-in, Ktrans en Kep 
hadden het beste onderscheidend vermogen tussen laag agressieve en hoog 
agressieve kanker in de perifere zone (AUC 0,75). Vanwege een laag aantal kankers 
in de transitiezone in dit patiënten cohort, konden we geen harde conclusies trekken 
over de prestatie van DCE-MRI in de transitiezone (Hoofdstuk 4).
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In de laatste studie van het eerste deel van dit proefschrift hebben we gezocht naar 
de ultieme combinatie van DWI, DCE-MRI en MRSI voor het differentiëren tussen 
laag agressieve en hoog agressieve prostaatkanker in een deel van de studiepopu-
latie. Vervolgens werd deze combinatie gevalideerd in het resterende deel van de 
studiepopulatie. Multiparametrische MRI blijkt bruikbaar om te kunnen differentiëren 
tussen laag agressieve en hoog agressieve kanker, en is superieur aan het gebruik 
van elke functionele techniek afzonderlijk. Voor de perifere zone kan dan de 
ADC-waarde (DWI parameter) het beste gecombineerd worden met wash-out (DCE 
parameter), met een AUC van 0,85. Het toevoegen van andere parameters aan deze 
combinatie resulteerde niet in een verbetering van de AUC. In de transitie zone bleek 
echter een andere optimale combinatie te bestaan voor het differentiëren tussen laag 
agressieve en hoog agressieve kanker (AUC 0,92): wash-out dient hier gecombineerd 
te worden met de choline / spermine + creatine ratio (C/SC, verkregen middels 
MRSI). Ook kunnen we concluderen dat de ADC van geen enkele toegevoegde 
waarde is bij het bepalen van de agressiviteit van prostaatkanker in de transitiezone 
(Hoofdstuk 5).
(Pre-)klinische ontwikkelingen op verschillende magneetveld sterkten 
De technieken voor het in beeld brengen van de prostaat met behulp van MRI zijn 
continue in ontwikkeling. Het is dan ook belangrijk om nieuwe ideeën of nieuwe 
technieken te evalueren en om te bepalen of het zinvol is om deze ontwikkelingen 
verder te onderzoeken. Het doel van het tweede deel van dit proefschrift is om de 
waarde van nieuwe instrumenten of attributen en nieuwe MRI technieken te 
beoordelen voor een eventuele klinische toepassing.  
 In een prospectieve studie op 1,5 Tesla (T) en 3 T hebben we een nieuw 
ontwikkelde dubbel kanaals endorectale spoel getest en de resultaten vergeleken 
met de enkel kanaals endorectale spoel die momenteel klinisch in gebruik is. In totaal 
werden acht patiënten geïncludeerd in deze studie, waarin de endorectale spoel 
zowel kwantitatief als kwalitatief onderzocht werd. Ten eerste werd de signaal-ruis 
verhouding bepaald voor beide spoelen (kwantitatief). Vervolgens werd door twee 
radiologen de beeldkwaliteit gescoord (kwalitatief). De nieuwe dubbel kanaals 
endorectale spoel had een hogere signaal-ruisverhouding dan de huidige spoel. 
Ook had de nieuwe spoel minder geometrische distorsie bij zowel T2-gewogen 
beelden als DWI wanneer de parallel imaging techniek werd gebruikt. In het algemeen 
scoorde de nieuwe endorectale spoel hoger op beeldkwaliteit dan de huidige 
klinische endorectale spoel. Hieruit kunnen we concluderen dat het nuttig is om de 
ontwikkeling van deze dubbel kanaals endorectale spoel voort te zetten (Hoofdstuk 6).
 In onze eerste studie op de 7 T MRI scanner hebben we laten zien dat een 
T2-gewogen turbo spin-echo sequentie veilig en consistent vervaardigd kan worden 
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in zowel gezonde vrijwilligers als in patiënten met prostaatkanker. Radiofrequente 
(RF) shimming werd uitgevoerd, en zowel T1 als T2 relaxatietijden in de prostaat 
werden bepaald voor iedere patiënt. Met behulp van deze resultaten werd een ge-
standaardiseerd protocol opgesteld voor het T2-gewogen scannen van de prostaat 
op 7 T (Hoofdstuk 7).
 Vervolgens werd dit protocol toegepast op 17 mannen die net waren gediagnos-
ticeerd met prostaatkanker. Zij werden hiermee een van de eerste patiënten wereld - 
wijd die onderzocht werden op een MRI-scanner met een ultra-hoog magnetisch 
veld, namelijk 7 T. Beeldkwaliteit werd gescoord in alle 17 patiënten. Ook werd de 
zichtbaarheid van prostaatkanker beoordeeld. Op een ultra-hoog magneetveld van 7 
T is het vetweefsel rond de prostaat hypointens, wat normaliter hyperintens is op een 
lagere magneetveldsterkte. Prostaatkanker was ook op de 7 T beelden zichtbaar, 
vergelijkbaar met de zichtbaarheid op 1,5 en 3 T. Drie ervaren radiologen gaven de 
beeldkwaliteit op 7 T een score van ‘voldoende’ tot ‘goed’ (Hoofdstuk 8). 
Wetenschappelijk onderzoek op het gebied van prostaatkanker, en dan met name 
onderzoek met de MRI op zowel 3 T als 7 T, is blijvend in ontwikkeling. De resultaten 
en toekomstperspectieven in dit proefschrift laten zien dat er vooruitgang is geboekt, 
enkele vragen nog onbeantwoord zijn gelaten, en dat sommige antwoorden 
tegelijkertijd weer nieuwe vragen oproepen. En hiermee blijkt dat het tijdperk van MRI 
onderzoek voor de prostaat nog lang niet is afgelopen.
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448-55.
Hoeks CM, Vos EK, Bomers JG, Barentsz JO, Hulsbergen-van de Kaa CA, Scheenen 
TW. Diffusion-weighted magnetic resonance imaging in the prostate transition zone: 
histopathological validation using magnetic resonance-guided biopsy specimens. 
Invest Radiol. 2013; 48: 693-701.
Vos EK, Sambandamurthy S, Kamel M, McKenney R, van Uden MJ, Hoeks CM, 
Yakar D, Scheenen TW, Fütterer JJ. Clinical comparison between a currently available 
single-loop and an investigational dual-channel endorectal receive coil for prostate 
magnetic resonance imaging: a feasibility study at 1.5 and 3 T. Invest Radiol. 2014; 
49: 15-22.
Vrenken H, Vos EK, van der Flier WM, Sluimer IC, Cover KS, Knol DL, Barkhof F. 
Validation of the automated method VIENA: an accurate, precise, and robust measure 
of ventricular enlargement. Hum Brain Mapp. 2014; 35: 1101-1110.
Maas MC, Vos EK, Lagemaat MW, Bitz AK, Orzada S, Kobus T, Kraff O, Maderwald 
S, Ladd ME, Scheenen TW. Feasibility of T2-weighted turbo spin echo imaging of the 
human prostate at 7 Tesla. Magn Reson Med. 2014; 71: 1711-1719.
Lagemaat MW, Vos EK, Maas MC, Bitz AK, Orzada S, van Uden MJ, Kobus T, 
Heerschap A, Scheenen TW. Phosphorus magnetic resonance spectroscopic 
imaging at 7 T in patients with prostate cancer. Invest Radiol. 2014; 49: 363-72.
Vos EK, Lagemaat MW, Barentsz JO, Fütterer JJ, Zámecnik P, Roozen H, Orzada S, 
Bitz AK, Maas MC, Scheenen TW. Image quality and cancer visibility of T2-weighted 
magnetic resonance imaging of the prostate at 7 Tesla. Eur Radiol. 2014; 24: 
1950-1958.
Lagemaat MW, Maas MC, Vos EK, Bitz AK, Orzada S, Weiland E, van Uden MJ, 
Kobus T, Heerschap A, Scheenen TW. 31P MR spectroscopic imaging of the human 
prostate at 7 T: T1 relaxation times, Nuclear Overhauser Effect, and spectral charac-
terization. Magn Reson Med. 2015; 73: 909-920.
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Vos EK, Kobus T, Litjens GJ, Hambrock T, Hulsbergen-van de Kaa CA, Barentsz 
JO, Maas MC, Scheenen TW. Multiparametric magnetic resonance imaging for 
discriminating low-grade from high-grade prostate cancer. Invest Radiol. 2015; 50: 
490-497.
Lagemaat MW, Breukels V, Vos EK, Kerr AB, van Uden MJ, Orzada S, Bitz AK, Maas 
MC, Scheenen TW. 1H MR spectroscopic imaging of the prostate at 7 T using spectral- 
spatial pulses. Magn Reson Med. 2015; in press.
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Presentations
“ Dynamic contrast-enhanced MR imaging for the assessment of prostate 
cancer aggressiveness at 3T”
ISMRM Benelux Chapter meeting 2012; Leuven, Belgium (oral presentation)
ISMRM annual meeting 2012; Melbourne, Australia (poster)
Radboud Radiology scientific paper awards 2013; Nijmegen, The Netherlands  
(oral presentation)
“ Clinical comparison between a currently available single-loop and an 
investigational dual-channel endorectal coil” 
ISMRM annual meeting 2012; Melbourne, Australia (E-poster)
“MRI of prostate cancer at 7 Tesla”
ISMRM Benelux Chapter meeting 2013; Rotterdam, The Netherlands (poster)
ISMRM Workshop series 2013 – MR of cancer gone multimodal; Valencia,  
Spain (poster)
ISMRM annual meeting 2013; Salt Lake City, USA (poster)
“ Magnetic resonance imaging and phosphorus spectroscopic imaging at 7 Tesla”
ESUR 2013; Istanbul, Turkey (oral presentation)
“ Multiparametric MRI for the assessment of prostate cancer aggressiveness 
at 3 Tesla”
ISMRM Benelux Chapter meeting 2014; Maastricht, The Netherlands (oral presentation)
ISMRM annual meeting 2014; Milan, Italy (oral presentation)
Awards
“ Assessment of prostate cancer aggressiveness using dynamic contrast- 
enhanced Magnetic Resonance Imaging at 3 Tesla”
3rd best publication from the department of Radiology in 2013 (Radboud Radiology 
scientific paper awards) 
“ Multiparametric MRI for the assessment of prostate cancer aggressiveness 
at 3 Tesla”
ISMRM Magna Cum Laude award (ISMRM annual meeting 2014)
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Wie zo’n 5 jaar geleden aan mij vroeg of ik wilde promoveren, heb ik destijds 
waarschijnlijk keihard in het gezicht uitgelachen. Achteraf ben ik meer dan blij dat ik 
deze kans heb gekregen. Er zijn zoveel mensen die me geholpen hebben in deze 
afgelopen 4½ jaar, op welke manier dan ook. Van baas tot vrijwilliger, van kamergenoot 
tot vriend, van motivator tot praatpaal; ik hoop niet dat ik iemand vergeet... Komt ‘ie 
dan:
Allereerst wil ik Tom Scheenen, mijn copromotor bedanken. Beste Tom, jij bent een 
baas in de letterlijke en figuurlijke zin van het woord! Je hebt me in korte tijd ontzettend 
veel geleerd op het gebied van wetenschap en MRI (wat volgens mij niet makkelijk 
was bij de eerste “niet-wetenschappelijk-opgeleide” promovendus van je team). Ik 
vond het als dokter aanvankelijk maar raar en nogal lastig om de dagen door te 
komen in wetenschapsland, maar je hebt me toch weten te boeien met je kennis op 
het gebied van de MRI. Jouw kritische blik heeft ervoor gezorgd dat ik ook kritischer 
ben gaan kijken, artikelen op waarde heb leren schatten en zelf ben gaan nadenken 
over onderzoeksmogelijkheden. Je toegankelijkheid, je relaxte instelling en de vele 
genuttigde biertjes en enkele danspasjes op meerdere congressen maakte het 
geheel alleen maar leuker! Zonder jouw hulp had ik dit boekje nooit zo kunnen 
afronden. Ontzettend bedankt voor de goede begeleiding en voor de leuke jaren, 
zo’n baas krijg ik nooit meer.
Daarnaast wil ik graag prof. dr. Barentsz, mijn promotor, bedanken. Beste Jelle, in 
mijn ogen ben je de beste prostaatradioloog die er is. Zoveel kennis, zoveel inzicht, 
zoveel passie, zoveel empathie, zo betrokken. Ook al zijn we het niet altijd op alle 
punten met elkaar eens geweest (ik kan me nog een kleine discussie herinneren over 
de “high b-value” tijdens de research meeting, haha) en heb ik nog een lange weg te 
gaan, ik ben vereerd dat je mijn promotor bent en dat je me alvast een deel van je 
kennis hebt mogen bijbrengen. Ik hoop in de toekomst nog veel van je te leren! 
Bedankt ook wat je voor ons hebt betekend op een iets ander vlak, dat zal ik nooit 
vergeten. 
Dokter Fütterer, beste Jurgen! Mijn eerste studie-opzet (het “spoelenartikel”) komt uit 
jouw koker, waarvoor dank! Wat hebben we gelachen over het schoonmaak protocol. 
En niet alleen daarover. Bedankt ook voor jouw begeleiding, zowel klinisch als weten-
schappelijk; en voor de gezelligheid en de goeie slechte grappen, wat maakte dat ik 
me stiekem toch wel snel thuis ging voelen in Nijmegen.
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Prof. dr. Heerschap, beste Arend, bedankt voor het warme nest waar ik in terecht ben 
gekomen. De fijne sfeer in de MRS-groep is waardevol: iedereen denkt mee met 
elkaar, er is geen onderlinge concurrentiestrijd en ook op sociaal vlak kan menig 
onderzoeksgroep er denk ik nog wel een puntje aan zuigen. Ik denk dat jij met je 
vriendelijkheid, je laagdrempeligheid en je enorme schat aan kennis aan de basis 
staat van zo’n werksfeer.
Lieve paranimfen, Thiele en Marnix. Allereerste bedankt dat jullie de taak van paranimf 
op je willen nemen. Jullie hebben beiden enorm veel bijgedragen aan mijn promotie. 
Thiele, heuj! Bedankt voor het delen van je spectroscopie database en kennis, en 
voor het geduld wat je met me hebt gehad als ik weer eens wat probeerde uit te 
vogelen in Matlab. Wat zal je af en toe hoofdschuddend hebben toegekeken.. Je bent 
voor je postdoc ‘eventjes’ weggeweest naar Boston, maar het is wel weer te merken 
dat je terug bent: het pubquiz – bier – Aesculaaf – tijdperk is weer begonnen, super 
mooi!
 Marnix, yo! Bedankt voor al je hulp op eigenlijk elk gebied: prostaat research 
werkstation, statistiek, natuurkundige kennis. Ik vond het daarom onwijs fijn om je 
kamergenootje te zijn, maar vooral ook omdat ik zo lekker druiven naar je hoofd kon 
werpen of heerlijk met je kon vloeken als ik we weer eens de kriebels kregen! Het was 
een mooie tijd daar in de mooiste kamer van de afdeling. Toodaloo, mthrfckrrrrrr!
 
Lieve Miriam, het grootste deel van onze promotie hebben we samen gewerkt. De 
eerste paar maanden voor de verhuizing waren we nog roomies in de kelder en we 
zijn ontelbare keren samen met Marnix naar Essen geweest om ons kunstje uit te 
halen op de 7T. Respect voor het knutselen aan al die moeilijke sequenties, ik snap 
nog steeds niet hoe je het doet.. Ook voor gezelligheid ben jij altijd wel te porren! Ik 
denk nog vaak terug aan de vele vrijdagen samen in de Aesculaaf of de etentjes en 
mogelijkheid tot crashen bij jou thuis, jullie deur stond altijd open. Hoe gaaf dat we nu 
in dezelfde maand gaan promoveren?! Ik wens jou en Sten heel veel succes met jullie 
carrière en een goeie tijd in Duitsland!
Lieve Joyce, we hebben elkaar vooral goed leren kennen op de congressen. Het 
begon al schitterend in Melbourne, dat werd vrolijk herhaald in Salt Lake City en 
Milaan maakte het rijtje compleet. Gelukkig vond jij Victoria’s Secret en schoenen 
shoppen soms, heel soms, net als ik, belangrijker dan de ochtendsessies van het 
congres. Het wordt tijd dat we weer eens gaan, dan kunnen we onze buikspieren 
trainen met al dat dansen en lachen! Ik zeg Hawaii 2017??
501341-L-bw-Vos
199
DANKWOORD
Uiteraard wil ik ook alle andere coauteurs bedanken. Geert, bedankt voor je hulp met 
het prostaat research werkstation en de DCE-parameters, wat heeft geresulteerd in 
een mooi artikel in European Urology! Mark, bedankt voor het knutselen aan alle 
spoelen. Dr. Hulsbergen-van de Kaa, ontzettend bedankt voor het beoordelen van 
alle prostatectomie preparaten gedurende alle jaren, het is een substantieel onderdeel 
van mijn artikelen geweest. Caroline, bedankt dat ik mocht meewerken aan het DWI 
artikel voor de transitie zone. Het heeft wat voeten in aarde gehad, maar uiteindelijk 
is er een mooie publicatie uit gerold!
 Verder uiteraard Thomas, Derya, Henkjan, Patrik en Henk, bedankt voor jullie input. 
Sriram Sambandamurthy, Robert McKenney and Maged Kamel, thank you for your 
input on the next-generation endorectal coil study. Danach, ich versuche auf Deutsch, 
besonderen Dank an alle Koautoren aus Essen: Stephan, Stefan, Oliver, Andreas und 
professor Ladd. Und Lena, obwohl keine Mitverfasserin, vielen Dank für Ihre Hilfe.
Beste leden van de manuscriptcommissie, prof. dr. Philip Poortmans, prof. dr. Peter 
Luijten en dr. Inge van Oort, bedankt voor het beoordelen van mijn manuscript. 
Ook wil ik graag alle collega’s van de MRS-groep bedanken voor de leuke tijd. Bob, 
Bart B, Mark, Morteza, Devashish, Mariët en Ilse, jullie waren fijne kamergenoten. 
Sjaak, bedankt voor je altijd oprechte interesse. Andor, bedankt voor je gezelligheid, 
ooit ga ik nog een keer mee carnavallen. Isabell, bedankt voor de leuke tijd en heel 
veel succes met de laatste loodjes van jouw proefschrift. En natuurlijk ook Alan, 
Andreas, Anne, Barbara, Bart P, Edwin, Evita, Frits, Hetty, Houshang, Kim, Linda, 
Marc, Nassim, Patricia, Tom P, Valerio, Vincent en Yi.
 De overige onderzoekers mag ik natuurlijk ook niet ongenoemd laten: Oeike, wat 
een lol hebben we gehad de afgelopen jaren, gelukkig kunnen we dat nog een paar 
jaartjes voortzetten nu je ook in opleiding bent! Maarten R, fijn dat wij ook nog een 
paar jaar collega’s blijven. Kristian, Kroeske, Martijn, Esther, Martin, Wendy B en 
Ansje, uiteraard ook bedankt!
 Slechts een klein onderdeel van mijn promotietijd, maar wel een belangrijk 
onderdeel: het nemen van MRI-geleide prostaatbiopten in de kliniek. Martijn S, 
Caroline en Joyce, bedankt voor de goede lessen! Maarten R, Esther, Kristian, Martijn 
H, Martin en Bart P, mooi dat jullie de groep uiteindelijk compleet hebben gemaakt.
 Ten slotte de collega’s van de Prostaatwerkgroep die ik hierboven nog niet heb 
genoemd – Oscar en Wendy V – bedankt voor jullie input.
Beste Solange, Leonie, Marijke, Manita, en na het samenvoegen van de afdelingen 
ook Sonja; bedankt voor jullie steun en hulp met de kleine en grote dingen van het 
promoveren. Altijd leuk om even bij jullie binnen te lopen! 
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Dank ook aan alle laboranten die ervoor gezorgd hebben dat de MRI-geleide prostaat-
biopten altijd soepel verliepen. Daarnaast is er een enorme hoeveelheid mannen 
gescand met (verdenking op) prostaatkanker, waarmee ik een hoop analyses heb 
kunnen doen. Zonder jullie inzet zou dit boekje geen inhoud hebben.
De alinea hierboven zegt het al: ook alle mannen die in de scanner hebben gelegen 
hebben ervoor gezorgd dat dit boekje inhoud kreeg. In het bijzonder de vrijwilligers 
die mee hebben gedaan aan de “spoelenstudie” (hoofdstuk 6) en alle mannen die 
bereid zijn geweest om helemaal naar Essen af te reizen: ontzettend bedankt! 
De allertofste AIOS groep van het land is zeker weten die van ons! Ik heb het 
ontzettend naar mijn zin met jullie, bedankt voor de gezelligheid en voor de fijne sfeer 
onderling. Dat maakt het afronden van mijn promotie naast het werk weer een stukje 
makkelijker. 
Lieve familie, schoonfamilie, vrienden en kennissen. Eigenlijk teveel om op te noemen, 
dat doe ik dus ook niet. Wie de schoen past trekke hem aan, jullie weten zelf wel 
hoeveel ik het waardeer dat jullie altijd geïnteresseerd zijn geweest. Bedankt!
Karin, schitterend om te zien hoe jij in die korte tijd je promotie bij de Chirurgie hebt 
afgerond, diep respect. Zo fijn ook om in hetzelfde schuitje te zitten, en om zo lekker 
samen te mopperen over alle promotie-gerelateerde zaken. De avondjes pubquizzen 
in Schinkelhaven of Maxwell blijven we wat mij betreft voortzetten (samen met onder 
andere Gabor en Jesse, waarvoor ook grote dank en een dikke knuffel, wanneer 
gaan we weer naar de Joop?!). Je motivatie zag ik trouwens laatst nog langslopen 
hier, die zal ik zo snel mogelijk terugsturen naar Amsterdam. Doe jij die van mij dan 
even retour? Dan kan ik er ook weer voor de volle 30% tegenaan..
En natuurlijk mijn beste vriendinnetjes! Heel knullig op alfabetische volgorde, want 
eigenlijk verdient iedereen een eerste plekje in de rij. Annick, Kim, Linda, Linn, 
Marloes en Monique, wat heerlijk om jullie om me heen te hebben. Het stelt me 
gerust dat de afstand Wijchen tot Amsterdam, Groningen of zelfs Stockholm onze 
vriendschap niet in de weg staat! Ik hou stuk voor stuk van jullie, dikke kus!
Lieve papa en mama. Allereerst een kleine rectificatie: waar op de eerste pagina 
“voor papa” staat, bedoel ik natuurlijk ook mama; ik vind het heel knap en fijn om te 
zien hoe jij papa steunt. Ik kan niet genoeg woorden bedenken om jullie te bedanken 
voor alles. Voor de schop onder m’n kont toen ik wilde afhaken na drie maanden, 
voor de onvoorwaardelijke steun, voor de interesse, voor de peptalks, voor de 
gezelligheid en gewoon om wie jullie zijn. Jullie zijn op alle fronten een groot voorbeeld 
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voor me en ik heb enorm veel bewondering en respect voor jullie. Ook al wonen we 
nu in Wijchen en dus “ver” bij jullie vandaan, jullie voelen altijd dichtbij. Ik hou van 
jullie.
And last but not least, lieve Paul, alle mooie life-events in 1 jaar! Trouwen, jij klaar met 
je huisarts opleiding, ik klaar met de promotie, en ook nog eens zwanger. Doen we 
even, maar wél samen. Jij snapte als geen ander hoe moeilijk het vorig jaar was om 
de promotie af te maken, toen we van dichtbij meemaakten hoe papa zijn prostaat-
kanker in alle hevigheid terug kreeg. Bedankt voor je enorme steun. En voor je 
geduld, met name sinds de start van de Radiologie opleiding! Hoeveel avonden en 
weekenden heb ik niet ongezellig achter de computer gezeten (of was ik weer eens 
chagrijnig omdat ik eigenlijk achter de computer zou móeten zitten), zonder dat jij hier 
ook maar een klein beetje moeilijk over deed of teleurgesteld over was? Dat is voorbij, 
nu volgt hopelijk weer wat meer vrije tijd en dat kunnen we mooi besteden aan ons 
samen en aan ons kleine wurmpje! Ik hou ontzettend veel van je.
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Eline Vos werd geboren op 8 juni 1985 te Amsterdam. In 2003 behaalde zij haar VWO 
diploma aan het VeenLanden College in Mijdrecht, waarna zij begon aan de opleiding 
geneeskunde aan de Vrije Universiteit te Amsterdam. Al vroeg in de opleiding groeide 
haar interesse voor de radiologie. Een wetenschappelijke stage van 6 maanden 
bij de afdeling Neuroradiologie in het VUmc resulteerde in een publicatie. In 2010 
behaalde zij haar arts examen. Aansluitend deed ze klinische ervaring op als ANIOS 
bij de afdeling Interne Geneeskunde van het Spaarne ziekenhuis te Hoofddorp, waar 
ze naast de afdelingen algemene interne geneeskunde, cardiologie en longziekten 
voornamelijk gestationeerd was op de afdeling maag-, darm- en leverziekten en de 
spoedeisende hulp.
 Op 1 maart 2011 startte zij met haar promotieonderzoek bij de afdeling Radiologie 
van het Radboud umc te Nijmegen, onder leiding van dr. ir. Scheenen en prof. dr. 
Barentsz. Tijdens dit promotietraject deed zij klinische ervaring op met het verrichten 
van MRI-geleide prostaatbiopten. In mei 2014 startte ze in ditzelfde ziekenhuis met 
de opleiding tot radioloog.
 In maart 2015 gaf zij het jawoord aan Paul, en sindsdien gaat ze door het leven 
als Eline Hanrath.
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